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■ Chapter 1 Type 2 diabetes mellitus: prevalence and burden Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease with a dramatically increasing prevalence throughout the world and with no cure as of 2010. It is associated with an impaired glucose cycle, altering metabolism, and without adequate treatment serious complications may 
occur.1;2 
The global prevalence of diabetes among adults is high, varying between 2.8 percent to 4 percent 
in the year 2000, and this number is expected to reach 350 million world-wide in 2030.3 In the 
Netherlands, the prevalence ofT2DM is estimated to be 41.6 per 1000 women and 40.1 per 1000 
men. In 2007 there were 740.000 people diagnosed with diabetes mellitus, with 90% of them being 
diagnosed as having T2DM.4 In addition, it is estimated that 30% of population aged over 60 have 
undiagnosed impaired glucose tolerance in the Netherlands.5 
T2DM is an independent risk factor for several forms of cardiovascular disease (CVD) in both men and 
women.6 The overall yearly mortality among patients with diabetes is 2.9%, with the most common 
cause of death being related to cardiovascular disease. When patients with diabetes develop clinical 
CVD, they sustain a worse prognosis for survival than do CVD patients without diabetes.7;8 
Management of type 2 diabetes mellitus 
As patients with T2DM have an increased risk for CVD, controlling several risk factors including 
hyperglycemia, which may give rise to secondary conditions is one of the main goals of diabetes 
management. Measurements of cholesterol, LDL, HDL and triglyceride levels may indicate 
dislipidemia, which may require treatment with lipid lowering medication. Measurement of the 
blood pressure and keeping it within strict limits by using diet and antihypertensive treatment 
protects against the retinal, renal and cardiovascular complications of diabetes. Annual eye and 
foot exams are recommended to monitor for progression of diabetic foot and diabetic retinopathy, 
etc. 
Over the past 5-10 years, there have been substantial improvements in many processes of diabetes 
care (e.g., conducting laboratory tests at indicated intervals), but less dramatic improvements in 
intermediate outcomes (e.g., value of blood pressure or glycemic control). Indeed, recent studies 
have shown that substantial quality gaps in glycemic, blood pressure and lipid control exist in 
management of diabetic patients and are of considerable concern.9;10 
Importance of prescribing in type 2 diabetes mellitus 
Management of T2DM includes carefully managing diet, exercising, taking oral glucose lowering 
medication, using some form of insulin, and self-monitoring and may be further complicated by 
other factors such as presence of other risk factors and diseases. Carefully managing diet and 
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physical activity play an important role for diabetes and contribute to improved patients outcomes.11 
However, lifestyle modifications may not be sufficient for controlling the risk factors as the diseases 
progresses, and pharmacotherapy is in due course required for majority of diabetic patients.12 
Appropriate glucose and blood pressure control, lipid-lowering therapy, rennin-angiotensin 
aldosteron system (RAAS) inhibition, and antiplatelet treatment significantly reduce the risk of 
cardiovascular complications in diabetic patients.13;14 
Despite the development of clinical guidelines describing key recommendations concerning 
appropriate pharmacotherapy in T2DM, many patients do not receive optimal drug treatment.15•11 
Undertreatment of diabetic patients has a large impact on individuals, societies, and health care 
costs. 
Quality assessment in healthcare 
Donabedian's classic paradigm for assessing quality of care was developed in 1988 and is based on 
a three-component approach-structure, process, and outcomes.18 Structure refers to the attributes 
of the settings in which providers deliver health care, including material resources (e.g., electronic 
health records), human resources (e.g., staff expertise), and organizational structure (e.g., hospitals 
vs. outpatient clinics). For example, a health care provider may use a disease registry to track whether 
a patient with increased levels of cholesterol is receiving drugs for lowering cholesterol. 
Process of care denotes what is actually done for the patient in terms of giving and receiving of care. 
Examples of processes of care include measuring and documenting clinical measurement values, 
such as glucose and blood pressure, prescribing medications to eligible patients, educating and 
empowering patients, etc. 
Health outcomes are the direct result of a patient's health status as a consequence of contact with 
the health care system. For example, the patient's receiving the appropriate medications could 
decrease the chance of dying from a heart attack. 
Donabedian's model proposes that each component has a direct influence on the next one, i.e. 
structure of care influence processes of care, and process of care determines outcomes of care. 
Prescribing is a typical example of health care process. In the field of diabetes care, pharmacotherapy 
is the best researched process of care in terms of its influence on health outcomes with a very good 
link established between the two dimensions of the paradigm.19;20 
Assessing prescribing quality 
Quality of health care can be improved without explicit quality assessment using different 
methods including peer-review21, educational programs22, use of standardized patients23, implicit 





constitute a method of choice in specific situations, they share two major disadvantages. First of all, 
none of these methods can be routinely applied as they require considerable man power, resource 
investment and are time consuming. Next, use of these methods does not provide a measurable 
basis for reliable comparisons over time or between providers that is crucial for continuous quality 
improvement and evaluation of interventions. 
To overcome these limitations, prescribing quality indicators (PQI) are developed. A PQI is a 
measurable element of prescribing for which there is evidence or consensus that it can be used for 
measuring and hence improve quality of prescribing.26 Usually, a PQI is defined as a percentage of 
patients that received the recommended drug treatment, with numerator comprising the number 
of patients actually receiving the treatment and denominator comprising the number of all patients 
for whom the treatment is appropriate. Prescribing quality indicators have explicitly defined criteria 
regarding what constitutes good quality of care, and the scores of the PQI can be compared over 
time and across different providers. Usually PQI are developed based on scientific evidence and/or 
acceptance by professionals in the field.27 Therefore, they can be used to measure the compliance 
to drug recommendations as given in clinical guidelines. In addition, measurability of prescribing 
quality indicators provides a great opportunity for research, for example for comparison of indicator 
scores to assess their concurrent validity or by linking the scores of prescribing indicators to different 
patients outcomes for predictive validity assessment.28 
Rationale for this thesis 
Availability and validity of POI for diabetes care 
In the past decade there has been a lot of attention to diabetes care worldwide. In many countries, 
including the Netherlands, diabetes was among the first diseases for which disease management 
program have been developed.29 Subsequently, a number of different quality indicators have been 
developed to monitor quality of diabetes care. Such indicators have been included in different 
national sets of indicators worldwide.30;31 In addition, specific national and international projects 
involving quality indicators have been developed to improve quality of diabetes care.32;33 Although 
some of these programs include prescribing quality indicators for diabetes management, a 
comprehensive set of prescribing indicators for diabetes care is lacking. In addition, there is lack of 
information on the validity of existing prescribing quality indicators of diabetes care. 
Prescribing quality indicators for T2DM care have the potential to inform and improve quality of 
diabetes care.34;35 However, to be useful, they have to meet a number of criteria. As a minimum, a PQI 
should reflect the best available evidence and be accepted by professionals in the field.36The data for 
calculating PQI should be readily available and collected on a routine basis. The PQI should be reliable 
and allow fair comparisons between health care providers. Information on these characteristics is 
necessary for choosing the best indicators in relation to the aim of quality assessment.37 
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An increasing number of quality indicators 
PQI are demanded and used by different stakeholders, including policy makers, health insurance 
companies, professionals, and patient organizations. These stakeholders have to deal with an 
increasing number of quality indicators developed for a growing number of diseases.38 This adds 
to the administrative and financial burden of collecting, reporting, and processing large amounts 
of quality information.39 Application of scientifically sound methods to select the most relevant 
indicators is a key to reduce the workload and costs involved in quality assessment. 
Objectives and structure of this thesis 
In this thesis we describe the development, validation, and selection of prescribing quality indicators 
for diabetes care. We focus on three primary aims centered on pharmacological management of 
type 2 diabetes mellitus: 
1. To develop a comprehensive, valid, and operationally feasible set of prescribing quality 
indicators for diabetes care 
2. The improve the general understanding on clinimetric characteristics of PQI for diabetes care 
3. To build up the knowledge on selection of relevant PQI from existing sets of indicators using 
different research methods 
Chapter 2 presents the development of a set of prescribing quality indicators for diabetes care 
based on several international and national diabetes guidelines, and their validation in a panel of 
nationally recognized experts followed by a panel of diabetologists and general practitioners using 
the RAND Appropriateness Method (RAM). In addition, we assessed the operational feasibility of the 
selected PQI in the view of available data using electronic health records of T2DM patients. 
In Chapter 3 we assessed the impact of the type of clinical information used for identifying the 
target population (denominators) of several prescribing quality indicators. Patients with certain 
conditions, such as hypertension or being overweight are usually identified in electronic health 
records by using corresponding diagnostic codes. Alternatively these patients can be identified 
using elevated values of clinical measurements, i.e. blood pressure and body mass index. We studied 
how this choice of clinical information to define the target population affected the PQI scores and 
their ability to correctly identify treated and untreated T2DM patients. 
In Chapter 4 we reviewed existing PQI for T2DM and cardiovascular management. We conducted 
a systematic literature search in MEDLINE and EMBASE databases without language restriction, 
and reviewed clinimetric properties (face, content, concurrent, and predictive validity, operational 
feasibility, reliability, sensitivity to case-mix, and minimum sample size) of more than 200 extracted 





clinimetrics. The study presents an overview of clinimetric characteristics for existing PQI and 
provides a short list of the indicators with the best validity results. 
Chapter 5 summarizes the preferences for different prescribing quality indicators as expressed 
by important stakeholders in the Netherlands, such as the Healthcare Inspectorate, healthcare 
professionals (GPs, diabetologists, diabetes nurses, and pharmacists), patient representatives, and 
insurance companies. In a qualitative study, we explored the perceived importance of including 
PQI in quality assessment of diabetes care by different stakeholders and elicited the preferred types 
of PQI per stakeholder. In addition, we revealed the preferred way of receiving prescribing quality 
information by the included stakeholders. 
In Chapter 6 we describe a selection process of a minimal set of PQI forT2DM management using 
factor analysis. We show the value of this technique for reducing the number of prescribing quality 
indicators by identifying the relationships between prescribing quality indicators on a general 
practice level that might not be obvious otherwise. 
Finally, in Chapter 7 the findings, implications, and methodological considerations regarding the 
above mentioned studies are discussed. The recommendations for future research are provided in 
the same chapter. 
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Existing performance indicators for assessing quality of care in type 2 diabetes mellitus (T2DM) focus 
mostly on registration of measurements and clinical outcomes, and not on quality of prescribing. 
Objective 
To develop a set of valid prescribing quality indicators (POI) for internal use in T2DM, and assess the 
operational validity of the POI using electronic medical records. 
Methods 
Potential POI for hypertension, hyperglycaemia, dyslipidaemia, and antiplatelet treatment in T2DM 
were based on clinical guidelines, and assessed on face and content validity in an expert panel 
followed by a panel of GPs and diabetologists. Analysis of ratings was performed using RAND/UCLA 
Appropriateness Method. Operational validity of selected indicators was assessed in a dataset of 
3214 T2DM patients registered with 70 GPs. 
Results 
Out of 31 potential prescribing indicators, the expert panel considered 18 indicators as sufficiently 
valid, of which 14 indicators remained valid after assessment by the panel of GPs and diabetologists. 
Of these 14 indicators, one could not be calculated because of absence of eligible patients. For 
the remaining indicators, outcomes varied from 10% for timely prescribing of insulin to 96% for 
prescribing of any antihyperglycemic medication in patients with elevated HbA 1 c levels. 
Conclusions 
This study provides a set of face and content valid POI for pharmacological management of patients 
with T2DM. While outcomes of some POI were limited to patients with registration of clinical values, 
the selected POI had good operational validity to be used in practice for assessment of prescribing 
quality. 
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INTRODUCTION 
Efforts to measure and improve quality of care in outpatient settings have focused especially on 
care for chronic medical conditions, such as type 2 diabetes mellitus (T2DM). This has resulted in 
publication of clinical guidelines to assist doctors in management of diabetes, and the development 
of performance quality indicators. T2DM is a disease with a dramatically increasing prevalence 
throughout the world and serious complications may occur if the disease is not adequately treated1 :2 • 
Appropriate blood pressure control, lipid-lowering therapy, angiotensin-converting enzyme(ACE) 
inhibition, and anti platelet drugs significantly reduce the risk of cardiovascular and microvascular 
complications in diabetic patients3:4• 
Quality information has been demanded not only by policy makers, consumers, and media, 
but also by health care providers themselves for internal use. In order to measure quality of 
prescribing in T2DM patients, valid prescribing quality indicators (PQI) are needed. Such PQI can 
be used by health care providers as a "screening tool" to help flag potential problem areas that 
need further investigation, for giving feedback to individual doctors, and to assess the impact 
of quality improvement initiatives. Although quality of care can be improved without explicit 
quality assessment, for example by peer review or educational programs, measurements provide 
valuable information for monitoring and feedback5• Quality improvement initiatives using quality 
measurements and achievable standards have been shown to improve diabetes outcomes, such as 
long term glucose control measurement6:7• 
Several sets of quality indicators for diabetes care have been developed. Many of them include 
outcome indicators or focus on processes of care, such as registration of clinical characteristics, but 
do not include any PQl.[8-10] PQI are process measures that can help to identify patients who may 
benefit from initiation or intensification of treatment. Such information is helpful for improving 
prescribing quality and dealing with so called 'therapeutic inertia'1 1 :1 2 Although some PQI for 
diabetes care are included in national sets of quality indicators1 3:14, and some detailed PQI forT2DM 
management have been described1 5:1 6, a comprehensive set of PQI for diabetes care is lacking. 
We aimed to develop a set of PQI for pharmacological management in T2DM patients for internal 
use and to assess their operational validity using electronic medical records. 
METHODS 
Development of indicators 
A list of 30 potential PQI for pharmacological management in T2DM was developed based 
on the latest versions of English language and Dutch diabetes guidelines1 7-24. Key guideline 
recommendations regarding drug treatment were transformed into potential indicators on the 
basis of measurability. Indicators comprised the number of patients actually receiving the drug 




(numerator) over the number of patients for whom the drug was appropriate (denominator). 
Potential PQI were developed for the following areas: hypertension, hyperglycaemia, dyslipidaemia, 
antiplatelet treatment, and secondary prevention of cardiovascular disease (CVD). Developed 
indicators focused on undertreatment, drug choice, dosage, and safety. 
Assessment of face and content validity 
The face and content validity of potential indicators was assessed in a two-round expert panel 
followed by a panel of physicians from the field for whom the PQI were intended using the RAND/ 
UCLA Appropriateness Method (RAM)25• The expert panel consisted of nationally recognized 
authorities from relevant specialties involved in ambulatory diabetes care: two GPs, two 
diabetologists, and a professor of endocrinology. The panel members had considerable practice and 
scientific experience and were members of Dutch College of General Practitioners, Dutch Institute 
for Healthcare Improvement, or Dutch Diabetes Association. For the field panel, fourteen general 
practitioners (GPs) and six diabetologists were recruited from two regions in the Netherlands. 
Both panels were asked to rate the PQI on a 9-point scale for two criteria: reflection of the key 
recommendations in the guidelines, and relevance for patient health gain. Before rating the 
indicators, participants of both panels received background information including the evidence­
base and definitions used for PQls, and it was made clear that the potential PQI were intended for 
internal use. 
In the first round, potential PQI were mailed to the experts for individual rating. In addition, 
experts were asked to suggest new indicators if they believed that important drug treatment 
recommendations were insufficiently addressed. The ratings were analyzed and PQI rated with 
disagreement were identified. In the second round, panel members met to discuss PQI rated with 
disagreement. The intention of the discussion was to resolve misinterpretations, and improve 
definitions of PQI. In case of ambiguity, the experts were asked to introduce changes in the 
definitions or wording of indicators. Discussion was facilitated by a moderator experienced in 
chairing expert panels. After the discussion, the definitions of PQI were refined, and the panellists 
were asked to rate the indicators a second time. Based on these second ratings, indicators classified 
as having insufficient validity were discarded. PQI considered valid by the expert panel were mailed 
to GPs and diabetologists participating in the third round. After analysis of their ratings, the final PQI 
were selected. 
Operational validity 
To assess operational validity, the selected PQI were calculated in a dataset extracted for the GIANTT 
project from electronic records of 3214 T2DM patients registered with 70 GPs working in 37 practices 
in the north of the Netherlands26• The dataset included information on demographics, prescribed 
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medication, comorbidities, physical examination and laboratory measurements as documented 
in medical records of GP practices and a regional diabetes facility, which offers support to GPs by 
providing 3-monthly and yearly diabetes follow-up examination of patients. 
Analysis 
A PQI was considered to be valid if it met the following predefined criteria: both panels rated it with 
median score of seven or more and without disagreement for either criterion25• Disagreement was 
analyzed using the interpercentile range between the first and last tertials adjusted for symmetry 
(IPRAS) method developed in the RAM25• The rationale behind this adjustment is that when ratings 
are symmetric with respect to the middle (5 on the 1-9 scale), the interpercentile range (IPR) 
required to identify disagreement is smaller than when they are asymmetric. The detailed formulas 
and examples for calculation of IPR and IPRAS are available on the RAND WebPage27• 
Operational validity was defined as the feasibility of calculation of PQI using electronic medical 
records. Indicators were calculated using SPSS for Windows version 1 1 . For calculation of the PQI, 
we used values of blood pressure and HbA 1 c registered in the first half of 2004 and prescription 
data registered in the second half of 2004. This way we made sure that prescription occurred after 
observing elevated values of clinical measurements. 
For albuminuria and BMI the last value in 2004 was used. Three PQI focusing on intensification of 
antihypertensive and antihyperglycaemic therapy were calculated in a longitudinal way by looking 
for patients who in spite of a treatment had two clinical values above target level in a period of any 
4 months in 2004, and received treatment intensification in the following month. This approach 
has been selected since sequential indicators have been shown to provide better estimates of 
treatment intensification.[28] Detailed operational definitions for calculating all PQI are provided 
in the Appendix 2. 
RESULTS 
Selecting the face/content valid PQI 
No indicator was discarded after the first round, but one new indicator was suggested. Therefore, in 
the second round the experts rated 3 1  indicators (Appendix 1 ). The panel of experts considered 18 
indicators to be valid. The other 13  indicators were rated either with disagreement or with a median 
lower than seven for reflection of guidelines and patient health gain and were discarded (Tablel ). 
Reasons for disagreement identified during the discussion included: too much dependence on 
case-mix, insufficient evidence, irrelevance for ambulatory care, and disagreement on guideline 
recommendations (Table 1 ). In particular, there was disagreement between GPs and diabetologists 
regarding the recommendation from Dutch diabetes guidelines to prescribe thiazides as a first 
choice antihypertensive drug in T2DM patients without albuminuria. Diabetologists considered 





T a b l e  1 .  D i s c a r d e d  P Q I  
P Q I  c o n s i d e r e d  a s  h a v i n g  i n s u ffi c i e n t  v a l i d i t y  b y  t h e  e x p e r t  p a n e l  
R K R  P H G  
R e a s o n s  f o r  d i s a g r e e m e n t  p r o v i d e d  b y  p a n e l l i s t s  
M  D  M  D  
%  o f T 2 D M  p a t i e n t s  i n c i d e n t  fo r  h y p e r t e n s i o n  w i t h o u t  a l b u m i n u r i a  p r e s c r i b e d  a  8  
+  7  +  N o t  r e l e v a n t  f o r  p a t i e n t  h e a l t h  g a i n  i n  l o n g  t e r m  
t h i a z i d e  a s  a  fi r s t  c h o i c e  d r u g  T h i a z i d e s  a r e  n o t  a  fi r s t  c h o i c e  d r u g  fo r T 2 D M  
%  o f T 2 D M  h y p e r t e n s i v e  p a t i e n t s  w i t h o u t  a l b u m i n u r i a  t r e a t e d  w i t h  a  m u l t i p l e  d r u g  
6  
7  +  N o t  r e l e v a n t  f o r  p a t i e n t  h e a l t h  g a i n  i n  l o n g  t e r m  
r e g i m e  i n c l u d i n g  a  t h i a z i d e s  
T h i a z i d e s  a r e  n o t  a  fi r s t  c h o i c e  d r u g  fo r T 2 D M  
%  o f T 2 D M  p a t i e n t s  w i t h  a l b u m i n u r i a  a n d  p r e s c r i p t i o n  o f  a n g i o t e n s i n  r e c e p t o r  7  
+  
6  +  
A R B s  a r e  t h e  fi r s t  c h o i c e  f o r  R A S - i n h i b i t i o n  
b l o c k e r  ( A R B )  p r e s c r i b e d  a n g i o t e n s i n  c o n v e r t i n g  e n z y m e  ( A C E )  i n h i b i t o r  b e f o r e  A R B  L a c k  o f  e v i d e n c e  f o r  A C E - i n h i b i t o r s  f o r  a l l  e n d p o i n t s  
p r e s c r i p t i o n  
%  o f T 2 D M  h y p e r t e n s i v e  p a t i e n t s  p r e s c r i b e d  a  b l o c k e r s  i n  m o n o t h e r a p y  3  
3  
P e r c e n t a g e  o f T 2 D M  p a t i e n t s  r e c e i v i n g  a  d r u g  r e g i m e  i n c l u d i n g  t h i a z i d e  a n d  5  
5  +  T h i a z i d e s  a r e  n o t  a  g o o d  c h o i c e  f o r T 2 D M  
13 - b l o c k e r  w h e r e  t h i a z i d e  i s  p r e s c r i b e d  i n  a  l o w  d o s a g e  
J3  - b l o c k e r  a n d  A C E - i n h i b i t o r  i s  b e t t e r  c h o i c e  
%  o f T 2 D M  p a t i e n t s  w i t h  r e n a l  i m p a i r m e n t ,  h e a r t  f a i l u r e  o r  i m p a i r e d  l i v e r  f u n c t i o n  
8  
+  7  +  T o o  s e n s i t i v e  t o  v a r i e t y  o f  p a t i e n t  c h a r a c t e r i s t i c s  
p r e s c r i b e d  m e t fo r m i n  
%  o f T 2 D M  p a t i e n t s  w i t h  r e c o r d e d  h y p e r c h o l e s t e r o l e m i a  t r i g l y c e r i d e  > 2 . 3  m m o l / 1  7  
+  6  +  L a c k  o f  e v i d e n c e :  n o  e n d p o i n t  e v i d e n c e ;  N o  
a n d  L D L  < 3 . 0  m m o l / 1  p r e s c r i b e d  a  fi b r a t e  
c o n s e n s u s  o n  fi b r a t e s  i n  t h e  N e t h e r l a n d s  a n d  G P s  
s h o u l d  c o n t a c t  i n t e r n i s t s  f o r  p r e s c r i b i n g  a  fi b r a t e  
%  o f T 2 D M  p a t i e n t s  o v e r  4 0  y e a r s  p r e s c r i b e d  a  s t a t i n  
7  
+  
7  +  A g e  a l o n e  i s  n o t  s u ffi c i e n t  f o r  p r e s c r i b i n g  a  s t a t i n  
%  o f T 2 D M  p a t i e n t s  w i t h o u t  h i s t o r y  o f  C V D  b u t  w i t h  h i g h  c a r d i o v a s c u l a r  r i s k  a n d  
7  
+  5  +  C a s e - m i x :  H i g h  c a r d i o v a s c u l a r  r i s k  a l o n e  i s  n o t  
w e l l - c o n t r o l l e d  h y p e r t e n s i o n  p r e s c r i b e d  a c e t y l  s a l i c y l i c  a c i d  
s u ffi c i e n t  f o r  p r e s c r i b i n g  a c e t y l  s a l i c y l i c  a c i d  
%  o f T 2 D M  p a t i e n t s  w i t h  u n c o n t r o l l e d  h y p e r t e n s i o n  p r e s c r i b e d  a c e t y l  s a l i c y l i c  a c i d  7  
+  5  +  L a c k  o f  e v i d e n c e  
%  o f T 2 D M  w i t h  d i a b e t e s  a n d  a c u t e  M l  p r e s c r i b e d  i n t e n s i v e  i n s u l i n  t r e a t m e n t  5  
+  6  +  R e l e v a n t  f o r  h o s p i t a l  c a r e  
%  o f T 2 D M  w i t h  d i a b e t e s  a n d  a c u t e  M l  r e c e i v i n g  t h r o m b o l y t i c  t h e r a p y  
5  
+  6  +  R e l e v a n t  f o r  h o s p i t a l  c a r e  
%  o f T 2 D M  w i t h  d i a b e t e s  a n d  c o r o n a r y  h e a r t  d i s e a s e  a n d  p r e s e n t  a c u t e  c o r o n a r y  2  
+  6  +  R e l e v a n t  f o r  h o s p i t a l  c a r e  
s y m p t o m s  p r e s c r i b e d  c o m b i n a t i o n  o f  c l o p i d o g r e l  a n d  a c e t y l  s a l i c y l i c  a c i d  
N o  c o n s e n s u s  o n  c l o p i d r o g e l  i n  t h e  N e t h e r l a n d s  
P Q I  c o n s i d e r e d  a s  h a v i n g  i n s u ffi c i e n t  v a l i d i t y  b y  t h e  fi e l d  p a n e l  
%  o f T 2 D M  h y p e r t e n s i v e  p a t i e n t s  r e c e i v i n g  a  d r u g  r e g i m e  i n c l u d i n g  t h i a z i d e s  
8  
+  
6  +  N o t  r e l e v a n t  fo r  p a t i e n t  h e a l t h  g a i n  
p r e s c r i b e d  a  t h i a z i d e  i n  l o w  d o s a g e  
%  o f  a l l  i n c i d e n t T 2 D M  p a t i e n t s  p r e s c r i b e d  m e t f o r m i n  a s  a  fi r s t  c h o i c e  d r u g  8  
+  7  +  M o r e  r e l e v a n t  f o r  o v e r w e i g h t  p a t i e n t s  
%  o f T 2 D M  p a t i e n t s  w i t h  i m p a i r e d  l i v e r  f u n c t i o n  o r  h i s t o r y  o f  h e a r t  f a i l u r e  8  
+  7  +  
To o  s e n s i t i v e  t o  v a r i e t y  o f  p a t i e n t  c h a r a c t e r i s t i c s  
p r e s c r i b e d  P P A R y - a g o n i s t s  ( t h i a z o l i d i n e d i o n s )  
%  o f T 2 D M  p a t i e n t s  a g e d  � 4 0  w i t h o u t  h i s t o r y  o f  C V D  b u t  w h o  h a v e  2  o r  m o r e  
7  
+  7  +  
C a s e - m i x :  H i g h  c a r d i o v a s c u l a r  r i s k  a l o n e  ( n o  o v e r t  
c a r d i o v a s c u l a r  r i s k  f a c t o r s  p r e s c r i b e d  a  s t a t i n  
C V D )  i s  n o t  s u ffi c i e n t  f o r  p r e s c r i b i n g  a  s t a t i n  
R K R - r e fl e c t i o n  o f  k e y  r e c o m m e n d a t i o n  i n  t h e  g u i d e l i n e s ;  P H G - p a t i e n t  h e a l t h  g a i n ;  M - m e d i a n  r a t i n g  f o r  t h e  c r i t e r i o n ; D  +  a  P Q I  w a s  r a t e d  w i t h  d i s a g r e e m e n t  o n  t h e  c r i t e r i o n ;  
D  - a  P Q I  w a s  r a t e d  w i t h o u t  d i s a g r e e m e n t  o n  t h e  c r i t e r i o n ; M I - m y o c a r d i a l  i n f a r c t i o n ;  P P A R y - a g o n i s t s  - p e r o x i s o m e  p r o l i f e r a t o r - a c t i v a t e d  y  r e c e p t o r s ' a g o n i s t  
"-'  
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The field panel of GPs and diabetologists considered 1 4  indicators out of the 1 8  selected by the 
expert panel as being sufficiently valid. The four discarded POI were rated with disagreement, 
because some members of the field panel gave low ratings to these POI for reasons including lack 
of relevance for patient health gain and sensitivity to individual patient characteristics (Table 1 ). The 
final POI covered the main aspects of pharmacological treatment in T2DM patients (Table 2). 
Table 2. Outcome measures for the selected PQI 
Definitions of PQI 
Hypertension management 
% ofT2DM patients with systolic blood pressure L 140 and 
prescribed any antihypertensive drug 
% of T2DM patients prescribed a second anti hypertensive 
drug from a different class if systolic blood pressure 
remained � 140 with first class of anti hypertensive drug 
% of T2DM patients without hypertension with albuminuria 
prescribed ACE inhibitor or ARB 
% of T2DM incident for hypertension patients with 
albuminuria prescribed ACE inhibitor or ARB as a first 
choice drugs 
% of T2DM prevalent for hypertension patients with 
albuminuria prescribed a multiple drug regime containing 
ACE inhibitor or ARB 
% of T2DM patients with hypertension and history of 
ischemic heart disease or myocardial infarction prescribed 
�-blocker 
Hyperglycaemia management 
% of prevalent T2DM patients with HbA 1 c >7 % and 
prescribed any oral antihyperglycaemic agent or insulin 
% of prevalent T2DM patients not receiving insulin 
prescribed a second oral anti hyperglycaemic drug from 
a different class if with one oral antihyperglycaemic drug 
HbA 1 c remained > 7% 
% ofT2DM patients who are prescribed insulin if with 
combination of two oral drugs HbA 1 c remained >7 % 
% of overweight incident T2DM patients prescribed 
metformin as a first choice drug 
% of overweight prevalentT2DM patients prescribed a 
multiple drug regime containing metformin 
Dyslipidaemia management 
% T2DM patients with high cardiovascular risk who are 
prescribed a statin 
% of T2DM patients aged s40 with history of cardiovascular 
disease prescribed a statin 
Antiplatelet treatment 
% of T2DM patients with history of cardiovascular disease 
prescribed acetyl salicylic acid 
Outcome measure, 





























Hypertension was defined as diagnosis registered by GPs and/or average values of systolic blood pressure 
L 140 mm/Hg;High cardiovascular risk:T2DM women age>60 years old and men >50 years old or/and with 
duration of diabetes L 10 years or/and with uncontrolled hypertension or/and with albuminuria or/and HbA 1 c 
> ?%;History of cardiovascular disease: history of myocardial infarction, ischemic heart disease, transient cerebral 
ischemia, stroke/cerebrovascular accident, or/and atherosclerosis/peripheral vascular disease as registered by 





It was feasible to calculate 13 PQI using data routinely documented in medical records. One indicator 
focusing on prescription of statins to T2DM patients younger than 40 years and with history of 
cardiovascular disease could not be calculated because of lack of eligible patients (Table 2). 
Five PQI required information on BMI and albuminuria, which were not available for over a third of 
patients. The other eight indicators were calculated based on variables available at least for 70% of 
patients (Table 3). 
Table 3. Completeness of the dataset for variables used to calculate PQls 
Name of the variable 
Age 
Gender 
Duration of diabetes 
Systol ic b lood pressure 
HbA l c  
BMl 
Albuminuria 




80% (in the first half of 2004) 
70% (in the first half of 2004) 
65% (in 2004) 
43 % (in 2004) 
The best performance was observed for the indicators focusing on prescribing any anti hypertensive 
or antihyperglycaemic drugs. The lowest PQI outcomes were observed for timely intensification of 
antihypertensive or antihyperglycaemic treatment. 
DISCUSSION 
Out of 31 potential prescribing indicators derived from diabetes guidelines, fourteen were assessed 
by both expert and field panel as sufficiently valid for internal quality assessment. Thirteen of them 
were feasible to calculate using data available from electronic medical records. 
To our knowledge, this is the first study that aimed to develop a set of PQI for diabetes care. We 
used the RAM methodology, which is considered the best method for systematically combining 
recommendations from clinical guidelines with opinion of health care providers29, to develop PQI 
that are face and content valid. Another strong point in the assessment of validity was the use of 
IPRAS to measure disagreement between participants in both rounds, as this method has shown 
excellent sensitivity and good specificity to measure the degree of dispersion among ratings25• 
In addition, we followed a procedure of discussing reasons for disagreement, and improving 
definitions and wordings of the indicators before the final rating. This ensured that ambiguity was 
not the reason for disagreement or rejection of indicators. 
It was our objective to develop and validate indicators for internal use by health care providers 
treating patients with T2DM. We selected the PQI using two different panels. The additional 
assessment of the prescribing indicators as selected by the experts in a field panel ensures 
24 
Prescribing quality indicators of type 2 diabetes mellitus ambulatory care 
acceptability of indicators for everyday practice by those for whom the indicators are actually 
intended. The majority of the indicators validated by the expert panel were also selected by the 
field panel. 
A limitation of our method is that panel members from different groups may have different judgments 
which affects the ratings30• Judgments made by any expert panel may not be representative 
for all health care professionals. However, in our study we had two different panels, making the 
final selection of indicators more reliable and generalizable. Our results show the significance of 
combining evidence with expert and field opinion. In particular, we found that diabetologists and 
GPs disagreed on some recommendations in guidelines. Since our aim was to select indicators 
for which there was a consensus between both groups, indicators considered relevant by only 
some experts were not included in the final selection. In addition, we used a selection of seven 
diabetes guidelines for this POI development. Therefore, it is possible that POI based on relevant 
recommendations from other guidelines were not considered. There is, however, international 
consensus on the key clinical recommendations for diabetes care in different guidelines31 • Our POI 
covered these central recommendations. 
In all five areas of pharmacological management, several indicators of undertreatment and/or drug 
choice were considered valid. Except for aggressive management of hyperglycaemia, these were 
indicators with evidence grade A23 • None of the indicators focusing on dosage or safety reached 
sufficient face and content va I id ity because of disagreement with the recommendations or expected 
influence of other patient characteristics which may not always be documented in records. 
Two POI selected in our study were also considered face or content valid in previous studies, and 
some are being used at national level, i.e. POI focusing on prescribing ACE-inhibitors in T2DM 
hypertensive patients with albuminuria 13;14;32;33 and prescribing f3-blockers in T2DM patients with 
history of myocardial infarction 1 4;34-35_ The PQI focusing on prescribing ACE-inhibitors before 
prescribing ARBs did not reach face and content validity in our study, but was considered valid 
previously37• POI focusing on hypertension and hyperglycaemia undertreatment have been 
selected also by other panels albeit with higher targets e.g. 150 for systolic blood pressure and 
9% for HbA 1 c32• This can be explained by emerging evidence and by the differences in diabetes 
guidelines regarding specific recommendations in different countries38• None of the proposed POI 
was included in the set of diabetes quality measures owned by the National Committee for Quality 
Assurance36 or in the Australian set of indicators of quality prescribing in general practice13• This 
implies that the proposed set of indicators can be seen as a welcome addition to the existing sets 
of indicators. 




absence of young T2DM patients with history of cardiovascular disease in our dataset. We combined 
clinical information stored in two data sources to enhance completeness of data collection, but 
some variables were not available for all patients, possibly because they are not measured each year. 
Missing data are a problem of any clinical registry. However, it was shown that proportion based POI 
are robust to data loss up to 35% of an entire sample39• Considering that our POI are also proportion 
based and any change in denominator will cause change in numerator, the POI based on variables 
available for at least 70% of patients can be considered sufficiently generalizable. The outcomes 
of POI based on albuminuria and BMI with data missing for 43 and 57 % of patients respectively 
may not reflect prescribing quality for whole population in this particular dataset. Nevertheless, 
they can be used by doctors to identify potential problems among patients with available clinical 
information. Some patients who are eligible for particular treatment may be missed, but those 
who meet the eligibility criteria for treatment (denominator) are expected to be prescribed an 
appropriate medication scheme (numerator). 
Although we did not aim to assess quality of prescribing in this study, outcome measures for 
many POI showed room for improvement. More problems were seen regarding prescribing of 
statins, acetyl-salicylic-acid, and timely intensification of antihypertensive and antihyperglycaemic 
treatment. However, it should be noted that we used a dataset of 2004, and prescribing patterns 
may have changed since then. 
In contrast, performance for some POI was very good, e.g. POI focusing on prescription of any 
anti hyperglycaemic agent showed very high outcome (96%). If a POI shows such high performance 
over time for the same health care provider, it may be retired, since there is no potential for further 
improvement, as recently happened to one of the National Committee for Quality Assurance 
measures40• 
The main restriction for the use of these disease-oriented POI is availability of patient clinical 
information, which is not present in all administrative datasets. However, improvement of 
measurement and registration of clinical values as a part of quality improvement, and development 
of new data collection methods will provide databases for effective use of the POI in the future. POI 
are by definition proxy measures of prescribing quality. There will always be patient and clinical 
characteristics that will legitimate deviations from the recommended treatment6• Finally, the 
recommendations in guidelines change over time, and POI should be periodically updated to reflect 
the best evidence. 
The study provides a set of face and content valid POI for pharmacological management in T2DM 
that were tested for internal use by health care providers. This set can be used to make health 
care providers aware of specific areas of prescribing that may be suboptimal, including issues of 
undertreatment and drug selection. 
26 
Prescribing quality indicators of type 2 diabetes mellitus ambulatory care 
ACKNOWLEDGEMENTS 
The authors would like to thank H.J.Aanstoot MD, PhD, Prof. B.H.R.Wolfenbuttel, and all GPs and 
diabetologists for participation in the project. 
FUNDING: Graduate School for Health Research, University Medical Center Groningen, University 
of Groningen 
REFERENCE LIST 
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and 
projections for 2030. Diabetes Care 2004;27:1 047-53. 
2 Pinhas-Hamiel 0, Zeitler P. Acute and chronic complications of type 2 diabetes mell itus in chi ldren and 
adolescents. The Lancet 2007;369:1 823-3 1 .  doi:1 0.1 01 6/S01 40-6736(07)6082 1 -6 [Published On l ine First: 
24 May 2007] 
3 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and 
management. JAMA 2002;287:2570-81 .  
4 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and 
microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1 998; 3 1 7:703-1 3. 
5 Campbel l  5, Cantri l !  J, Roberts D. Prescribing indicators for UK genera l  practice: Delphi consultation study. 
BMJ 2000;321 :425-8. 
6 Kiefe Cl, Al l ison JJ, Wil l iams OD, Person SD, Weaver MT, Weissman NW. Improving qual ity improvement 
using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA;2001 ;285:287 1 -
9. 
7 de Grauw WJ, van Gerwen WH, van de Lisdonk EH, van den Hoogen HJ, van den Bosch WJ, van Weel C. 
Outcomes of audit-enhanced monitoring of patients with type 2 d iabetes. J Fam Pract 2002;51 :459-64. 
8 de Beaufort CE, Reunanen A, Raleigh V, Storms F, Kleinebreil L, Gal lego R, et al. European Union diabetes 
indicators: fact or fiction? Eur J Public Health 2003;1 3:51 -4. 
9 Nicolucci A, Greenfield 5, Mattke 5. Selecting indicators for the quality of diabetes care at the health 
systems level in  OECD countries. Int J Qua/ Health Care 2006;1 8:26-30. 
1 0  Fleming B, Greenfield S, Engelgau M ,  Pogach L, Clauser 5, Parrott M .  The Diabetes Qual ity Improvement 
Project: Moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care 
2001 ;24:1 8 1 5-20. 
1 1  Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in  qual ity indicators. BMJ 
2007;335:542-4. 
1 2  Voorham J ,  Haaijer-Ruskamp FM, Wolffenbuttel BHR, Stalk R P,  Denig P; Groningen I n itiative to 
Analyse Type 2 Treatment (GIANTT) group. The influence of elevated cardiometabolic risk factor 
levels on treatment changes in type 2 diabetes. Diabetes Care 2008 DOI: 1 0.2337 /dc07-1 043 
[Published Onl ine First: 1 0  Dec 2007] 
1 3  Austral ian National Prescribing Service. Ind icators of Quality Prescribing i n  Austral ian General Practic. 
http://www.nps.org.au (accessed 7 January 2008) 
1 4  Prescribing I nd icators National Group. Quality Prescribing Related I ndicators. http://www.ic.nhs.uk 




1 5  
1 6  
1 7  
1 8  
1 9  
20 

















Kerr EA, Smith DM, Hogan MM, HoferTP, Krein SL, Bermann M, et al. Building a better quality measure: are 
some patients with,poor quality' actually getting good care? Med Care 2003;41 : 1 1 73-82. 
Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, et al. Therapy modifications in response 
to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006;1 44:475-84. 
American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care 2006;29:54-42. 
Australian Government National Health and Medical Research Council. National Evidence Based Guidelines 
for the Management of Type 2 Diabetes Mellitus. http://www.diabetesaustralia.com.au (accessed 7 
January 2008) 
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes 
Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. 
Canadian Journal of Diabetes 2003;27:1 - 1 52. 
European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabetic Medicine 
1 999;1 6:71 6-30. 
International Diabetes Federation. Global Guideline for Type 2 Diabetes. 2005. http://www.idf.org 
(accessed 7 January 2008) 
Rutten G, De Grauw W, Nijpels G, Goudswaard AN, Uitewaal P, Van der Does F, et al. NHG-Standaard 
Diabetes Mellitus Type 2. Huisarts & Wetenschap 2006;49: 1 37-52. 
Scottish Intercollegiate Guidelines network. Management of Diabetes, a UK National Clinical Guidelines 
(SIGN). http://www.sign.ac.uk (accessed 21 December 2007) 
National Institute for Health and Clinical Excellence. Full guideline:Type 2 diabetes - Management of blood 
glucose. http://guidance.nice.org.uk (accessed 7 January 2008) 
Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness 
Method User's Manual. Santa Monica, CA: 200 1 .  
Voorham J, Denig P. Computerized Extraction o f  Information on the Quality o f  Diabetes Care from Free 
Text in Electronic Patient Records of General Practitioners. J Am Med Inform Assoc 2007 May;l 4(3):349-54. 
Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness 
Method User's Manual. Chapter 8. Classifying appropriateness. http://www.rand.org/pubs/monograph_ 
reports/MRl 269/mrl 269.ch8.pdf (accessed 21 December 2007) 
Voorham J, Denig P, Wolffenbuttel BHR, Haaijer-Ruskamp FM. Cross-sectional versus sequential quality 
indicators of risk factor management in patients with type 2 diabetes. Med Care 2008; 46(2):1 33-1 4 1 .  
Naylor CD. What is appropriate care? N Engl J Med 1 998;338: 1 91 8-20. 
Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and 
applying quality indicators in primary care. BMJ;326:81 6-9. 
Burgers JS, Bailey JV, Klazinga NS, Van der Bij AK, Grol R, Feder G. Inside Guidelines: Comparative analysis of 
recommendations and evidence in diabetes guidelines from 1 3  countries. Diabetes Care 2002;25:1 933-9. 
Campbell SM, Hann M, Hacker J, Durie A, Thapar A, Roland MO. Quality assessment for three common 
conditions in primary care: validity and reliability of review criteria developed by expert panels for angina, 
asthma and type 2 diabetes. Qua/ Saf Health Care 2002;1 1 : 1 25-30. 
NHS Health and Social Care Information Centre (HSCIC). Quality and outcomes framework guidance. 
http://www.bma.org.uk (accessed 7 January 2008) 
Ashworth M, Golding S, Majeed A. Prescribing indicators and their use by primary care groups to influence 
prescribing. J Clin Pharm Ther 2002;27:1 97-204. 
Katz A, Soodeen RA, Bogdanovic B, De Coster C, Chateau D. Can the quality of care in family practice be 
measured using administrative data? Health Serv Res 2006;41 :2238-54. 
National Committee for Quality Assurance (NCQA). HEDIS 2007. http://web.ncqa.org (accessed 7 January 
2008) 
Prescribing quality indicators of type 2 diabetes mellitus ambulatory care 
37 Muijrers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA. Prescribing indicators. Development and 
validation of guideline-based prescribing indicators as an instrument to measure the variation in the 
prescribing behaviour of general practitioners. Eur J Clin Pharmacol 2004;60:739-46. 
38 Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G. Inside guidelines: comparative analysis of 
recommendations and evidence in diabetes guidelines from 1 3  countries. Diabetes Care 2002;25:1 933-9. 
39 Stuart B, Singha I PK, Magder LS, Zuckerman IH. How robust are health plan quality indicators to data loss? 
A Monte Carlo simulation study of pediatric asthma treatment. Health Serv Res 2003;38:1547-61. 




Appendix 1 Preliminary Prescribing Quality Indicators for Type 2 Diabetes Mellitus (T2DM) management 
Definition of indicators 
Hypertension management 
% ofT2DM patients with systol ic blood pressure L 1 40 and prescribed 
any anti hypertensive drug 
% of T2DM patients prescribed a second anti hypertensive drug from a 
different class if systo l ic blood pressure remained � 1 40mm/Hg with 
1 st class anti hypertensive drug 
% ofT2DM patients incident for hypertension without a lbuminuria 
prescribed a th iazide as a first choice drug 
% of T2DM hypertensive patients without a lbuminuria treated with a 
multiple drug regime including a thiazide 
% ofT2DM non-hypertensive patients prescribed (ACE) inh ibitor or 
(ARB) if they have a lbuminuria 
% ofT2DM incident for hypertension patients with a lbuminuria 
prescribed ACE inh ibitor or ARB as a first choice d rugs 
% ofT2DM hypertensive patients with a lbuminuria prescribed a 
multiple drug regime including ACE inh ibitor or ARB 
% ofT2DM patients with a lbuminuria prescribed ARB prescribed ACE 
inh ibitor before ARB prescription 
% ofT2DM hypertensive patients receiving a drug regime including 
th iazides prescribed a th iazide in low dosage 
% ofT2DM hypertensive patients receiving a drug regime including 
th iazide and � -blocker prescribed a th iazide in low dosage 
% ofT2DM hypertensive patients prescribed 6 blockers in 
monotherapy 
Hyperglycaemia management 
% of preva lent T2DM patients with HbA 1 c >7% and prescribed any oral 
antihyperglycaemic agent or insul in 
% of prevalent T2DM patients not receiving insul in who a re prescribed 
a second oral anti hyperglycaemic drug from a different class if with 
one oral antihyperglycaemic drug HbA 1 c remained >7% 
% ofT2DM patients who are prescribed insul in if with combination of 
two oral d rugs HbA 1 c remained >7 % 
% of a l l  incident T2DM patients prescribed metformin as a first choice 
drug 
% of overweight incident T2DM patients prescribed metformin as a 
fi rst choice drug 
% of overweight preva lent T2DM patients receiving a multiple drug 
regime including metformin 
% ofT2DM patients with renal impairment, heart fa i lure, or impaired 
l iver function prescribed metformin 
% ofT2DM patients with impaired liver function or  h istory of heart 




u ndertreatment A 
u ndertreatment A 
fi rst choice d rug B 
drug choice B 
undertreatment A 
fi rst choice drug A 
drug choice A 




u ndertreatment B 
undertreatment B 
undertreatment B 
fi rst drug choice B 
fi rst choice drug A 
drug choice A 
safety B 
safety B 
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Definition of indicators 
Dyslipidaemia management 
% T2DM patients with high cardiovascular risk risk prescribed a 
statin 
% of T2DM patients over 40 years prescribed a statin 
% of T2DM patients aged L40 without history of cardiovascu lar 
disease but who have two or more cardiovascular risk factors 
rescribed a statin 
% of T2DM patients aged s40 with history of cardiovascu lar d isease 
prescribed a statin 
% ofT2DM patients with recorded hypercholesterolemia triglyceride 
>2.3 mmol/I and LDL <3.0 mmol/I prescribed a fibrate 
Antiplatelet therapy 
% ofT2DM patients with history of cardiovascu lar disease 
prescribed acetyl sal icyl ic acid* 
% ofT2DM patients without h istory of cardiovascu lar disease but 
with high cardiovascular risk and well-controlled hypertension 
prescribed acetyl sal icylic acid 
% ofT2DM patients with uncontrol led hypertension prescribed 
acetyl sal icyl ic acid 
Secondary prevention of CVD in T2DM 
% ofT2DM patients with hypertension and history of ischemic heart 
disease or myocardial infarction prescribed �-blocker 
% ofT2DM with diabetes and acute myocard ial infarction prescribed 
intensive insul in treatment 
% ofT2DM with diabetes and acute myocardial  infarction receiving 
thrombolytic therapy 
% of T2DM patients with coronary heart disease and present acute 
coronary symptoms prescribed combination of clopidogrel and 





























High risk includes T2DM women age> 60 years old and men > 50 years old or/and with duration of diabetes 
more than 1 0  years or/and with uncontrolled hypertension or/and with albuminuria or/and H bA 1 c > 7%; ACE 
angiotensin converting enzyme; ARB angiotensin receptor blocker 
Grade A: evidence coming from at least one meta-a nalysis of RCTs 
Grade B: evidence coming from prospective or case-control studies 
Grade C: evidence coming from expert opinion or descriptive studies 
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■ Chapter 2 Appendix 2 Operational definitions for calculation of prescribing quality indicators {PQI) for type 2 diabetes mel litus ambulatory care • All patients in our database were patients with diagnosis of type 2 diabetes mel litus • The international classification of primary care is used for coding of diagnosis1 • Medication is coded using Anatomical Therapeutic Chemica l Classification System2 PQI for hypertension management % ofT2DM patients with systolic blood pressure.:: 1 40 and prescribed any antihypertensive drug 
Inclusion criteria: 
Patients with average systolic blood pressure (SBP) 2: 1 40 in the period of 01 /01 /2004 -30/06/2004(first half of 
2004) 
Outcome: 
• yes ( 1 ) if el igible patients (who correspond to inclusion criteria) were prescribed the fol lowing 
antihypertensive (AH) grou ps: CO2 (miscel laneous AHD), and/or C03 (diu retics), and/or C07 (beta-blockers), 
and/or COB (ca lcium antagonists) and/or C09 (ACE inh ibitors and ATI I  antagonists) in the period of 
01 /07/2004 -31 /1 2/2004 (second ha lf of 2004) 
• no (0) if el igible patients are prescribed none of the mentioned medication groups in the mentioned time 
period 
% of T2DM patients prescribed a 2nd antihypertensive drug from a different class if SBP remained .:: 
1 40mm/Hg with 1 st class antihypertensive drug 
Inclusion criteria: 
Patients with prescription of one anti hypertensive drug and with 2 sequential SBP > 1 40 (time period between 2 
SBP measurements is up to 4 months) in 2004 
Outcome: 
• yes ( 1 ) if el igible patients (who correspond to inclusion criteria) were prescribed a second AH drug (i.e. 
added to fi rst AH drug) within 5 months (starting from the date of the 1 '1 SBP measurement) 
• no, (O) if el igible patients were not prescribed (added) a second AH drug with in  5 months (starting from the 
date of the fi rst SBP measurement) 
% ofT2DM patients without hypertension with albuminuria prescribed ACE inhibitor or ARB 
Inclusion criteria: 
Patients without hypertension (no ICPC codes K85, K86 or K87) a nd with a lbuminuria in 2004 
Outcome: 
• yes (1 ) if el igible patients (who correspond to inclusion criteria) were prescribed any medication from C09 
group (ACE inhibitors and ATI I  antagonists) in the second ha lf of 2004 
• no (0) if el igible patients were not prescribed any medication from CO9 group in the second half of 2004 
1 ICPC-2, lnterational classification of primary care, Second Edition, Oxford University Press, 1 998 
2 World Health Organization Collaborating Centre for Drug Statistics Methodology, 2007, available at http://www.whocc.no/atcddd/ 
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% ofT2DM incident for hypertension patients with albuminuria prescribed ACE inhibitor or ARB as a first 
choice drugs 
Inclusion criteria: 
Patients incident for hypertension (codes K85, K86 or K87 registered in 2004) 
Outcome: 
• yes ( 1 )  if first antihypertensive medication prescribed in eligible patients (who correspond to inclusion 
criteria) was a medication from CO9 group 
• no (0) if eligible patients were prescribed other antihypertensive medication 
% of T2DM prevalent for hypertension patients with albuminuria prescribed a multiple drug regimen 
containing ACE inhibitor or ARB 
Inclusion criteria: 
Patients with hypertension (SBP� 140 in the first half of 2004 or ICPC codes K85, K86 or K87) and with albuminuria 
in 2004 and prescribed more than 1 anti hypertensive medication in the second half of 2004 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed a drug regimen that 
included any medication from CO9 group in the second half of 2004 
• no (0) if eligible patients were not prescribed any medication from CO9 group in the second half of 2004 
% of T2DM patients with hypertension and history of ischemic heart disease or myocardial infarction 
prescribed �-blocker 
Inclusion criteria: 
Patients with hypertension (SBP� 140 in the first half of 2004 or ICPC codes K85, K86 or K87) and history of 
ischemic heart disease (codes K75 or K76) 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed a P-blocker in the second 
half of 2004 (any medication from CO7 group) 
• no (0) if eligible patients were not prescribed any medication from CO7 group in the second �alf of 2004 
PQI for hyperglycaemia management 
% of prevalent T2DM patients with HbA 1 c  >7 % and prescribed any oral antihyperglycaemic a gent or 
insulin 
Inclusion criteria: 
Patients with average HbA 1 c > 7% in the first half of 2004 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed any oral anti hyperglycaemic 
medication (group A 1 OB) or insulin (group A 1 0A) in the second half of 2004 






% of T2DM patients with prescription of one oral anti hyperglycaemic drug and not receiving insulin who 
are prescribed a 2nd second oral antihyperglycaemic drug from a different class if HbA 1 c remained > 7 .0% 
Inclusion criteria: 
Patients with prescription of one oral antihyperglycaemic drug and no insulin and with 2 sequential HbA 1 c >7% 
(period between 2 HbA 1 c measurements is up to 4 months) in 2004 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed a second (added) oral 
anti hyperglycaemic drug within 5 months (starting from the date of the pt HbA 1 c measurement) 
• no (0) if eligible patients were not prescribed (added) a second antihyperglycaemic drug within 5 months 
starting from the date of the first HbA 1 c measurement 
% of T2DM patients with 2 oral antihyperglycaemic drugs and not receiving insulin who are prescribed 
insulin if HbA 1 c remained > 7 .0 % 
Inclusion criteria: 
Patients with prescription of two oral antihyperglycaemic drugs and no insulin and with 2 sequential HbA 1 c >7% 
(period between 2 HbA 1 c measurements is up to 4 months) in 2004 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed (added) insulin within 5 
months (starting from the date of the 1st HbA 1 c measurement) 
• no (0) if eligible patients were not prescribed (added) insulin within 5 months starting from the date of the 
first HbA 1 c measurement 
% of overweight incident T2DM patients prescribed metformin as a first choice drug 
Inclusion criteria: 
Incident diabetic patients (duration of diabetes <1 year in 2004) and body mass index (BMI) � 25 in 2004 
Outcome: 
• yes (1) if the first drug prescribed to eligible patients (who correspond to inclusion criteria) was metformin 
(A10BA02) 
• no (0) if eligible patients were prescribed another antyhyperglycaemic medication 
% of overweight prevalent T2DM patients prescribed a multiple drug regime containing metformin 
Inclusion criteria: 
All T2DM patients (jn our case all patients are T2DM patients) with BMI � 25 in 2004 and prescribed more than 1 
anti hyperglycaemic agent in the second half of 2004 
Outcome: 
• yes (1) if eligible patients (who correspond to inclusion criteria) were prescribed a drug regimen containing 
metformin (A 1 0BA02) in the second half of 2004 
• no (0) if eligible patients were not prescribed metformin (A 1 0BA02) in the second half of 2004 
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PQI for dyslipidaemia management 
% T2DM patients with high cardiovascular risk who are prescribed a statin 
Inclusion criteria: 
Patients with high cardiovascu lar risk (women aged >60 years and men >50 years old, or duration of diabetes 
� 1 0  years, or average SBP� 1 40, or with a lbuminuria, or HbA 1 c �7%) 
Outcome: 
• yes (1 ) if el igible patients (who correspond to inclusion criteria) were prescribed a statin in the second half of 
2004 (any medication from C1 0AA group) 
• no (0) if eligible patients were not prescribed any medication from C1 0AA group in the second half of 2004 
% ofT2DM patients aged s40 with history of cardiovascular disease prescribed a statin 
Inclusion criteria: 
All T2DM patients younger than 40 years with history of cardiovascu lar  diseases caused by atherosclerosis (codes 
K74, K75, K76, K89, K90, K91 , K92) 
Outcome: 
• yes ( 1 )  if eligible patients (who correspond to inclusion criteria) were prescribed a statin in the second half of 
2004 (any medication from C1 0AA group) 
• no (0) if eligible patients were not prescribed any medication from C1 0AA group in the second half of 2004 
PQI for antiplatelet treatment 
% ofT2DM patients with history of cardiovascular disease prescribed acetyl salicylic acid 
Inclusion criteria: 
All T2DM patients with history of cardiovascular diseases caused by atherosclerosis (codes K74, K75, K76, K89, 
K90, K91 ,  K92) 
Outcome: 
• yes ( 1 ) if eligible patients (who correspond to inclusion criteria) were prescribed acetyl salicylic acid (B01 AC06 
or B01 AC06) in  the second half of 2004 
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Information on prescribing quality is increasingly used by policy makers, insurance companies 
and health care providers. For reliable assessment of prescribing quality it is important to correctly 
identify the patients eligible for recommended treatment. Often either diagnostic codes or clinical 
measurements are used to identify such patients. We compared these two approaches regarding the 
outcome of the prescribing quality assessment and their ability to identify treated and undertreated 
patients. 
Methods 
The approaches were compared using electronic health records for 3214 diabetes patients from 
70 general practitioners. We selected three existing prescribing quality indicators (PQI) assessing 
different aspects of treatment in patients with hypertension or who were overweight. We compared 
population level prescribing quality scores and proportions of identified patients using definitions 
of hypertension or being overweight based on diagnostic codes, clinical measurements or both. 
Results 
The prescribing quality score for prescribing any antihypertensive treatment was 93% (95% 
confidence interval 90-95%) using the diagnostic code-based approach, and 81 % (78-83%) using 
the measurement-based approach. Patients receiving antihypertensive treatment had a better 
registration of their diagnosis compared to hypertensive patients in whom such treatment was not 
initiated. Scores on the other two PQI were similar for the different approaches, ranging from 64 to 
66%. For all PQI, the clinical measurement -based approach identified higher proportions of both 
well treated and undertreated patients compared to the diagnostic code -based approach. 
Conclusions 
The use of clinical measurements is recommended when PQI are used to identify undertreated 
patients. Using diagnostic codes or clinical measurement values has little impact on the outcomes 
of proportion-based PQI when both numerator and denominator are equally affected. In situations 
when a diagnosis is better registered for treated than untreated patients, as we observed for 
hypertension, the diagnostic code-based approach results in overestimation of provided treatment. 
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BACKGROUND 
In the last decade, many prescribing quality indicators (POI) have been developed to measure 
whether the right drugs are prescribed to the right patients1 • They are being used for quality 
improvement initiatives, and to identify and reward providers who meet predefined standards of 
quality. For assessing prescribing quality, it is important to correctly identify the target population, 
i.e. patients with a specific condition who should receive a specific treatment . .  The validity of such 
identification depends not only on source of data but also on the type of information used to define 
a condition2• 
It has been recognized that the data source used can influence the outcome of the quality 
assessment. Administrative data, which are created mainly for billing purposes, often do not provide 
sufficient detail for reliable quality assessment3-5• Medical records provide a good alternative since 
they contain more detailed information although it can be difficult to extract all relevant information 
from this data source6• Aside from the data source, the operational definition of a condition may 
influence the outcome of the quality assessment. To identify the target population, i.e. patients 
in need of a specific treatment, either diagnostic codes or clinical measurements indicative of a 
disease or condition can be used. For example, to assess the quality of treatment in patients with 
hypertension, one can calculate the percentage of patients with the diagnosis of hypertension 
prescribed the recommended treatment7-1 0, or the percentage of patients with elevated blood 
pressure levels being prescribed the recommended treatment1 1 -14• 
These different approaches to define the target population give rise to several possible problems. 
Using information from recorded diagnoses can introduce bias due to incomplete registration 
when some patients with a condition do not have a corresponding diagnostic code registered in 
the data or due to incorrectly registered diagnostic codes1 5;16• Missing eligible patients is especially 
problematic for internal quality assessment, when health care providers use PQI as screening tools 
to identify patients who may benefit from the improved treatment. Using clinical measurements, 
on the other hand, may lead to missing patients with well-controlled disease states. In both cases, 
incorrect estimates of prescribing quality can occur when the accuracy of identification is not 
equal for treated and untreated patients. If this bias varies between providers, it can introduce 
misclassification on provider level and mislead pay-for-performance programs when better score 
on quality indicators is linked to financial incentives. 
Little is known about the impact of the chosen approach to define the target population on the 
assessment of prescribing quality. The objective of our study was to compare the approach based 
on diagnostic codes registered in electronic health records (EHR) to the approach based on clinical 
measurements registered in EHR addressing the following questions: 




2. What is the ability of the two approaches to identify well treated and undertreated 
patients? 
For this study, existing PQI were selected focusing on glucose lowering and antihypertensive 
treatment in patients with type 2 diabetes mellitus. This is a field where both internal and external 
quality assessment are becoming priority for health care systems, and knowledge about the impact 
of the chosen approach to define the target population is important for accurate and meaningful 
quality measurement. 
METHODS 
Study setting and sample 
In The Netherlands, patients are registered with a single general practitioner (GP) who has a 
gatekeeper role in coordinating their medical care. Almost all GPs used electronic health records. 
For our study, we used data from all T2DM patients registered with 70 GPs working in 37 practices 
in the North of the Netherlands. These GPs participate in the GIANTT project that collects 
routinely documented data, such as demographics, prescribed medication, diagnoses and clinical 
measurements, from the EHR of the patients. An approval to use the data for this study was obtained 
from the Steering Committee of the GIANTT project was obtained on April 7, 2006. 
Patients with T2DM were identified through screening of the electronic medical records of the GPs 
using text terms for diabetes (including diab*, dm, type 2, type 1 1), diagnostic codes for diabetes 
(ICPC-code T90.x)1 7, record flags for diabetes, and diabetes medication (ATC-code A 10)1 8• All 
identified patients were classified by a research assistant and verified by their GP as having type 2 
diabetes mellitus using the WHO classification of diabetes 1 9• In general, T2DM patients visit their GP 
every three months, and routine blood pressure measurements are usually conducted during these 
visits. 
Data collection 
An automatic data extraction method was used which was described previously, and is very sensitive 
(97-100%) in detecting relevant clinical measurement information, e.g. blood pressure and body 
mass index (BMI) values, irrespective of registration method or information system used by the GP20• 
The method relies on text recognition to ensure retrieval of information from 'free text' segments 
of the records in addition to data collection from structured tables, comparable to a manual chart 
review. Diagnoses are collected from the problem lists in the EHR where the GPs document medical 
problems pertaining to the patient using either the International Classification for Primary Care 
(ICPC)1 7  coding or text lines, which were manually recoded into the corresponding ICPC codes by 
two researchers verified by an experienced GP. All participating GPs prescribed electronically, which 
means that the dataset included full information regarding prescribed medication. 
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Prescribing quality indicators (PQI) 
We included POI that have been developed for assessing prescribing quality in T2DM patients. 
These POI were derived from evidence-based diabetes guidelines, and previously tested in expert 
panels9;io;21;22• For this study, we selected two POI focusing on the treatment of patients with 
hypertension and one POI focusing on glucose management in obese or overweight patients. 
Both hypertension and overweight can be defined using diagnostic codes or clinical measurement 
values, and the required information is commonly available in the EHR (table 1 ). These three POI 
represent different aspects of prescribing in different subgroups of T2DM patients. For the first 
indicator (POl-1 ), the clinical measurement is directly influenced by the recommended treatment 
which may result in missing patients with a wel l-controlled disease state when using clinical 
measurements. This is partly the case for POl-2, a lthough the recommended 13-blocker may not be 
the main treatment prescribed for lowering the blood pressure. For POl-3, there is no direct effect of 
the recommended treatment on the control of the condition. 
Table 1 .  Definitions of the POI according to the diagnostic code-based approach, the cl inica l  measurement-
based approach, and the reference method 
Diagnostic code-based Cl inical measurement-based Reference (hybrid) method 
PQl-1 Denominator:T2DM patients Denominator:T2DM patients Denominator: T2DM 
with diagnostic codes for with SBP�1 40 mmHg patients with diagnostic 
hypertension codes for of hypertension 
OR SBP� 1 40 mmHg 
Numerator: Denominator Numerator: Denominator Numerator: Denominator 
AND prescription of any AND prescription of any AND prescription of 
antihypertensive medication antihypertensive medication any anti hypertensive 
medication 
PQl-2 Denominator: T2DM patients Denominator:T2DM patients Denominator:T2DM 
with diagnostic codes for with SBP�1 40 mmHg AND patients with diagnostic 
hypertension and history of history of IHD or Ml codes for hypertension 
IHD or Ml OR SBP� 1 40 mmHg AND 
history of  IHD or M l  
Numerator: denominator AND Numerator: Denominator AND Numerator: Denominator 
prescription of beta blocker prescription of beta blocker AND prescription of beta 
blocker 
PQl-3 Denominator:T2DM patients Denominator: T2DM patients Denominator:T2DM 
with diagnostic codes for with BMl �25 patients with diagnostic 
overweight OR obesity codes for overweig ht OR  
obesity OR BMl�25 
Numerator: Denominator AND Numerator: denominator AND Numerator: denominator 
prescription of metformin prescription of metformin AND prescription of 
metformin 
T2DM: Type 2 Diabetes Mell itus, IHD: lschaemic Heart Disease, Ml: myocardial infarction, SBP: Systolic Blood 




All the analyses were conducted using data from the EHR. The PQI were calculated using prescribing 
information from the second half of 2004. All preceding diagnosis information regarding 
hypertension (ICPC-codes K85, K86 and K87) and overweight or obesity (ICPC-codes T82 and T83) 
was used for the diagnostic code-based approach. For the clinical measurement-based approach, 
an average systolic blood pressure (SBP) of � 140 mmHg during the first half of 2004 was used to 
define hypertensive patients, and the most recent BMI value in 2004 being �25 was used to define 
overweight patients. We used an average SBP� 140mmHg as a cut off value to identify patients with 
hypertension following the recommendations for treatment of T2DM patients with hypertension 
described in the Dutch Hypertension Guidelines for General Practitioners23 • 
■ To check whether the inclusion of patients with an 'average' of only one elevated SBP value in the 
study period might be unjustified, we assessed how many of such patients had no preceding or next 
SBP values �140mm/Hg. This was the case for only 2% of the patients with elevated average SBP 
levels in the first half of 2004. 
To select T2DM patients with history of ischemic heart disease or myocardial infarction (PQl-2) we 
have used ICPC codes K74, K76, and K75. All analyses were conducted using SPSS version 16.0 (SPSS, 
Inc., Chicago, I l linois). 
To answer our first question, we calculated the PQI scores with 95% confidence intervals using only 
diagnostic codes or only clinical measurement values. The unit of analysis for calculation of the PQI 
scores was an individual patient, therefore the prescribing quality scores discussed in this paper are 
population level scores. We used mixed model analysis to adjust the scores of PQI and their 95% 
confidence intervals for correlation within GP practices. For our second question, we calculated 
the ability of each approach to identify 'well treated' patients (patients receiving the treatment as 
recommended), and 'undertreated' patients (patients in need of treatment but not receiving the 
recommended treatment). This was expressed as the proportion of 'wel l treated' (respectively 
'undertreated') patients identified with either approach from the total number of 'well treated' 
(respectively 'undertreated') patients identified with the reference method, where we combined 
diagnostic codes with clinical measurement values (boxl ). 
Finally, we repeated the analyses in a subset of patients that had at least one registered blood 
pressure or BMI value during the study period to assess the impact of incomplete registration of 
clinical measurements on the comparison of the two approaches. 
42 
Methods to identify the target population 
RESULTS 
The dataset included 3214 T2DM primary care patients with an average age of 67 years and diabetes 
duration of 6 years; 55% were women (Table 2). Of the patients, 32% had a registered diagnosis of 
hypertension, and 7% had a diagnosis of overweight. Blood pressure measurements were available 
for 80% of the patients, and BMI measurements for 66% of patients. Among patients with registered 
measurements, 55% had an average systolic blood pressure � 140mmHg, and 55% had a BMl�25. 
Table 2 Characteristics of the study population (N=3214) 
Characteristic 
Age, mean in years (SD) 
Women, n {%) 
Duration of diabetes, mean in years (SD) 
Registered diagnosis of hypertension, n (%) 
Registered diagnosis of overweight or obesity, n (%) 
Registered diagnosis of IHD or Ml, n (%) 
Registered systolic blood pressure, n (%) 
Registered Body Mass Index, n (%) 
Systolic blood pressure �140 mmHg, n (%) 
Body Mass Index �25, n (%) 
IHD: lschaemic heart disease 









2106 (65.5 ) 
1 749 (54.4) 
1 767 (55.0) 
Concurrence between registration of diagnostic codes and the corresponding clinical measurements 
was low. Among patients with an elevated systolic blood pressure, 62% (1086) did not have a 
registered diagnostic code for hypertension. In case of overweight, 92% (1624) of patients with BMI 
�25 did not have a registration of a corresponding diagnostic code (table 3). 
Scores of PQI 
The choice of approach affected the outcome of only PQl-1 focusing in prescription of any 
anti hypertensive treatment. For this POI the diagnostic code-based approach resulted in 12% higher 
prescribing quality score than measurement-based approach. For the remaining two indicators, the 
prescribing scores observed with different approaches were nearly identical (table 4). 
Ability of identifying well treated and undertreated patients 
The use of either diagnostic codes or clinical measurements to identify well treated or undertreated 
patients resulted in absolute differences in proportions of identified patients ranging from 15% 









SBP�1 40 663 1 086 1 749 
SBP< 1 40 1 90 627 81 7 
No SPB 1 3 1  5 1 7 648 
Tota l  984 2230 321 4 
BMl�25 1 43 1 624 1 767 
BMl<25 5 334 339 
No BMI 65 1 043 1 1 08 
Total 2 1 3  300 1 321 4 
SBP: Systolic Blood Pressure 
BMI: Body Mass I ndex (weight in ki log rams d ivided by height in meters-squared) 
Table 4 Scores of prescribing quality indicators identified with different approaches 
Prescribing qua lity ind icators (PQI) Outcome of the PQI, %, (95% Cl) numerator/denominator 
PQl-1 Prescription of any 
antihypertensive medication in 
hypertensive T2DM patients 
PQl-2 Prescription of beta blocker 
in hypertensive T2DM patients with a 
history of IHD or Ml 
PQl-3 Prescription of metformin in 
overweight T2DM patients 
T2DM: Type 2 Diabetes mell itus 
IHD: lschaemic Hea rt Disease 
Ml: Myoca rd ial I nfarction 
Diagnostic code-based 
93(90-95) 
14 1 2/1 749 
65(57-72) 
1 00/1 55 
65(59-72) 





1 25/1 94 
66(62-69) 
1 1 54/1 767 
undertreated patients than the diagnostic code-based approach. For well treated patients, the 
proportion identified raised from 54% (diagnostic code-based) to 84% (measurement-based) for 
anti hypertensive treatment in general (PQl-1 ), from 63% to 79% for beta blocker treatment after 
ischemic heart diseases (PQl-2), and from 12% to 97% for metformin treatment in overweight 
patients (PQl-3). Similarly, the proportion of undertreated patients identified increased from 21 % 
(diagnostic code-based) to 88% (measurement-based) for PQl-1, from 60% to 75% for PQl-2, and 
from 11 % to 95% for PQl-3 when clinical measurements were used (table 5). 
Using the diagnostic code-based approach, a clear difference was observed in its ability to identify 
well treated versus undertreated patients for anti hypertensive treatment in general (PQI-1 ). This 
approach identified 54% of the well treated but only 21 % of the undertreated patients, indicating 
that the registration of a hypertension diagnosis in the EHR is more likely when drug treatment is 
initiated than when drug treatment is not (yet) initiated. Such bias was not observed for the other 
two PQI (table 5). 
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Table 5 Identification of well treated and undertreated patients using the diagnostic code-based and clinical 
measurement-based approach 
Well treated patients Undertreated patients 




PQl-1 Prescription of any anti hypertensive medication in hypertensive T2DM 
patients 
Reference method 1687 
Diagnostic code-
based, 54 (905/1687) 905 21 (79/383) 
hypertension 
Measurement-






PQl-2 Prescription of beta blocker in hypertensive T2DM patients with a history of 
IHD or Ml 
Reference method 159 92 
Diagnostic code-
based, 63 (100/159) 100 60 (55/92) 55 
hypertension 
Measurement-
based, 79 (125/159) 125 75 (69/92) 69 
SBP�140 
PQl-3 Prescription of metformin in overweight T2DM patients 
Reference 1193 644 
Diagnostic code-
based, 
12 (139/1193) 139 
11 
74 
overweight or (74/644) 
obesity 
Measurement-
based, 97 (1154/1193) 1154 95 (613/644) 613 
BMl�25 
T2DM: Type 2 Diabetes mellitus 
SBP: Systolic Blood Pressure 
BMI: Body Mass Index (weight in kilograms divided by height in meters-squared) 
N 





*Number of treated patients detected through the tested approach divided by the number of treated patients 
according to the reference method 
**Number of untreated patients detected through the tested approach divided by the number of untreated 
patients according to the reference method 
Subset analysis 
We repeated the analyses in subsets of patients that had at least one recorded blood pressure 
measurement for PQl-1 (1939 of the 2070 hypertensive patients) and PQl-2 (227 of the 251 
hypertensive patients with IHD or Ml), and at least one BMI value for PQl-3 (1772 of the 1837 
overweight patients). The POI scores for the subset were quite similar to scores observed for 





calculated for the subsets changed from 81% to 82% for PQl-1, from 63% to 64% for PQl-2, and 
remained 65% for PQl-3. For the diagnostic code-based approach, observed changes were 92% 
to 94% (PQl-1 ), 65% to 66% (PQl-2), 65% to 70% (PQl-3). As could be expected, the proportion of 
identified well treated and undertreated patients with the measurement-based approach increased 
for this subset of patients, and approached the reference method with proportions of 89%, 86%, 
100% for well treated and 95%, 85%, 100% for undertreated patients. 
DISCUSSION 
Our study showed that prescribing quality scores do not necessarily change when using different 
approaches to define the number of patients eligible for treatment. However, when diagnosis is 
registered better for treated than for untreated patients, as was the case for hypertension, the 
diagnostic code-based approach resulted in overestimating the prescribing quality (93 versus 81%). 
In addition, it became clear that incomplete registration of diagnostic codes is a big problem for 
conditions such as hypertension and overweight, leading to the identification of low proportions of 
patients in need of treatment (11-60%) when using a diagnostic code-based approach. 
In general, PQI are proportion-based measures which can be quite robust to changes in the 
numerator, as any change in the numerator causes changes in the denominator24• This was the 
case for the indicators focusing on the prescription of beta blockers and of metformin in specific 
patient groups (PQl-2 and PQl-3). However, for the indicator focusing on the prescription of any 
anti hypertensive drug (PQl-1 ), the diagnostic code-based approach resulted in a higher score on 
prescribing quality compared to the clinical measurements-based and reference methods. The 
explanation of this finding is that the registration of the diagnostic codes for hypertension is more 
likely once antihypertensive treatment is prescribed, as was illustrated by the low percentage of 
untreated in comparison to treated hypertensive patients identified with the diagnostic code-based 
approach. A similar finding was observed in non-diabetic population, where treated patients also 
had a better registration of the diagnosis of hypertension25• 
In our study population, the clinical measurement-based approach identified higher proportion 
of patients who are in need of treatment compared to the diagnostic code-based approach. This 
is due to the fact that many patients with either high blood pressure or BMI levels did not have 
a registration of the corresponding diagnostic code in the EHR. Poor registration of conditions 
such as hypertension and especially overweight in the EHR seems to be a common problem26•28• 
It has therefore been advocated to use clinical measurements to improve documentation of such 
conditions29• Improved registration of diagnostic codes as a part of quality improvement programs 
may make diagnostic code-based PQI more reliable. It is important to realize, however, that the 
validity of registered diagnoses is influenced by many factors including the purpose of registration, 
skills and knowledge of the coder, insensitive coding schemes for registering specific diseases, 
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prioritizing the coding of some conditions over others by physicians, and completeness of a disease 
classification system is;3o_ 
Clinical measurement values appear to be a better choice for prescribing quality assessment, 
especially for internal quality assurance, when it is crucial to correctly identify as many patients who 
could benefit from the improved treatment. When the clinical measurement values are influenced 
by the recommended treatment, as is the case for PQl-1 and PQl-2, a clinical measurement-based 
approach for assessing the treatment may result in missing patients with well-controlled disease 
states. This is particularly a problem when patient eligibility and prescribed treatment are assessed 
cross-sectionally14• When prescribing is assessed in a sequential way (i.e. after the observed clinical 
measurement), as was done in our study, missing well-controlled patients appeared not to affect 
the quality scores. In situations where there are already much higher percentages of well-controlled 
patients, however, a measurement-based approach can result in lower prescribing quality scores in 
comparison to a diagnostic code-based approach. 
In our study we used cut off levels of SBP �140mmHg to identify patients with hypertension as 
advised by Dutch hypertension guidelines. However, World Health Organization (WHO) and 
International Society of Hypertension (ISH) advised to use lower cut off levels of SBP to diagnose 
hypertension in T2DM patients31 • Use of lower values of SBP to identify hypertensive patients may 
result in larger differences between the PQI scores when the different approaches are used. 
We used a sensitive method for data abstraction from medical records. Registration of diagnostic 
codes was complemented by recoding diagnoses from text lines. Our reference method was based 
on a combination of available information about diagnosis and measurements documented in the 
EHR. Although EHR are often considered the gold standard for quality measurement, inadequate 
registration of both diagnoses and clinical measurements affects this reference method. Our subset 
analysis, however, showed that the prescribing quality scores were not affected by incomplete 
registration of clinical measurements. The PQI scores and proportions of identified patients may 
not be generalizable to other databases with different registration rates of clinical measurements 
or diagnostic codes but the identified problems are likely to occur in other settings. The registration 
rates in our dataset were similar to those described in other studies conducted in different parts of 
the world using EHR of both diabetic and general primary care population2s;32;33_ 
Finally, it has to be kept in mind that if these PQI are used for comparison of individual GPs, the 
number of eligible patients per PQI per GP may not be sufficient for reliable benchmarking. To 
address the problem of a small sample size per PQI, one could choose from several existing methods 
including pooling data from several health care providers or time periods or excluding indicators or 




Although in our study setting the ICPC codes were used, we expect that the results of our study are 
also relevant for health care systems using the International Classification of Diseases (ICD), as this 
classification system also includes diagnostic codes for hypertension, overweight and obesity that 
could be combined or substituted with clinical measurement values. 
CONCLUSION 
To our knowledge, this is the first study addressing the impact of using different types of information 
to define a condition on the assessment of prescribing quality. With the increasing use of electronic 
health records, which offer more complete information than administrative data, EHR have the 
potential to provide sensitive estimates of healthcare quality. Our study shows some drawbacks of 
using either diagnostic codes or clinical measurement values from the EHR for prescribing quality 
assessment. Although both approaches resulted in missing patients who could benefit from the 
recommended treatment, the use of clinical measurements is more sensitive to screen for poorly 
treated patients. This is important for quality improvement purposes. When there is information bias 
in the documentation of diagnoses in relation to the treatment status, the use of diagnostic codes 
alone can mislead both policy makers and health care providers about the performance scores 
of quality indicators. In such cases, a combination of diagnostic codes and clinical measurement 
information is recommended for prescribing quality assessment. 
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Valid prescribing indicators (Pl) are needed for reliable assessment of prescribing quality. The 
purpose of this study is to describe the validity of existing Pl for type 2 diabetes mellitus and 
cardiovascular risk management. 
Methods 
We conducted a systematic literature search for studies describing the development and assessment 
of relevant Pis between January 1990 and January 2009. We grouped identified Pl as drug- or 
disease-oriented, and according to the aspects of prescribing addressed and the additional clinical 
information included. We reviewed the clinimetric characteristics of the different types of Pl. 
Results 
We identified 59 documents describing the clinimetrics of 16 types of Pl covering relevant prescribing 
aspects, including first-choice treatment, safety issues, dosing, costs, sufficient and timely treatment. 
We identified three types of drug-oriented, and five types of disease-oriented Pl with proven face 
and content validity as well as operational feasibility in different settings. Pl focusing on treatment 
modifications were the only indicators that showed concurrent validity. Several solutions were 
proposed for dealing with case-mix and sample size problems, but their actual effect on Pl scores 
was insufficiently assessed. Predictive validity of individual Pl is not yet known. 
Conclusion 
We identified a range of existing Pl that are valid for internal quality assessment as they are evidence­
based, accepted by professionals, and reliable. For external use, problems of patient case-mix and 
sample size per Pl should be better addressed. Further research is needed for selecting indicators 
that predict clinical outcomes. 52 
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INTRODUCTION 
Appropriate drug prescribing has been recognized as an important quality of care issue in the 
management of chronic conditions. Insight into the quality of prescribing is demanded by health 
care providers, payers, and the public. Such information is used for internal quality improvement 
through audit, feedback, and benchmarking in educational contexts. 1-3 External stakeholders use 
prescribing information for comparison of health care providers, and to implement performance­
based reimbursement programs that reward health care providers for meeting preset targets.4•5 
To measure quality of prescribing, prescribing indicators (Pl) have been developed. Distinct types 
of Pl exist that address different aspects of prescribing quality, such as recommended drug­
choice, ineffective drugs or timely treatment.6 There are drug-oriented Pl which focus on the drugs 
prescribed irrespective of the indication, and disease-oriented Pl looking at the prescriptions in 
relation to a specific condition.7 Furthermore, there are indicators that link prescribing to clinical 
outcomes.8•9 
Although there are no consensus-based criteria for the development of quality measures, they 
are expected to reflect the best available evidence, to be relevant, and to be accepted by the 
professionals in the field. 1 0•1 1  Effective use of Pl requires understanding of what aspect of prescribing 
is measured, how the indicators were developed, and whether their clinimetric characteristics, e.g. 
validity and reliability, were assessed.1 1  The requirements regarding these characteristics might 
depend on the aim of the indicator. For internal purposes, Pl need to be relevant for healthcare 
providers: they have to be specific and sufficiently detailed to show potential problems and capture 
pertinent changes in prescribing. However, to make fair comparisons between health care providers 
for external use, e.g. by third party payers, there are additional requirements, like adjustment for 
patient case-mixes and having adequate number of patients per provider.1 2• 1 3 
A large number of Pl have been developed in recent years for chronic conditions, such as type 2 
diabetes mellitus (T2DM) and cardiovascular risk management. These conditions where one of 
the first for which disease management programs, as well as quality assurance programs were 
developed. We have focused on these conditions as they are closely related. While the prevalence 
of T2DM and cardiovascular diseases is dramatically increasing, appropriate pharmacological 
treatment of risk factors can prevent complications in both diabetic and non-diabetic populations. 
For reliable measurement of prescribing quality valid indicators are needed. In spite of a large 
number of existing Pl forT2DM and cardiovascular risk management, no information is available on 
their validity. The purpose of this study is to identify the various types of existing Pl, and describe 
their clinimetric evaluation. The results of this study will help health care providers and policy 
makers to choose the most appropriate Pl for quality assessment by pointing out their clinimetric 
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values as well as possible limitations. 
METHODS 
Search and selection strategy 
We performed a systematic search in MEDLINE and EMBASE databases without language restrictions 
from January 1 990 to January 2009 for studies focusing on the development or assessment of quality 
indicators including Pl related to T2DM or CV risk management (Appendix 1). In addition, we hand 
searched the WebPages of professional organizations that have sets of quality indicators in English 
speaking countries and the Netherlands. Pl was defined as a measurable element of prescribing that 
can be used to assess quality or efficiency of treatment at drug, patient or provider level. 
Two reviewers independently screened the titles and abstracts of 5,121 retrieved manuscripts and 
excluded papers not focusing on T2DM or CV risk management. Using full copies of the papers, we 
excluded reviews, letters, commentaries, studies that did not include any Pl and studies that merely 
used indicators to assess prescribing quality without assessment of clinimetrics. 
Classification of papers and indicators 
All selected papers were independently reviewed and classified by two researchers in a two-stage 
process, focusing first on classification of studies, and secondly, on classification of the Pl identified 
from the studies. Disagreement between reviewers was resolved through discussion. 
On study level, we recorded whether and how clinimetric properties, i.e. face, content, concurrent, 
and predictive validity, operational feasibility, reliability, robustness to case-mix, and minimal 
sample size needed, were assessed (Table 1 ). Furthermore, we recorded the aim and intended 
setting for the indicators. We classified the identified indicators as drug- or disease-oriented. We 
further grouped indicators according to the different aspects of prescribing addressed, and the type 
of clinical information included. As it has been argued that sequential assessment of prescribing 
in reaction to a clinical event or outcome would provide more meaningful indicators than simple 
cross-sectional assessment of the prescribed treatment,8 we also divided the indicators regarding 
this aspect. In case of similar indicators, differing slightly in the way of formulation, we provided a 
general description of the indicator with some typical examples. At this generic indicator level, we 
reported the studies that have included such an indicator, as well as the outcomes regarding validity, 
reliability, and operational feasibility. Results on these clinimetrics were classified as 'positive' when 
all referenced studies reported the clinimetric to be present, 'negative' when the clinimetric was 
shown to be absent, and 'doubtful' if mixed or inconclusive results were reported. 
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Table 1. Definitions of clinimetric characteristics 
Definitions of Clinimetric Characteristics 
Content va l idity 
Face val id ity 
Concurrent va l idity 
Predictive va l idity 
Operational feasibi l ity 
Reliabil ity 
Case-mix adjustment 
Minimal sample size 
Pl are based on literature review or evidence-based cl in ical guidelines 
P l  a re assessed and accepted by a group of experts or  professionals in the 
field 
P l  correspond to a gold standard or other measures 
Pl have the capacity for predicting patient ( intermediate) outcomes 
Feasibi l ity of calculation of Pl is demonstrated or defended in the view of 
avai lable data 
Pl yield the same outcome when measured by different persons or at 
d ifferent times 
Patient-related attributes a re controlled, minimized or  checked to make 
measurement of prescribing qual ity as comparable as possible across 
providers or organizations seeing d ifferent mixes of patients 
Min imal sample size per Pl required for prescribing qual ity assessment is 
provided or solution to dea l  with smal l  numbers is offered 





Indicators a re meant for use by health care providers for qual ity 
improvement, educational  purposes and internal audit 
I ndicators are meant for use by policy makers for pay for performance, 
public reporting, or comparison across states or against national averages 
Ind icators can be used for both internal and external qual ity assessment 
Aim is not mentioned by the authors 
Intended setting 





To assess qual ity of prescribing in hospital setting 
To assess qual ity of prescribing in  hospital and ambulatory care 
We identified 46 studies published in peer-reviewed journals. By screening the references of 
these papers, we identified six additional published studies. From the WebPages of professional 
organizations, we found seven relevant documents that had not been formally published. Our 
final cohort thus included 59 papers focusing on the assessment of Pl related to T2DM or CV risk 
management (Table 2). 
Many studies described sets of quality indicators including not only Pl but also indicators focusing on 
other aspects of care, e.g. screening, referral, etc. In some sets, Pl were underrepresented,4•5•1 4  while 
others consisted of only Pl.3• 1 2•1 5-22 In general, the assessment of various clinimetric characteristics 
of some indicator sets, e.g. ACOVE indicators, were described in several studies,23-25 including 
adaptation of these indicators in different countries.26•27 For sets of indicators that were updated 
several times, e.g. Beers'criteria and ACOVE indicators, we have included the latest version.25•28 
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The development of indicators was described in 37 studies, which always included assessment 
of face and/or content validity. The other studies focused on the assessment of clinimetrics of 
previously developed Pl .  
Clinimetrics addressed and methods used in the studies (Table 2) 
Contentvaliditywas addressed in 37 studies.The most common approach to ascertain contentvalidity 
of the Pl was using recommendations from clinical guidelines. In two cases, authors first assessed 
the quality of available guidelines, and used the highest ranking guidelines to propose indicators.29•30 
In six studies, authors reviewed randomized controlled trials to propose indicators.2•28•31 •34 In three 
studies a literature review was conducted to identify potential indicators.26•35•36 
Face validity was addressed in 36 studies and assessed using different techniques including 
modified Delphi,2•10•20•25-28•31 •32•35-46 nominal group,47A8 focus group discussion, 1A9 surveys or panels 
of professionals,1 •1 0•1 9•29•30•50-53 continuous assessment of indicators using panels of various 
stakeholders,4•5•1 2•54 or iterative process.55 
Concurrent validity was assessed in four studies by comparing different data sources,24 different Pl ,8•68 
and different data collection methods.57 Medical records provided more detailed clinical information 
for quality assessment than administrative data, although scores for individual indicators did not 
change across sources.24 However, frequent misclassifications occurred when using automated 
measurement in electronic health records (EHR) in comparison to manual medical record review, 
because the automated method missed diagnosis or contraindications information registered in 
free-text notes.57 Sequential quality indicators provided more accurate estimates of quality of care 
compared to cross-sectional measures.B.68 
Predictive validity of Pl was assessed in six studies, all using composite indicator scores. In five 
studies the association between process of care and outcomes was assessed cross-sectionally. Only 
one study assessed the link between quality of care and survival of patients using a prospective 
design.23 Three studies used a composite score based on Pl,22•65•67 while others also included other 
process indicators. Some concluded that higher scores were associated with better controlled risk 
factor levels31 •67 or better survival,23 while others found at most weak associations.14•22•65 
Operational feasibility was the most frequently assessed characteristic (40 studies), using theoretical, 
implicit and explicit approaches. In case of theoretical assessment, Pl requiring information not 
available in existing databases were excluded during development.4•10•1 2•1 6•1 9A5•53•55 1ndicators that were 
explicitly tested for operational feasibility were applied to specific types of datasets or settings, e.g. 
administrative data, EHR or primary care and hospital settings.9•17•20•21A9.so.s2,56•58•60 Implicit assessment 
of operational feasibility occurred in all other studies when Pl were calculated during assessment of 
56 
1.11 ..... 
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ldanpaan-Heikkila e.a.35 To develop a set of quality indicators for cardiac care Fin E both + + + 
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To create a monitoring system for a range of measures of clinical 0 
Jencks e.a.66 performance that supports quality improvement us E both + + i:l 
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To explore the feasibility of using administrative data to develop Q 
ii;' Katz e.a.49 process indicators for measuring quality in primary care Can I amb + + + + + Cl. 
To determine the relative accuracy of quality assessment in diabetes 
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'<' using simple intermediate outcome versus tightly l inked quality "ti 
Kerr e.a.8 measures us N/A amb + + II) "" 
To develop a set of Canadian clinical indicators of preventable drug-
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MacKinnon e.a.40 related and care-related morbidity for type 2 diabetes Can I amb + + + 0" II) 
To rigorously develop and validate a set of quality indicators for type � 
Majumdar e.a.41 2 diabetes mellitus for researchers or decision-makers Can both amb + + + 3:: II) 
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To develop a set of prescribing quality indicators for pharmacological 
management in type 2 diabetes mellitus patients for internal use, Q ::i 
Martirosyan e.a.20 and to assess their operational validity NL I amb + + + + Cl. 
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To suggest performance indicators that could monitor use of .. 
McCol l  e.a.1 99834 important primary care interventions UK E amb + + 
ti 
To test the feasibility of deriving comparative indicators in al l "' I"\ 
McColl e.a.200059 practices within a primary care group UK E amb + s:: 
Q .. 
To evaluate the degree to which hospital process performance 
iii" ratings and eligibility for financial incentives are altered after � 
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Author(s) Objective of the study or organization \Q 
:i' 
To define and validate a battery of prescription indicators on the use e: 
of anti-hypertensives, l ipid-lowers, diabetes drugs and insulin, as 8 
Torrecilla-Rojas e.a.67 measurements of family doctors' quality of prescription Spain I amb + + + + 0 i:l 
� 
To develop an updated set of indicators to measure and improve Q 
Tu e.a.45 quality of care for patients with acute myocardial infarction Can both hosp + + + + � 
Q,, 
To adapt a set of systematically developed US quality indicators for 0 
Van der Ploeg e.a.27 health care of vulnerable elders in the Netherlands NL I amb + + + � ,:; 
n) 
To compare cross-sectional and sequential quality indicators for risk 
"" 
0 
Voorham e.a.68 factor management in patients with type 2 diabetes NL both amb + + a· 
0-
n) 
To update and increase the comprehensiveness of the Assessing Care � "' 
Wenger e.a. 25 of Vulnerable Elders (ACOVE) set of process-of-care quality indicators us I both + + + + + 3:: 
n) 
To search for potential evidence-based indicators within diabetes- ::; 
care guidelines and convert them into a manageable tool for "' 
Wens e.a.30 assessing quality of diabetes care at the primary health-care level Be I amb + + + Cl 
Q,, 
To determine whether qual ity measured with the process measures � 
used in Hospital Compare are correlated with and predictive of ... 
Werner e.a. 65 hospitals' risk-adjusted mortality rates us both hosp + + + + � 
i§ 
To investigate reactions to the use of evidence-based cardiovascular "' I"\ 
Wilkinson e.a.60 and stroke performance indicators within one primary care group UK I amb + C: Q ... 
studies published in peer-reviewed Journals identified through additional search ::i:, 
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O b j e c t i v e  o f  t h e  s t u d y  o r  o r g a n i z a t i o n  
T o  e x a m i n e  t h e  r e l a t i o n s h i p  b e t w e e n  p a t i e n t s '  c h a r a c t e r i s t i c s  a n d  
s e v e r a l  d o m a i n s  o f  q u a l i t y  o f  c a r e  u s  
N / A  
To  e x a m i n e  t h e  l i n k  b e t w e e n  q u a l i t y  o f  c a r e  t h a t  p a t i e n t s  r e c e i v e d  
a n d  t h e i r  s u r v i v a l  
u s  I  
To  c o m p a r e  m e a s u r e m e n t s  o f  q u a l i t y  b e t w e e n  m e d i c a l  r e c o r d s  a n d  
a d m i n i s t r a t i v e  d a t a  u s i n g  t h e  A s s e s s i n g  C a r e  o f  V u l n e r a b l e  A d u l t s  
( A C O V E )  q u a l i t y  i n d i c a t o r  s e t  
u s  b o t h  
To  b e t t e r  u n d e r s t a n d  t h e  p o t e n t i a l  u t i l i t y  a n d  t h e  f e a s i b i l i t y  o f  
m e a s u r i n g  t h e r a p y  m o d i fi c a t i o n s  i n  r e s p o n s e  t o  p o o r  r i s k  f a c t o r  
c o n t r o l  a s  a n  a d d i t i o n a l  m e a s u r e  o f  q u a l i t y  u s  N / A  
T o  a d a p t  a  s e t  o f  U S A  q u a l i t y  i n d i c a t o r s  t o  m e a s u r e  q u a l i t y  o f  c a r e  o f  
o l d e r  a d u l t s  fo r  u s e  i n  p a t i e n t  s u r v e y s  i n  E n g l a n d  U K  I  
p a p e r s  fo u n d  o n  w e b p a g e s  o f  p r o f e s s i o n a l  o r g a n i z a t i o n s  
To  i m p r o v e  A u s t r a l i a n  h e a l t h  o u t c o m e s  t h r o u g h  t h e  q u a l i t y  u s e  o f  
m e d i c i n e s  A u s t  I  
To  d e v e l o p  q u a l i t y  i n d i c a t o r s  o n  e ffi c a c y  a n d  s a f e t y  o f  d i a b e t e s  c a r e  
fo r  e x t e r n a l  u s e  N L  
E  
To  r e l i a b l y  c o m p a r e  t h e  p e r fo r m a n c e  o f  h e a l t h  p l a n s  u s  E  
To  p r o d u c e  a n d  r e v i e w  s e t s  o f  p r e s c r i b i n g  i n d i c a t o r s  i s s u e d  b y  t h e  
D e p a r t m e n t  o f  H e a l t h  i n  t h e  U K  U K  b o t h  
To  i m p r o v e  q u a l i t y  o f  c a r e  t h r o u g h  a  i n c e n t i v e  s c h e m e  r e w a r d i n g  G P  
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w 
To improve the quality of American healthcare by setting national 
NQF 5-4 priorities and goals for performance improvement us both amb + + + + + 
To develop and test the Quality AssessmentTools system, a 
comprehensive, clinically based system for assessing quality of care 
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Total number of times the clinimetric characteristics was assessed in a l l  included studies 
37 36 37 4 6 1 3  40 
*Aust-Australia, Be-Belgium, Can-Canada, Germ-Germany, Fin-Finland, NZ-New Zeeland, NL-the Netherlands, UK-United Kingdom, US -United States of America 
**Indicators intended for: !=internal quality assessment; E=external quality assessment; N/A= aim was not explicitly mentioned; both= internal and external quality assessment 
***Indicators intended for amb=ambulatory care, hosp=hospital care, both=both ambulatory and hospital setting 
****New indicator(s) were developed as part of the study or project 
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other clinimetric characteristics, e.g. reliability or concurrent validity.3•8•14• 1 5•22-24-3 1 ,34•37A3,5 1 ,57,61 -68 
The inter-rater reliability was evaluated in studies using manual chart review by means of kappa 
statistics. In all cases, good reliability was shown for manual data abstraction.19•21 -24,37A9,s , ,57 In some 
cases reliability was assessed theoretically during the indicator development process.4•17•53•54 
Case-mix problems were addressed in nine studies, of which seven included indicators with external 
aim (Table 2). This issue was not addressed in other studies with a clearly mentioned external 
aim. 14• 1 6•22•34•50•57•59•62 Two studies showed the influence of case-mix on performance scores.37•61 
Several approaches were proposed to minimize the effect of patient clinical or sociodemographic 
characteristics on Pl outcomes, including statistical adjustment,4•37 exclusion of indicators that are too 
much affected by such characteristics,53•55 or exclusion of patients for reasons like contraindications, 
perceived side-effects or refusing medication.5•25 Another approach to deal with case-mix was 
setting lower target levels.70 
Sample size was addressed in 13 studies. Two studies showed that sample size can affect 
performance scores and hinder comparisons between individual providers.61•62 Suggested solutions 
were exclusion of indicators or providers with small numbers,51 •55•62•65 use of hierarchical estimates,62 
or pooling data from several providers or time periods. 1 The minimal sample size suggested per 
indicator ranged from 5-1049 to 30-60 patients.1 Others suggested to include only providers with 
a certain number of patients,3•25•52 but did not support this with calculations. A paper related to 
measures proposed by the National Quality Forum69 provided guidelines for sample size calculations. 
It was shown that the minimal number of patients to get a reliability of 0.8 depends on the intraclass 
correlation coefficient (ICC), and could range from 36 for an ICC of 0.10 to 196 for an ICC of 0.02. 
Types of Pl and their reported clinimetrics 
We identified in total 16types of Pl, including seven drug-oriented and nine types of disease-oriented 
Pl. The same types of indicators were proposed for internal and external quality assessment. Pl for 
T2DM were typically developed for ambulatory care, whereas Pl for cardiac care and more general 
Pl were also developed for hospital care. 
Drug-oriented Pl 
The drug-oriented Pl were grouped on different aspects of prescribing: first choice drug (classes), 
second-step drugs, non-preferred drugs, safety issues, dosing issues, redundant prescribing, and 
cost-conscious prescribing (Table 3). For almost all types, several generic indicators were identified, 
and five of them were tested in several studies. Indicators focusing on prescribing of first-choice or 
non-preferred drugs were both wel l-studied, and mostly rated as face and content valid, since they 
were derived from guideline recommendations. Regular updating was deemed necessary to reflect 
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Table 3. Classification of drug-oriented prescribing indicators as assessed in the studies 
DRUG-ORIENTED Pl 
1. First choice or preferred drugs or drug classes 
% first choice drugs (e.g., enalapril or simvastatin) of a l l  drugs prescribed within 
its therapeutic class (ACE inhibitors or lipid lowering drugs). 3• 16•43•47,50,67 
o/o first choice drug class (e.g., biguanides) of all oral antidiabetic drugs 16•67 
patients on preferred drug classes (e.g., diuretics or betablockers) of al l 
antihypertensives 47•67 
ratio of preferred: less preferred drugs (e.g., plain:combination diuretics) 10 
number of prescriptions for (preferred) drugs per PU (or ASTRO-PU) 10 
2. Second step drugs 
patients prescribed ARB and prior to this an ACE inhibitor of al l patients 
prescribed ARBs 43 
3. Non-first-choice or not preferred drugs 
patients on long acting isosorbide nitrate, glibenclamide, combinations of 
diuretics or alpha-glucosidase inhibitor, etc. 16•26•67 
dose/1 000persons/day of lipid lowering drugs in elderly 47 
patients on novelty drugs, such as ARBs or thiazolidinediones, of al l patients 
receiving antihypertensives or oral g lucose-lowering drugs 47•67 
<=0.6 prescriptions/1 00 Pus for drugs with limited indications (e.g. cerebral and 
peripheral vasodilators) 50 
4. Safety indicators 
drugs to be avoided (in elderly) (e.g., chlorpropamide, long acting 
sulphonylurea, short-acting nifedipine) 4, 1s. 19,21.21.24,2s,26,21.2a.si.s6 
co-prescriptions to be avoided, e.g. of statins with macrolides , diuretic, ACE-
inhibitor with potassium or NSAID, metformin with glibenclamide, etc. 1•3• 18• 19 
S. Correct dosing of drugs (under/overdosing and number of daily dosings) 
prescription of high dose hydrochlorthiazide 52 
prescription of low dose bendrofluazide 16 
once-or twice- daily dosing of anti hypertensives in elderly 13•14•25•26,27 
6. Redundant prescribing 
patients prescribed more than 1 drug from the same therapeutic group 
simultaneously (e.g. thiazides) 19•47 
7. Cost-conscious prescribing or limited set of drugs prescribed 
cost of treatment per unit 16•47 
o/o prescribed generic drugs 3 
change amlodipine to felodipine 16 
number of different brands with the same active substance 3 














































+ characteristic is present; - characteristic is absent; ~ characteristic is assessed but doubtful or mixed results; empty cell-no 
information is available on characteristic 
PU: prescribing unit 
ASTRO PU: Age, Sex and Temporary Resident Originated Prescribing Units 
ARB: Angiotensin II receptor blocker 
ACE-inhibitor: Angiotensin converting enzyme inhibitor 




emerging evidence for drug choice. Pl expressing currently used ratios and number of prescriptions 
for specific drugs per prescribing unit (PU) were criticized, since there was no agreement about what 
defines quality in these cases.1 0•50 
Safety indicators focused on potentially inappropriate drugs or drug combinations to be avoided, 
and both groups were widely studied. They were considered face and content valid but criticized 
for reflecting only a limited part of prescribing quality. 1 5•1 9  Since in specific cases there can be 
good reasons to use "inappropriate" drugs, these indicators were recommended for internal use to 
identify potential problems. 1 9  Indicators focusing on redundant prescribing, e.g. number of daily 
dosing or co-prescribing of more than one drug from the same therapeutic group, were studied in 
two and five studies respectively, which showed that this group of indicators is reliable, face and 
content valid. Difficulties were encountered regarding the operational feasibility of some safety and 
redundant prescribing indicators because of the absence of eligible patients or lack of information 
on duration of prescriptions.1 9•56 
Indicators focusing on cost were seldom assessed for face and content validity47 or doubts were 
raised for their relation to quality.43 Furthermore, the value of the DU90% focusing on the number 
of different drugs prescribed within a drug class was disputed, because it does not discriminate 
between physicians, and high scores can be obtained while prescribing less preferred drugs.43 
In summary, the drug-oriented indicators that have repeatedly shown face and content validity 
focus on: (a) proportions of first choice drugs within a therapeutic class, (b) drugs to be avoided, 
(c) number of preferred daily dosings. In general, drug-oriented Pl have shown good operational 
feasibility. 
Cross-sectional disease-oriented Pl 
We identified more than 30 generic disease-oriented indicators assessing prescribing in a cross­
sectional way. They were grouped reflecting prescribing of: drugs for a specific indication (subdivided 
for different drugs), drugs for a specific indication unless contra-indicated (subdivided for different 
drugs), drugs for elevated risk factor levels, first-choice drug for a specific indication, and drugs to 
be avoided in specific patients (Table 4). 
From the first group, the indicator "prescription of glucose-lowering treatment in diabetic patients" 
was criticized for not reflecting quality.41 •53 The other Pl from this group were considered face and 
content valid but adjustment for case-mix was recommended to deal with patients that either 
do not require or should not receive the specified treatment. Alternatively, this could be solved 
by excluding patients with contraindications to the recommended treatment from the indicator. 
Several of such Pl with exclusion criteria, however, lacked face or content validity across different 
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Table 4. Classification of cross-sectional disease-oriented prescribing indicators as assessed in the studies 
CROSS-SECTIONAL DISEASE-ORIENTED Pl 
1. Patients prescribed drugs for a specific indication 
prescribed statins (or lipid lowering drugs) : 
-in patients with high cardiovascular risk or CVD 1,1, 12, 16, 1B,10,10,15,19,41,55,54,5B 
- in diabetic patients or treated with glucose lowering medication 40•41•43 
prescribed (a specific type of) glucose lowering treatment 4 1•53 
prescribed daily aspirin (or antiplatelet drug or anticoagulants) in: 
- diabetic patients or treated with glucose lowering medication (and additional cardiac 
factor) 14,26,4o,41,44,47,54 
- patients with history of CVD or high cardiovascular risk 1, 12. 14, 16, 19,10,26,10,14,41,41,54,5B,5960 
prescribed any antihypertensive treatment 
-in patients with stroke 26 
-in (elderly) patients with diabetes and hypertension or albuminuria 4 1•53 
prescribed ACE inhibitor (or ARB) of: 
-in patients with CHD or history of Ml 5 
- T2DM patients 40 
- T2DM patients with hypertension and/or microalbuminuria or (macro)albuminuria 1•5• 12• 1 
B,10,26,33,4 1,44,47,51,53,5B 
prescribed beta blockers to (diabetic) patients with Ml or CHD 4• 16• 18•10•26•30,42.47•54 
T2DM or high cardiovascular risk patients received influenza immunization 5•39•54•55 
appropriate treatment for patients with diabetes or CVD or hypertension or 
cardiovascular risk 7•3o.4B.52 
2. Patients prescribed drugs for a specific condition unless contraindicated or not needed 
prescribed ACE inhibitor or ARB unless contraindicated to patients with: 
- CAD and diabetes 5•7 
-in elderly patients with IHD 23•24•25 
- hypertension and kidney disease 5 
- (elderly patients) with diabetes and microalbuminuria or proteinuria 23•24•25•26•27•30 
(elderly) patients with CHD (and diabetes or elevated LDL) prescribed lipid lowering 
drugs unless contraindicated 23,24,25,57 
prescribed antiplatelet drug in patients with diabetes or CVD unless contraindicated or 
already on other anticoagulants 5,1B,21,24,25,26,21,29,1:z.11,19,46,56,57 
prescribed aspirin in elderlyT2DM patients unless on other anticoagulants 23•24•25•26•27 
prescribed beta blockers in patients with coronary disease and/or Ml (and hypertension) 
unless contraindicated 5,21,24,25,21,29,12.15,19,51 
% of eligible T2DM patients who received influenza immunization or refused 
immunization 54 
3. Patients prescribed drugs for elevated risk factor level 
treatment of (diabetic) patients with concurrent high level risk factor: 
- cholesterol above specified level in (elderly) patients with diagnosis of CHD, diabetes or 
high cardiovascular risk i6,11,34,44,41,51,59,60,64 
- HbA 1 c above specified level (age dependent) 20,33•57,64 
- BP above specified level, average of 2 readings, last 3 readings above (age dependent) 
level 10.1 ,.12,11,11,19,46,53,64 
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■ Chapter4 4. First-choice drug in patients with specific condition prescribed first choice drug (e.g. metformin or first-choice antihypertensive) in (overweight} diabetic patients zo.i 1,11.41,46,47 5. Drugs to be avoided in patients with specific conditions glyburide to be avoided in elderly diabetic patients 40 thiozolidinedions to be avoided in diabetic patients with heart failure 40 patients older than 75 years prescribed l ipid lowering drugs for primary prevention 3 + + + + + + + + characteristic is present; - characteristic is absent; ~ characteristic is assessed but doubtful or mixed results; empty cell-no information is available on characteristic CVD: cardiovascular disease CHO: coronary heart disease Ml: myocardial infarction T2DM: type 2 diabetes mellitus HbA 1 c: g lycosylated hemoglobin BP: blood pressure ARB: Angiotensin II receptor blocker ACE-inhibitor: Angiotensin converting enzyme inhibitor LDL: low density l ipoprotein settings. For example, indicators focusing on prescription of ACE-inh ibitors and aspir in in elderly 
patients with diabetes un less contra-indicated were accepted as  face and content va l id by expert 
panels in the USA and UK, but rejected by a Dutch panel.25-27 Furthermore, the operational  feasibi l ity 
of such indicators was fou nd to be hampered in one study using automated data col lection methods, 
because information on contraindications entered as text data in  medica l records was missed.s7 
Another type of disease-oriented Pl that was widely tested consists of indicators that focus on 
prescribed drugs in patients with an elevated risk factor level (Table 4). The cut-off levels varied 
depending on the literature used for developing the indicator, and in some cases age-dependent 
levels were specified.33•51 Face and content va l idity was considered present but again case-mix 
problems were mentioned, especia l ly regarding treatment in re lation to cholesterol levels. In one 
case, this resulted in rejecting indicators that were considered too sensitive to patient case-mix.53 We 
identified relatively few d isease-oriented Pl focusing on first-choice drugs or d rugs to be avoided 
(Table 4). 
In summary, the most widely assessed disease-oriented Pl, showing good c l inimetric resu lts 
in different settings, focus on prescribed drugs for a specific ind ication or elevated risk factor, in 
particu lar: (a) statins in h igh cardiovascu lar risk patients. (b) aspirin or antiplatelet med ication in 
h igh cardiovascular risk patients, (c) ACE-inhibitors in T2DM patients with hypertension and/ 
or a lbuminuria, (d) beta blocker in patients with coronary heart d isease or h istory of myocard ial 
infarction, (e) treatment of patients with elevated HbA 1 c levels; (f) treatment of patients with 
elevated blood pressure levels. 
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Sequential disease-oriented Pl 
Among the 12 identified generic indicators that incorporate a sequential assessment strategy, we 
acknowledged four groups: treatment modification after an event, treatment modification after 
an event unless contra-indicated, start of a first-choice drug in specific patients, and continuum 
of post-discharge treatment (Table 5). These include indicators such as "if a patient has a certain 
risk factor level, then he should receive a treatment start or intensification'; either with or without 
a defined maximal time period for such modifications. In two studies, a return to control without 
treatment modification was included in the indicators as adequate care.8•9 Similar to the cross­
sectional indicators, sequential indicators incorporated exclusions to deal with patients that have 
contraindications or already receive maximal treatment. All except one indicator were considered 
face and content valid. This one focused on treatment of elderly patients with an elevated LDL­
level, which was considered valid by one panel but rejected by another.25•27 Treatment modification 
indicators have shown concurrent validity,8•68 and operational feasibility was good for the first three 
types of Pl in this category. For Pl focusing on the continuum of hospital through post discharge 
ambulatory care, the operational feasibility was hampered by the lack of adequate data systems.52 
In summary, sequential Pl focusing on treatment modifications after elevated risk factors (cholesterol, 
BP, HbA 1 c) showed face and content validity in several studies and settings, and are the only Pl for 




Table S. Classification of sequential prescribing indicators as assessed in the studies 
SEQUENTIAL DISEASE-ORIENTED Pl 
1. Treatment modification after indication or persistent high risk factor levels 
treatment start/modification offered to specific (high risk) patients with: 
- total cholesterol or LDL level above specified level (and no return to control within 
3-6 months) or with hyperlipidaemia 9•32•37•46•64,68 
- uncontrolled/above goal BP level -dependent of other risk factors e.g. diabetes­
(and no return to control within 3-6 months) 9,20,32•4244,48,68 
- failed dietary/lifestyle modification (start oral glucose lowering or 
antihypertensive treatment) 2430,3,.37•46 
- elevated HbA 1 c or fasting glucose level 9•44•64•68 
- failed ora l  glucose lowering treatment (and no return to control within 3-6 
months) 20,30,31,40,46 
- with history of CVD or high cardiovascular risk (anti platelet or anticoagulant) 36 
pharmacologic or lifestyle intervention offered to elderly with diabetes and fasting 
LDL>1 30mg/dl (within 3 months) 25•27 
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2. Treatment modification after indication or persistent high risk factor level unless not possible or needed 
treatment start/modification in patients with history of CVD or with elevated risk 
factor level (LDL, HbA 1 c, BP) unless contraindicated (and no return to control 
within 3 or 5 months) 8, 18,23,24,25.26.21,31,39,42,46 
patients with diabetes and proteinuria or patients with hypertension prescribed 
ACE inhibitor (or ARB) within 3 months unless contraindicated 37•46 
3. Start first choice treatment in specific patients 
+ 
+ 
- metformin in overweight incident diabetic patients 20 + 
- ACE-inhibitor or ARB in incident hypertensive diabetic patients with albuminuria 20 
4. Continuum of post discharge care 
patients with Ml prescribed treatment (ACE-inhibitor, aspirin, clopidogrel, statin, or 
b-blocker) at discharge or after a specified time period (from 1 month up to 1 year) 






















+ characteristic is present; - characteristic is absent; ~ characteristic is assessed but doubtful or mixed results; empty cell-no 
information is available on characteristic 
BP: blood pressure 
HbA 1 c: glycosylated hemoglobin 
CVD: cardiovascular disease 
LDL: low density l ipoprotein 
T2DM: type2 diabetes mellitus 
Ml: myocardial infarction 
ACE-inhibitor: Angiotensin converting enzyme inhibitor 
ARB: Angiotensin I I receptor blocker 
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DISCUSSION 
We have identified 16 types of Pl covering important aspects of drug prescribing related to T2DM 
and CV risk management, including first-choice treatment, safety issues, dosing, costs, sufficient and 
timely treatment. Face and content validity, as well as operational feasibility were most frequently 
assessed. Less attention has been paid to predictive and concurrent validity, and case-mix issues 
were addressed mostly for Pl intended for external use. Sample size problems were discussed for 
indicators with both aims, but the minimal sample size required per Pl was seldom provided. There 
was no difference in the choice of indicators for internal or external quality assessment. 
The Pl that showed good results fortheir clinimetrics in different settings and studies, e.g. prescription 
of beta blockers in patients after myocardial infarction, share a good evidence base that does not 
leave room for disagreement between health care providers across the countries. Therefore, such 
indicators can be used for cross country comparisons of prescribing quality. Other indicators showing 
good clinimetric results, e.g. proportion of first choice drugs within a therapeutic class or treatment 
of patients with elevated risk factor levels, leave room for discussion which drugs to include as first 
choice, and which levels to consider as being elevated. Therefore, these indicators always need to be 
adapted to the prevailing evidence or guidelines. Sequential Pl focusing on treatment modification 
after elevated risk factors are the indicators with the most extensive evidence of validity. 
Most Pl for T2DM and CV risk management have been developed for ambulatory care, i.e. both 
primary and secondary care. This is not surprising since the same treatment standards apply to both 
settings. It was shown that several drug-oriented Pl that were initially used for hospital care,19 can 
be adjusted for use in primary care.56 
Validity assessment 
The vast majority of the Pl was based on review of literature or guidelines and was therefore 
considered content valid. Combining evidence with expert opinion appeared to be an established 
norm. This provides face validity and ensures acceptance of Pl. Face validity of the same Pl may vary 
according to differences in medical culture or expert panel.26•27 Drug-oriented Pl focusing on first­
choice drugs or (co-)prescriptions to be avoided, and disease-oriented Pl focusing on patients with 
a specific disease or risk factor level receiving treatment have shown face and content validity across 
a number of different settings. In addition, sequential disease-oriented Pl focusing on treatment 
modifications showed concurrent validity.8•68 
No information is yet available on the predictive validity of individual prescribing indicators. 
Studies assessing predictive validity used a composite measure score, which does not allow 
judging the contribution of individual indicators. Furthermore, the results on predictive validity 




between process of care and patient outcomes, it remains unclear if the observed associations were 
due to adequate treatment or to other unmeasured processes of care. 
Feasibility and reliability 
The operational feasibility of Pl has seen much progress in the last decades. The use of EHR is 
increasing rapidly, and quality assessment using automated measures is replacing time consuming 
manual chart review. Automated data collection may lead to underestimating the quality of care 
when critical information is not captured. It was recommended that better recording of diagnosis, 
and development of specific codes for contraindications and patient choices, is needed before Pl 
based on automated data collection can be used for external assessment.8•57 On the other hand, 
the use of computerized methods that can reliably extract relevant information also from free text 
parts of such records shows promising results.64•7 1  One should keep in mind, however, that medical 
records may not reflect all processes of care.72 Especially when there is limited electronic prescribing 
or drugs are prescribed by several providers, data can be incomplete. 
In general, operational feasibility of drug-oriented Pl is good for prescription databases.1 5•50 However, 
calculation of drug-oriented Pl focusing on co-prescribing of drugs may not be possible in prescription 
databases if they do not contain information on duration of prescriptions.56 Furthermore, in several 
European countries it is not possible to assess generic prescribing using pharmacy databases 
because generic substitution can take place on initiative of the pharmacist.43 Disease-oriented Pl 
can be calculated from administrative datasets and EHR.24A9•59 Sequential disease-oriented Pl can 
be calculated from EHR.8•68 Problems with quality and availability of information were encountered 
in all types of datasets. In general, operational feasibility of the Pl should be assessed in a new 
environment, as this largely depends on the particular dataset to be used for quality assessment. 
All studies that assessed inter-rater reliability showed good agreement for Pl. Their explicit nature 
and clear operational definitions, leaving little room for personal opinions, make Pl reproducible 
when used by different assessors. This is in contrast to implicit review, where quality of care is 
assessed without predefined criteria using expert judgments.38 
Sample size and case mix 
The issue of sample size was addressed for Pl with both aims. For internal assessment, the suggested 
number of patients was always a convenience or arbitrary number. In contrast, the minimal number 
of patients per Pl intended for external comparisons should be justified to ensure sufficient power 
to detect differences. Although all organizations dealing with external assessment discussed this 
issue, explicit sample size calculations were presented only in one paper.69 
Another issue that can limit external use of Pl is patient case-mix. Several methods were suggested 
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to deal with this problem, including statistical adjustment or exclusion of patients. In general, both 
drug and disease-oriented Pl can be sensitive to case-mix. Although incorporating exclusions of 
patients with contraindications partially solves the problem, the Pl with such exclusions developed 
so far were often hampered by lack of face and content validity or operational feasibility. Some have 
argued that for internal quality assessment sophisticated case-mix adjustment may not be cost­
effective, and therefore, basic age/sex adjustment might be sufficient.12.7° On the other hand, it has 
been recommended to stratify performance measurement by gender, since this allows to detect 
specific areas for improvement.73 For external use, however, other patient case-mix characteristics 
remain important that are currently not adequately addressed for the existing Pl. 
Limitations and strengths 
Classification of the validity assessments was limited to the information provided in the publications. 
Al most a 11 Pl were assessed for face and content validity. However, because of the emerging evidence, 
some Pl considered content valid several years ago, may not be valid anymore. Furthermore, few 
papers included details on Pl that were discarded for lacking face or content validity. 
The strength of our study was that we searched both Medline and Embase with no language 
restriction. We also included relevant documents from national professional organizations, but we 
may have missed some not formally published documents, in particular from non-English speaking 
countries. However, we trust that we have uncovered the most relevant themes, and that this review 
reflects current Pl developments in diabetes and cardiovascular risk management. To our knowledge 
this is a first review that attempts to classify and report on the validity of prescribing indicators. 
CONCLUSIONS AND IMPLICATIONS 
We identified a large variety of prescribing indicators forT2DM and CV risk management that cover 
the important areas for prescribing, including recommended drug choices, safety issues, as well as 
timely and adequate pharmacological treatment of various risk factors. Our conclusion is that, in 
general, most developed Pl are evidence-based and face valid but few were tested for concurrent or 
predictive validity. Small variations in indicators are seen between different studies and countries, 
due to differences in medical culture and emerging evidence. Since face and content validity 
depend on setting and time, existing indicators always need to be scrutinized before use in a new 
environment. Inter-rater reliability seems not problematic for Pl assessment. Case-mix problems 
can affect most indicators. Problems with small sample size were especially observed for some 
safety issues. Operational feasibility can not be assumed without examining the available data. It 
seems especially problematic for Pl focusing on redundant prescribing, continuity of care, and Pl 
incorporating contraindications. 




choose the most relevant ones. Besides selecting Pl with proven validity and operational feasibility, 
it is important to decide which aspects of prescribing one wants to address. It is to be expected that 
different stakeholders will differ in their views on the most relevant aspects. Our review provides a 
large number of Pl that have shown good results regarding some basic clinimetrics, and examples 
of Pl with positive assessments in various settings. The lack of information on predictive validity of 
individual Pl is troublesome because of its importance for selecting indicators that are closely linked 
to clinical outcomes. 
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Appendix 1 Systematic Search Strategy 
Search strategy using embase.com (combined search in Embase and Med line) 
1. (EMTREE terms: health care quality OR quality control) 
AND 
EMTREE terms: coronary artery atherosclerosis OR cardiovascular disease OR diabetes mellitus 
OR non insulin dependent diabetes mellitus OR ischemic heart disease OR heart infarction OR 
hypertension OR angina pectoris OR hyperlipidemia OR chronic disease 
OR general practice OR primary health care OR general practitioner 
AND 
(Title words: (quality AND measure*) OR (quality AND assess*) OR indicator* OR perform* OR criteria 
OR profile*) 
2. (EMTREE terms drug utilization OR prescription) 
AND 
(Title words: (quality AND measure*) OR (quality AND assess*) OR indicator* OR perform* OR criteria 
OR profile*) 
3. 1 OR 2· 
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Information on prescribing quality of diabetes care is required by health care providers, insurance 
companies, policy makers, and the public. Knowledge on preferences of all involved parties 
regarding type of prescribing quality information is important for effective use of prescribing 
quality indicators. Between June and December 2009 we conducted semi structured interviews 
with 16 key-informants representing eight different organizations in the Netherlands involved in 
healthcare quality improvement. The interview guide included topics on participants' opinions 
and preferences regarding existing types of prescribing quality indicators in relation to the aim of 
using quality information. Content analysis methods were used to process the resulting transcripts. 
Findings from this qualitative study of stakeholder preferences showed that indicators focusing on 
undertreatment were prioritized by all stakeholders. Furthermore, health care providers and policy 
makers valued prescribing safety indicators, insurance companies prioritized indicators focusing on 
prescribing costs, and patients' representatives valued indicators focusing on interpersonal side of 
prescribing. All stakeholders preferred positive formulation of the indicators to motivate health care 
providers to participate in health improvement programs. A composite score was found to be most 
useful by all stakeholders as a starting point of prescribing quality assessment. Lack of information 
on reasons for deviating from guidelines recommendations appeared to be the most important 
barrier for using prescribing quality indicators. According to the health care providers, there are 
many legitimate reasons for not prescribing the recommended treatment, and these reasons are 
not always taken into account. The specific preferences of stakeholders found in this study can assist 
in minimizing the number of relevant POI and providing customized indicator sets. Furthermore, 
the implementation of an information system to register the reasons for not prescribing the 
recommended treatment will stimulate effective use of prescribing quality indicators. 
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INTRODUCTION 
Insight into the quality care is demanded by healthcare providers (HCP), payers, and the public. 
These different stakeholders use quality information for different purposes such as internal quality 
improvement, cost containment, and accountability. There is general agreement that due to varying 
aims of using quality information, the different stakeholders have specific preferences for the type 
of quality information.1 -3 However, not much is known about their actual preferences. In this study, 
we searched for preferences among different stakeholders for prescribing quality indicators in 
diabetes care. 
Appropriate drug prescribing has been recognized as an important quality of care issue in 
the management of chronic conditions, such as type 2 diabetes mellitus (T2DM). Diabetes is a 
chronic disease with a dramatically increasing prevalence throughout the world.4 Appropriate 
pharmacological treatment of diabetes and related risk factors helps to reduce complications in 
patients with T2DM.5 
To measure quality of prescribing in T2DM, a huge number of prescribing quality indicators (PQI) 
has been developed.6 Despite this fact, PQI for T2DM management are largely underrepresented 
in national sets of quality measures that are used for external accountability in different countries. 
For example, the National Voluntary Consensus Standards for Adult Diabetes Care includes two 
PQI focusing on management of diabetic patients 7, and only these PQI were included in the Health 
Employer Data Information Set (HEDIS) of measures.8 The Diabetes Quality Improvement Project, 
which was implemented in the United States as a comprehensive set of national diabetes quality 
measures, did not include any PQI for internal quality improvement or for accountability9• The 
PQI are also underrepresented in the Quality and Outcome Framework set of quality indicators in 
the United Kingdom with only one PQI relevant for diabetes care.10 The Australian national set of 
diabetes indicators does not include any explicit PQl.(1 1 )  On the other hand, in some countries, for 
example, the United Kingdom and Australia, there are sets of internal quality indicators exclusively 
focusing on prescribing issues.12;13 In the Netherlands, a similar situation exists with PQI mainly 
being used for internal quality improvement and only a few used for accountability purposes.14;15 
The challenge now faced by the stakeholders is not to develop more indicators but to choose the 
most relevant ones. Among the existing PQI there are distinct types of PQI that address different 
aspects of prescribing relevant for care, i.e. PQI focusing on undertreatment, safety, first choice 
medication, and costs.6 Previous studies investigating the preferences for PQI focused mostly on 
needs of one of the stakeholders, i.e. healthcare providers (HCP). It was found that PQI based on 
detailed patient clinical information are preferred to those based on aggregated data,16 and that 
physicians rank evidence-based PQI higher than those based on costs.17 However, knowledge is 
scarce regarding the types of PQI that are prioritized by other stakeholders. Furthermore, little is 
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known about the preferred format of the PQI. For instance, it is possible to focus either on numbers 
of patients receiving appropriate care or on patients receiving inappropriate care. Also, indicators 
can represent one specific item of care or can average several items into a composite score. The 
use of PQI could be more effective if we had a better understanding of ways to present quality 
information that are most meaningful to the stakeholders. 
The aim of the current study was to explore whether the PQI are considered a relevant part of 
quality assessment of T2DM care, and which types of PQI should be included according to different 
stakeholders. In addition, we wanted to elicit the preferred way of receiving quality information as 
well as the perceived barriers regarding PQI use. 
Study population 
The present study draws on 16 semi-structured interviews with key informants representing (1) 
the public, (2) healthcare providers, (3) payers, and (4) healthcare inspectorate. These participants 
worked for eight organizations involved in healthcare quality measurement or improvement in the 
Netherlands. (Table 1) 













The Federation of Patients and 
Consumers Organization 
Dutch Institute of Health Care 
Quality Improvement 
Dutch Col lege of General 
Practitioners 
Dutch Diabetes Federation 
Royal Association for the 
Advancement of Pharmacy 
Scientific Institute of Dutch 
Pharmacists 
Community health care providers 
Health insurance 
companies* 
Dutch Health Care Inspectorate 
Interviewed key informants 
Senior policy officer 
Medical advisor 
Senior advisor/diabetologist 
Authors of national diabetes 
guidelines for primary care/ 





Primary care physician 
Diabetes nurse 
Health program manager 
Health care purchaser 
Medical advisor 
Senior inspector 












*We have included three different insurance companies covering different geographical regions in the country 
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Purposive sampling was used to identify key informants from each organization, i.e. senior staff 
members who were engaged in quality of care issues within an organization. We have contacted our 
respondents directly or identified them through other members of the included organizations by 
asking them to suggest colleagues whose tasks are related to quality assessment or improvement. 
All participants received a letter containing information about the aim and methodology of the 
study. 
Instrument and data collection 
A semi-structured guide was used that included open-ended questions about aims of collecting 
and using quality information, and more specific questions related to opinions about and 
preferences for different types of existing PQI, the preferred way of receiving quality information, 
and factors limiting their use (Table 2). After eliciting opinions regarding existing types of PQI, on 
undertreatment, first choice-drug, safety and costs, we have asked the participants to choose the 
type(s) of PQI that were most relevant for their work and the reasons for their prioritization. The 
instrument was pilot-tested prior to the data collection. 
Data collection was carried out between July-December 2009. The interviews were conducted face­
to-face for 13 participants and by telephone for three participants who preferred to be interviewed 
this way. Interviews lasted on average 1.5 hours, ranging from one to two hours. The face-to-face 
interviews were conducted by two researchers; one was conducting the interviews and another 
one was making notes. The interviewer asked open-ended questions to reveal participants' views 
and preferences, and then probed for clarification or to explore new themes as they appeared. All 
interviews were recorded on digital recorders with permission of participants. All participants gave 
a written consent to participate in the interview. To ensure the accuracy of our data we used several 
techniques. First, the interviews were translated verbatim independently by the two researchers 
present at the interviews. The transcripts were compared and disagreement was resolved through 
discussion. Next, the accuracy of all transcripts was checked against the original recordings by an 
independent researcher. Finally, the transcripts of interviews were sent back to the interviewees 
who were asked to check their consistency and accuracy before the analysis. 
Table 2. Topics covered in the interview guide 
Current usage and aims of prescribing quality indicators 
Opinions regarding the relevance of including PQI on assessment of quality of diabetes care 
Opinions regarding and prioritization of existing types of PQI, i.e. focusing on undertreatment, safety, first 
drug choice, and costs 
Opinions regarding formulation of the PQI (positive or negative) 
Opinions regarding aggregation level of the PQI 






We analyzed data using a 5-stage iterative process to analyze each transcript: (1) familiarizing with 
data; (2) coding of the data; (3) description of the main categories; (4) linking of categories into 
major themes; and (5) interpreting the relations between themes. 1 8  First, the transcripts were read 
several times and parts of text that related to the same concepts were identified. Next, we coded 
data by giving descriptive codes to these concepts. Later, we grouped similar codes under the main 
themes. Finally, we organized our data by stakeholders to look across all parties in order to identify 
differences and similarities, and explored the relationships between recurring themes and aims of 
using quality information. 
The transcripts were initially coded by the first co-author with regular discussion of an emerging 
framework for data coding with other co-authors followed by the second co-author's review of 
coding. We used qualitative analysis software (ATLAS.ti Win 6.1) to facilitate organization of data 
into codes, categories and themes.19 
RESULTS 
Usage and aims of prescribing quality indicators by the stakeholders 
All interviewed stakeholders with the exception of the patient organization used some sort of PQI 
forT2DM management. Primary care physicians and diabetologists use PQI for T2DM management 
for internal quality improvement initiatives such as peer review. The representatives from the 
Dutch Health Inspectorate are primarily interested in investigating and following up on problems 
encountered in medical institutions. Therefore, they mainly use outcome quality indicators to 
identify the healthcare institutions that do not meet the minimal levels of predefined standards of 
quality. Recently, however, they launched a set of PQI for pharmacies to improve pharmaceutical 
care. Pharmacists in the Netherlands are increasingly being involved in pharmaceutical care and 
prescribing quality assessment, and are encouraged to search for patients not receiving the optimal 
treatment and alert physicians. For these purposes, they use various PQI for T2DM management 
and report the scores of these indicators to the Inspectorate. In addition, pharmacists report on 
PQI focusing on costs of medication to health insurance companies. Health insurance companies 
primarily collect PQI focusing on costs to provide fi na ncia I incentives to the HCP that keep prescribing 
costs low. Finally, the patient organizations collect quality information to support patients when 
making HCP choices, and to develop policies where patients' preferences are taken into account. 
Currently, no PQI are used by patient organizations. 
Relevance of including PQI on assessment of quality of diabetes care 
PQJ are an integral part of diabetes quality indicators set 
All stakeholders stressed the importance of combining PQI with other quality indicators of diabetes 
care to obtain a comprehensive picture of provided quality. It was noted that since diabetes is a 
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chronic disease, there is a large number of factors that determine the final outcome of the treatment, 
and it is precisely the combination of all relevant processes that defines quality of diabetes care. 
"The most important is overall treatment of an individual patient; therefore prescribing should 
be always seen in combination with other processes and outcomes of care:' Diabetes nurse 
"The prescribing quality for diabetes is as important as the eye or foot exam. All should be taken 
into consideration:' Medical advisor/health insurance company 
Some participants strongly argued against the use of PQI alone without other quality indicators, 
as different quality indicators of diabetes care are highly interrelated, i.e. the physicians need to 
measure and register certain clinical values first and subsequently make decisions about treatment 
options. 
"I think that PQI should be seen as an integral part of quality of diabetes care and should never 
be considered separately from other quality indicators:' Senior researcher/ Royal Association for 
the Advancement of Pharmacy 
" . . .  It is important only if combined with other quality indicators. Total care is more important 
then only the prescribing patterns:' General practitioner 
POI reflect actions of healthcare providers 
The HCPs noted that there is a lot of attention for quality indicators focusing on measurement and 
registration of HbA 1 c and other risk factors. Prescribing indicators, however, are more relevant 
as measures reflecting the actions of healthcare providers in response to observing elevated risk 
factors, as eventually most of the patients will need pharmacotherapy. 
"The fact that you have measured the blood pressure is a process indicator, as well as the 
indicator of whether you measured the cholesterol. These process indicators are preconditions 
to carrying on. Currently, a lot of attention is still being paid to this type of indicators [focusing 
on registration of measurements] that are actually not very important. The point is: what do you 
do after observing elevated values of risk factors, and prescription indicators play an important 
role in this:' General practitioner/Dutch College of General Practitioners 
POI reflect scientific evidence 
All stakeholders believed that it is important to include PQI, because PQI usually reflect evidence­
based recommendations. Moreover, the HCPs stated that prescribing is the most evidence-based 
part of diabetes treatment, as the other processes of care, i.e. registration of clinical measurements, 
lifestyle modification or diet are not so well researched in relation to patient outcomes as prescribing. 
" . . .  the evidence of education in relation to clinical outcomes is not so large, but prescribing has 
a lot more evidence and is a very important part of diabetes treatment:' General practitioner/ 
Dutch College of General Practitioners 
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Opinions regarding and prioritization of existing types of PQI 
PQI focusing on undertreatment 
PQI focusing on undertreatmentwere prioritized by all stakeholders (Table 3). Room for improvement 
and reflection of guidelines was the most frequently mentioned reason for being interested in these 
PQI. The HCP found these PQI very relevant for their work, because undertreatment of diabetic 
patients remains a major problem. 
"I think that this type of information [information on undertreatment] is really important, 
because clinical inertia [initiation or intensification oftherapy when indicated] is a big problem in 
treatment of type 2 diabetic patients. A good example is statines that are hugely underprescribed 
in patients with T2DM:' Diabetolgist/ Dutch Institute for Healthcare Improvement 
Pharmacists noted that they prefer these PQI because it is easy to improve these scores due to a 
large number of undertreated patients. 
"It is quite easy to improve on this type of indicators, and of course it is always nice for pharmacists 
to dispense more medications:' Senior manager/Scientific Institute of Dutch Pharmacists 
Representatives from health insurance companies mentioned that they find these PQI very 
important because they reflect the timeliness of start and intensification of treatment, and because 
undertreatment results in complications that add to the healthcare costs in long run. 
"When patients need certain treatment, they should be able to receive that treatment. In the 
end, poor care is more costly:' Healthcare program manager/health insurance company 
The representatives of the Inspectorate and the patient organization considered undertreatment of 
patients to be equal to the "wrong treatment': and noted that patients who are in need of therapy 
have the right to be prescribed the recommended treatment. 
"We are very much interested in PQI focusing on undertreatment, as it [undertreatment] can 
harm patients on the long run:' Primary Healthcare Inspector/ The Healthcare Inspectorate 
PQI focusing on safety 
PQI focusing on safety were prioritized by the HCPs and the Inspectorate (Table 3). The HCPs 
mentioned that diabetic patients with kidney function impairment are at higher risk of adverse drug 
events, and therefore, safety issues in diabetic patients with kidney impairment are high on their 
agenda. Besides, the HCP noted that the average diabetic patient requires multiple drugs and has 
other conditions besides diabetes. Therefore, according to the HCP, safety PQI focusing drug-drug 
and drug-disease interactions are very important for assessing quality of diabetes care. 
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reflect possible harm is very important for internal quality improvement:' General Practitioner/ 
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Dutch College of General Practitioners 
"That is very important; as I see a lot of problems in people with kidney disease, or swollen 
ankles who get NSAIDs in high doses, and the kidney function collapses because of that. I think 
interactions between different [drug] classes are very important:' Diabetologist/Dutch Institute 
of Healthcare Improvement 
Pharmacists prioritized the PQI focusing on safety as they felt that they have the best knowledge on 
safety of medication and, therefore, they have the capacity to have a direct impact on improvement 
of patient's safety in relation to prescribed medication. 
The representatives from the Inspectorate prioritized PQI focusing in safety, because 
pharmacotherapy involves many errors and suboptimal decisions, and patients will directly benefit 
from improvement of prescribing safety. In addition, it was noted that safety of healthcare is a 
priority for the Healthcare Inspectorate. 
The participants from health insurance companies felt that safety should remain a prescribing area 
to be monitored and improved internally. Although they accepted the importance of safety PQI for 
diabetes care, in their opinion, judging these indicators requires professional knowledge which they 
lack. 
"It is important that healthcare insurers do not take the place of healthcare providers and do 
not interfere too much in medication matters. I believe that professionals are perfectly able to 
improve on safety of prescribing themselves:' Healthcare purchaser/Health insurance company 
PQI focusing on first choice drug 
The value of PQI focusing on the first choice drug as seen by the stakeholders was that they usually 
reflect guideline recommendations and include a safety component. However, no stakeholder 
found these PQI very relevant for their own aims. The payers referred to these PQI as being only 
important in situations when the first choice drug recommendations implied prescription of 
cheaper medication. The representatives from the Inspectorate mentioned that although these PQI 
usually have good face validity, they do not always reflect prescribing quality. In particular, they 
noted that a high grade of evidence is not always available to guide an evidence-based drug choice, 
and in such situations the final drug choice needs to be made by physicians. The HCPs had a similar 
opinion about the PQI focusing on the first choice drug. One participant argued that these PQI might 
be used for internal purposes and never for external accountability. The HCP argued that the first 
choice drug recommendations cannot be applicable to all patients, as there will be many patients 
that experience side effects, have contraindications, or refuse the recommended medications, 
making these PQI very sensitive to patient case-mix. 





HCPs was the dynamic nature of the evidence supporting first choice drug recommendations. 
These participants noted that the recommendation in guidelines can change, because of emerging 
evidence recommending another first choice drug. 
"Fifteen years ago, a professional was considered incompetent if he used it [metformin] as 
there were too many side effects, whereas now it has become first-choice medication, which, of 
course, may change again:' Senior Inspector/The Healthcare Inspectorate 
In addition pharmacists mentioned that information on first choice drugs is not so crucial, as it often 
refers often to the choice from two drugs that can both be quite good, and therefore the difference 
is not as big as between safe and unsafe therapy. 
PQI focusing on cost 
PQI focusing on costs related to prescribing were recognized as being relevant for the healthcare 
system by all stakeholders but they were prioritized only by health insurance companies. Other 
stakeholders, while accepting the importance of reducing costs attributed to prescribing, felt that it 
is not their responsibility to control costs and mentioned that costs should not be the main factor in 
the prescribing process. The participants from patient organization believed that costs do not have 
a relation to quality, since quality is meeting the needs of an individual patient without considering 
costs. Similarly, representatives of the Inspectorate noted that PQI focusing on costs are hardly 
interesting for them as these PQI do not reflect quality of provided care. 
"Costs and quality go together, but costs are not a priority for the Inspectorate. For instance, if 
the Inspectorate knows that a certain medication is more effective than another, less expensive 
medication, it prefers the more effective medication in spite of the higher costs. Indicators 
relating to costs are hardly interesting:' Senior Inspector/The Healthcare Inspectorate 
In general, all HCPs including pharmacists mentioned that is not their priority to know if the cheapest 
medication is prescribed. However, pharmacists mentioned that they do collect and report on PQI 
focusing on costs to ensure payments from the health insurance companies. All stakeholders that 
did not prioritize PQI focusing on costs agreed that prescribing a cheaper medication is only relevant 
in a situation when choosing from several drugs with similar effectiveness. 
PQI focusing on communication between HCP and patients 
Representatives of the patient organization noted that although there will always be patients who 
would like to know the very detail about provided quality of care, for an average patient it is difficult 
to judge the quality of care with the existing PQI. In addition to the PQI focusing on undertreatment, 
they prioritized a different type of PQI that would reflect effective communication between HCPs 
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and patients regarding the prescribed medication.The aspects considered as important were related 
to patients' participation in the treatment process, self-management, patients' empowerment and 
motivation to comply with the prescribed treatment, and provision of sufficient information about 
prescribed medication in an acceptable, understandable way. 
"It is important to measure whether the [treatment] decisions have been shared with patients, 
for instance in deciding on the use of insulin . . . .  Doctors have to motivate patients enough to 
ensure that the patients comply with the therapy and that together they achieve the aim:' Senior 
policy officer/Federation of Patients and Consumer Organisations in the Netherlands 
"The HCP should provide information about the prescribed medication, such as what to expect, 
common side-effects, etc. And most importantly, patients should believe in the medication 
prescribed by a doctor:' Medical advisor/ Federation of Patients and Consumer Organisations 
in the Netherlands 
Table 3. Prioritization of PQI by stakeholders in relation to their user aims 
Undertreatment Safety 
Stakeholder 
The public ✓ 
Health care providers ✓ ✓ 
Payers ✓ 
Inspectorate ✓ ✓ 
Potential barriers for use of PQI 






The most frequently mentioned barrier for implementing POI was the concern that reasons for not 
prescribing the recommended medication are ignored. The strongest opinions were expressed by 
the HCPs, who noted that many POI are very sensitive to patient case-mix. Several patients may 
encounter side-effects to the recommended drugs, have contraindications, or simply refuse certain 
types of medication due to, for example, negative experiences in the past or influence of the media. 
There was a general concern raised by the HCPs that external bodies expect very high scores on 
indicators reflecting guideline recommendations, and that the external evaluators may not take 
into account all the legitimate reasons for not prescribing a recommended treatment to certain 
patients. 
"Those things [side effects, contraindications and patient refusals] are part of the equation and 
were never understood by the government, insurance or whatever. They say oooh, you score 
80% on metformin, that is very bad, it should be 100 % ... ok, it is right it should be as high as 
possible, but there can be very good reasons not to prescribe the recommended treatment and 




The Inspectorate and insurance companies, however, did recognize that there might be many 
legitimate reasons for deviating form the recommended treatment. They mentioned that usually 
they do not have insight to reasons for deviations, and knowing this information would be very 
relevant for fair prescribing quality assessment. 
Prescribing is a professional area 
Representatives of insurance companies and the Inspectorate mentioned that for some specific 
types of POI, such as focusing on safety, one would need sufficient professional knowledge to be 
able to judge the scores of the indicators. It was mentioned that lack of such knowledge could be 
solved by employing an expert panel. According to the representatives of the Inspectorate, the main 
reason why POI are not yet collected from medical practices is a traditional belief that prescribing 
is a professional domain in which they, in their capacity as supervisors, should not interfere unless 
obvious problems are encountered. The majority of the HCPs supported this view as they believed 
that they are capable of improving prescribing quality internally by audits and peer-review without 
external interference. 
"Measuring the quality of prescribing is new and tricky for the Inspectorate. Some managers 
believe that prescribing is a professional domain in which they, in their capacity as supervisors, 
should not interfere. The Inspectorate does not have enough knowledge and will therefore not 
interfere. It is, of course, possible to put together an expert panel, but the most important point 
to discuss is whether or not prescribing should remain the privilege of professionals. " Senior 
Inspector/The Healthcare Inspectorate 
"Doctors will not trust external evaluators in assessing prescribing quality. Cost control is more 
or less accepted, but quality assessment - no. We are capable of improving quality at the local 
level, and not by interference of the Ministry and other external bodies:' Community primary 
care physician 
Operational feasibility 
Although all stakeholders agreed that currently available data have the potential to provide 
information on the most important prescribing quality issues, operational feasibility was a frequently 
mentioned barrier to the actual use of POI. In particular, many mentioned that the feasibility of 
calculating safety POI is hampered, as additional clinical information is needed, such as kidney 
function, co-medication, etc. This type of information is not always available or easily retrievable 
from the registration systems. This was a particularly important issue for pharmacists. They believed 
to have the best knowledge related to medication safety issues but their involvement in prescribing 
quality improvement was limited by the lack of sufficient patient clinical data in the pharmacy 
registries. 
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"Prescription of certain medications in patients with impaired kidney and liver function requires 
a special attention, and pharmacists can be helpful in monitoring this. However, pharmacists 
normally do not have an access to the patients' clinical data:' Senior researcher/ Royal Association 
for the Advancement of Pharmacy 
Another important piece of information that, in particular, the HCPs and representatives of the 
patient organization felt was lacking, was the documentation of patient preferences for treatment, 
and socio-economic factors that might influence patient preferences. The HCP stressed the relevance 
of developing a registration system where this type of information could be entered in a systematic 
way, so it could assist shared-decision making and taking into account patient preferences. 
Finally, the HCP mentioned that the numbers of POI developed for different clinical areas is growing 
markedly, and there is great time burden for them to deal with such a large number of POI. The 
same problem was identified by the key informants from the Inspectorate, who mentioned that a 
large number of existing indicators related to quality of prescribing makes the choice of the most 
relevant POI difficult. 
Preferences for a method to report the scores of PQI 
Formulation of scores 
A positive formulation of POI scores was preferred by most participants and in particular by the 
HCPs. All HCPs mentioned that it is always better to start from the figures that focus on numbers 
of patients who are well treated, and only as a next step to discuss areas that need improvement. 
Starting with negative figures was thought as creating "a blaming culture" that can discourage 
and demotivate the HCPs from participation in quality improvement programs or from providing 
transparent data on quality. 
"Try to be positive . . .  What would be the incentive for those who perform worse than the 
others? If you put good guys in front and bad gays in the back, then everything is focused on 
the bad guys . . .  Negative formulation creates chaos and negative attitude:' Diabetologist/ Dutch 
I nstitute for Healthcare improvement 
Insurance companies were well aware of this fact, and preferred using positive figures to make 
successful contracts with HCPs. 
"Positive formulation is important for creating a positive and encouraging atmosphere in the 
communication with professionals. If you go to professionals and start off by presenting figures 
that represent good performance, this has a stimulating effect:' Healthcare program manager/ 






When asked about preferences for aggregating PQI, all participants mentioned that both 
"composite" and individual scores are useful. The HCPs preferred a "fold out" system for internal 
quality assessment, where first a composite score is used to get a comprehensive overview, and 
next, it is folded out to the individual PQI level to identify potential areas for improvement. For 
external reporting, the HCPs preferred using only a composite score. The main underlying reason 
was the fear that external stakeholders may misinterpret the scores on individual PQI because they 
may fail to acknowledge the possible legitimate reasons for not prescribing the recommended 
treatment to certain patients. All external stakeholders, however, preferred to be informed on both 
aggregated and individual indicator level using a "fold out" system. The use of composite scores 
was considered to be convenient by providing a quick overview and eliminating the necessity of 
dealing with too many quality indicators. Despite this, the composite score was never considered 
informative enough. Information on an individual PQI level would be desired eventually, since 
only individual PQI scores ensure transparency of the provided care and identify areas that require 
special attention. Several participants mentioned that composite scores should ideally aggregate 
only indicators focusing on a similar topic, for example, safety or undertreatment. 
DISCUSSION 
Our study showed that all stakeholders consider PQI to be relevant for assessing quality of diabetes 
care. They all prioritized PQI focusing on undertreatment for their own aims. In addition, the HCPs 
and the Inspectorate prioritized PQI focusing on safety. No stakeholder prioritized PQI focusing on 
the first choice drug. For the remainder, the stakeholders had differing priorities for the types of 
PQI. Health insurance companies prioritized PQI focusing on costs, and the patient organization 
valued quality indicators that would reflect effective communication between patients and HCPs. 
Important barriers for using PQI were concerns that legitimate reasons for not prescribing the 
recommended treatment are overlooked, and relevant clinical information is not always available 
for adequate prescribing quality assessment. As for the preferred way of presenting scores of the 
PQI, we found that a positive formulation of indicators is very important for encouraging the HCPs 
to participate in prescribing quality improvement programs. A composite score averaging several 
PQI was considered a convenient way to start the process of prescribing quality assessment by all 
stakeholders, but scores on individual PQI were always preferred to inform quality improvement 
initiatives. 
PQI are important tools for assessing quality of diabetes care 
We found that all stakeholders stressed the importance of including PQI for assessment of 
diabetes care. The reasons brought forward by different stakeholders included the relatively high 
level of evidence available for PQI compared to other quality indicators, and prescribing being a 
vital component of T2DM management. Although carefully managing diet, exercising, and self-
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monitoring contributes to improved health outcomes in diabetic patients,20;21  for the majority of 
patients these interventions alone are not going to be sufficient. To avoid or minimize chronic 
diabetic complications, some sort of pharmacological treatment will then be necessary because of 
progressing nature of the disease.22 Furthermore, there is an increased interest from the Healthcare 
Inspectorate in receiving information on quality and safety of medication use in the Netherlands. 
The recent endorsement of prescribing indicators for pharmacies confirms this trend. Similarly, 
the National Quality Forum in the United States acknowledged that there are too few measures 
available to improve the quality and safety of medication use and management, and endorsed 
18 prescribing quality measures as a starting point. These measures focus on managing over-the­
counter and prescription medication related to several conditions including diabetes.23 
Preferences of stakeholders regarding PQI 
Our results indicate that PQI focusing on undertreatment can be included in a uniform set of quality 
indicators appropriate for all stakeholders. For the rest, the stakeholders had differing preferences 
specific to their user aims. We have found that PQI focusing on costs were not interesting for the 
HCPs, and this is consistent with findings from other studies.17;24 In the past, PQI on costs have been 
a part of internal quality improvement programs.25;26 Auditing such information on prescribing 
appears to be less relevant for HCP nowadays, probably because health insurance companies now 
use different (reimbursement) strategies to control prescribing costs. 
The PQI focusing on first choice drugs were not prioritized by any stakeholder. The drug choice 
recommendations are an important component of many clinical guidelines. However, PQI reflecting 
these recommendations are likely to be affected by patient case-mix and the changing evidence 
base. In comparison with the PQI that focus on undertreatment which look at prescribing any drug 
from a certain class, these PQI look at prescribing of a specific drug within a class. Therefore, it is 
more likely that the scores of such PQI is lowered because of patients experiencing side effects or 
having contraindications to a specific drug. In addition, the changing nature of evidence supporting 
the PQI focusing on first drug recommendations hampers comparisons of prescribing quality scores 
over time. 
Patients and HCPs identified a gap regarding indicators measuring the interpersonal side of 
prescribing quality, i.e. shared decision making and respect for patients' preferences regarding 
the treatment options. Previous research has shown that patients value effective communication 
between HCP and patients in addition to technical measures of quality.17 Although reliable measures 
for assessing patients' experiences and perspective do exist, they are not widely incorporated 
into quality assessment.28 Knowing patients' experiences with their HCP is important, as there is 
evidence showing the link between positive attitudes of patients towards their HCP and improved 
patient outcomes.29 To facilitate patients' involvement in the treatment process, it is important to 
95 
■ 
Chapter s  
systematically register patient-related information, such as preferences for and experiences with 
(drug) treatment, in the medical records. Having such information may not only contribute to 
improved communication between HCPs and patients but will also provide the source for obtaining 
the type of quality information that patients value most. 
The stakeholders agreed that POI should be positively formulated to create an encouraging 
environment which is considered very important for participation of HCP in quality improvement 
programs. For the preferred aggregation level, we have found a discrepancy between HCPs and 
external stakeholders. The HCPs were reluctant to share the prescribing quality data on individual 
POI level because of mistrust to the external evaluators. This is in line with other studies showing 
the unwillingness of physicians to share the quality data with the "general public':(30) We expect 
that allowing legitimate deviations from the recommended treatment could help to minimize this 
tendency. 
Potential barriers for use of PQI 
Our results indicate that lack of information on reasons why the HCPs do not comply with the drug 
treatment recommendations is a major barrier for effective use of POI for all stakeholders. This 
finding echoes the results from other studies showing that adjustment to patients' case-mix is a 
concern for physicians when publishing quality information.31;32 Such concerns from the HCPs' side 
are not unsubstantiated, as it has been shown that for a prominent proportion of patients in clinical 
practice there are legitimate reasons for not prescribing the recommended treatment.33;34 
According to the Donabedian'sTriad Model of healthcare quality assessment,35 prescribing indicators 
are typical process indicators as they refer to the treatment of patients. In general, process indicators 
are considered to be less affected by clinical characteristics of patients compared to the outcome 
indicators.36 That is particularly true for process indicators that show percentages of patients in 
whom certain laboratory measurements have been conducted, or who have received a foot or eye 
exam. With regard to sensitivity to patient case-mix, however, POI may behave more like outcome 
indicators. Presence of comorbidities, patients' age, co-prescribed medications, contraindications, 
and possible side effects can all be relevant for the prescribing process, and subsequently the scores 
of POI. Therefore, use of POI requires the same caution with regard to patient characteristics as 
outcome indicators. 
Limitations 
There are some limitations to this study. We had a small number of participants for some stakeholders, 
and the participants may not necessarily be representative for all possible stakeholders in the 
country. However, we included the most relevant organizations in the Netherlands, and within 
these organizations we recruited the employees whose tasks were closely related to healthcare 
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quality assessment or improvement. 
Conclusions 
Prescribing quality indicators, especially those focusing on undertreatment, should be included in 
the quality assessment of diabetes care. Inclusion of PQI focusing on other aspects of prescribing 
quality will depend on the aim of the quality assessment. This study provides information on 
specific preferences of stakeholders which can assist in minimizing the number of relevant PQI and 
providing customized indicator sets. Development of information systems for documenting reasons 
for deviations and patient preferences are needed for a more widespread use of PQI for different 
aims. 
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To identify relevant prescribing quality domains of type 2 diabetes mellitus (T2DM) care for selection 
of a minimal set of prescribing quality indicators from a set of previously validated indicators. 
Study design 
Cross sectional study using electronic health records. 
Methods 
We used the principal factor analysis to identify the underlying dimensions of prescribing 
quality for 76 family practices participating to the GIANTT project in the Netherlands. From a set 
of 1 O prescribing quality indicators covering various aspects of cardiovascular and metabolic 
management, we selected a subset of indicators with the highest loading within each identified 
dimension. Next, we evaluated the impact of using this subset on the quintile ranking of practices 
on their prescribing quality scores. 
Results 
We identified five prescribing quality dimensions in our dataset: two dimensions assessing initiation 
of pharmacotherapy for different risk factors in diabetic patients, two on stepwise intensification 
of treatment, and one on treatment of patients with cardiovascular disease. A composite score 
comprising the indicators selected from each of the dimensions showed good agreement with the 
composite score comprising all indicators with 82 % of family practices either not changing their 
position or shifting their ranking by only one quintile. 
Conclusions 
We showed that a minimal set of PQI for T2DM care should not just focus on management of 
different clinical risk factors, but should also reflect different steps of treatment intensification. The 
results of our study are relevant for stakeholders when selecting quality indicators to assess quality 
of prescribing in diabetic patients. 
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INTRODUCTION 
The demand for accountability in health care and need for improving quality of provided care 
resulted in development of a large number of quality indicators for an increasing number of 
diseases.1 ;2 Quality measurement and reporting have the potential to improve quality of care and 
reduce health care costs, but can also cause administrative and financial burden of collecting and 
reporting quality information. In addition, the number of quality indicators included in national 
sets is varying from country to country. For example, the number of quality measures included 
in Healthcare Effectiveness Data and Information Set (HEDIS) 2010 set in USA is about half of the 
number of indicators included in Quality and Outcome Framework in UK.3;4 Although both sets 
are comprehensive, there is lack of understanding on what the number of indicators in such sets 
should be. Stakeholders using quality information, such as health care providers, policy makers, 
and payers, have to deal with a large number of quality indicators due to the growing number of 
different quality-reporting programs. In US hospitals, the administrative and financial burden of 
data collection has been considered to be very high, and different strategies are sough to reduce 
the number of quality indicators used5 To reduce the burden of collecting and reporting quality 
information, it is important to select a minimum set of relevant quality indicators.6;7 This paper 
describes the process and results of selecting a minimal set of prescribing quality indicators (PQI) 
for treatment of Type 2 diabetes mellitus (T2DM). 
Currently, to evaluate and improve quality of drug treatment in T2DM patients, a large number 
of prescribing quality indicators exists worldwide.8 Several approaches are available to make a 
selection of relevant prescribing indicators from a larger set. One can start choosing indicators 
based on stakeholders' specific preferences and areas of interest,6;9 It is possible to further narrow 
down the choice of indicators based on clinimetric characteristics, such as the grade of evidence 
supporting the indicators, concurrent and predictive validity, and the availability of datas; ,o or 
discard all indicators that do not show room for improvement. 1 1  
Combining measures to a composite score is another way to reduce the number of indicators 
included in quality assessment. Composite scores provide an advantage of quick overview of the 
provided quality of care in a certain area.12 However, they do not reduce the workload and financial 
burden of recording and collecting large amounts of data on an individual indicator level. 
Another approach to systematically minimize the number of quality indicators is the use of data 
reduction techniques, such as factor analysis, allowing to uncover hidden relationships between 
different prescribing quality indicators.13 Although such an approach has been shown to substantially 
reduce the number of indicators based on pharmacy registries, it has not been applied to reduce 
the number of indicators developed for a specific disease and based on electronic health records. 
1 01 
II 
■ Chapter 6 The aim of this study is to provide a minimal set of prescribing quality indicators (PQI) that can represent the quality of pharmacological management of T2DM patients on a healthcare provider level. METHODS Study Setting In The Netherlands, patients are registered with a single family physician who has a gatekeeper role in coordinating their medical care. Almost all family physicians use electronic health records (EHR). We used a dataset extracted for the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT) project which provides information from electronic records of all T2DM patients registered in participating family practices in the north of the Netherlands.14 For this study, we included the 76 practices that had eligible patients for all tested indicators in the year 2007 covering a total of 7944 T2DM patients. The dataset includes information on demographics, prescribed medication, comorbidities, and physical examination and laboratory measurements as documented in the medical records. All participating physicians prescribe electronically, which means that the dataset includes full information regarding prescribed medication. Prescribing Quality Indicators In a previous study, a set of 14 indicators for assessing prescribing quality in T2DM was selected on face and content validity. 1 s Two indicators were discarded from this original set due to a lack of eligible patients per family practice, i.e. focusing on patients younger than 40 with a history of cardiovascular disease (CVD), and on incident overweight T2DM patients. We modified one initial 
indicator focusing on prescription of statins in all diabetic patients with increased cardiovascular 
risk 1 5  to prescription of statins in patients with dislipidaemia to reflect changes in the Dutch diabetes 
guidelines regarding prescription of statins for the study time period.16 
Statistical Analyses 
We calculated the scores of PQI and their 95% confidence intervals (midP) using an individual 
family practice as a unit of analysis. The operational definitions of the PQI are described elsewhere.1s 
There were three indicators focusing on the management of albuminuria with a renin-angiotensin­
aldosterone system (RAAS) inhibitor in mutually exclusive subpopulations of T2DM patients, i.e. 
patients without hypertension, with incident hypertension and with prevalent hypertension. Since 
there were only 17 family practices that had eligible patients for all three indicators focusing on 
prescription of RAAS inhibitors, we combined them to one indicator to increase the number of 
eligible patients per practice for the factor analysis. (table2 ) 
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An exploratory factor analysis was conducted to identify the number of possible underlying 
dimensions. We used principal factor analysis to model correlation between indicators and show 
the extent to which they reflect the same underlying concepts. Next, we selected one PQI within 
each factor to represent a specific dimension of prescribing quality. 
We evaluated models with different numbers of factors and selected the model with best 
conceptual coherence, total variance explained, and communalities of the PQI. The communality of 
each indicator, i.e. the sum of the squared factor loadings for all factors for a given variable, shows 
the amount of variance in a given PQI explained by the selected factors. Furthermore, we repeated 
the analysis in a subpopulation of family practices that had at least 70 T2DM patients to assess the 
influence of a practice size. 
We selected the PQI with the highest loading within each factor to represent that specific dimension 
of prescribing quality. To evaluate the impact of selecting this subset of PQI on prescribing quality 
assessment at family practice level, we assessed the change in ranking of family practices using 
all or only this subset of indicators. For this, we calculated two composite scores for each family 
practice averaging scores of individual indicators, and ranked practices on these scores. The first 
composite score included all 10 initial PQI, and the second one included PQI selected by means 
of the factor analysis. Next, we ranked the family practices on the prescribing quality, distributed 
the composite scores using quintiles, and compared the differences in quintile allocation. We 
considered a difference of not more than one quintile as acceptable agreement. A difference of 2 
quintiles was considered as intermediate agreement, whereas more than 2 quintiles were defined 
as poor agreement. SPSS version 16.0 for Windows was used for the analyses. 
RESULTS 
The average number of patients per family practice was 119 (mean 105, standard deviation 64). The 
table 1 provides general characteristics ofT2DM patients included in the dataset. The scores of the 
prescribing quality indicators (PQI) calculated on a family practice level varied from 11 % (SE 20) to 
96% (SE 13).(table 2) 
We carried out the principal factor analysis to identify the model providing the clearest interpretation 
of factors. We extracted two-, three-, four-, and five- factor solutions and considered the five-factor 
model the best interpretable and conceptually meaningful. The factors explained a substantial 
part of the total variance with a cumulative variance of 16% (one factor), 30% (two factors), 43% 
(three factors), 56% (four factors), and 67 % (five factors) (Table 3). No PQI was excluded from the 
analysis, as all indicators loaded across the factors with correlation coefficients greater than 0.5. 





Table 1 Genera l characteristics of patient population (n=7944) 
Age 
Duration of diabetes (years) 
Average systolic blood pressure (mm/Hg) 
Glycated hemoglobin (HbA 1 c) 
Total Cholesterol 
Low density l ipoproteins (LDL) 
Body mass index* 
Sex (female), % 
Presence of a lbuminuria, % 
H istory of myocardial infarction, % 
H istory of cardiovascular disease (CVD)**, % 
Mean (Std. Error) 
66,3 ( 1 2,3) 
5,7 (5,8) 
1 42,0 ( 1 7,3) 
6,8 (0,9) 







*Body mass index: weight in kilograms divided by height in meters-squared 
** H istory of cardiovascu lar disease included history of myocard ial infarction, ischemic heart disease, transient 
cerebral ischemia, stroke/cerebrovascu lar accident, and atherosclerosis/peripheral vascu lar disease as registered 
by family physicians 
Table 2 Mean family practice scores of prescribing qual ity indicators forT2DM management (n=76) 
Mean PQI Mean number of 
Prescribing quality indicators included in the factor score, eligible patients 
analysis (SE) per PQI (SE) 
% ofT2DM patients with systolic blood pressure 2: 1 40 and 78.7 (8.8) 73.9 (5.6) 
prescribed any antihypertensive drug 
2 % of T2DM patients prescribed a second anti hypertensive 24.8 (20.7) 1 3.5 ( 1 .3) 
drug from a different class if systolic blood pressure 
remained � 1 40 with first class of antihypertensive drug 
3 % ofT2DM patients with a lbuminuria prescribed RAAS- 75.5 ( 1 6.5) 1 5.3 ( 1 .4) 
inhibitor 
4 % ofT2DM patients with history of ischemic heart disease 63.3 ( 1 9.0) 25.7 (3.3) 
or  myocardial infarction prescribed �-blocker 
5 % of not incident T2DM patients with HbA 1 c >7 % and 96.9 (4.0) 34.0 (2.5) 
prescribed any oral  antihyperglycaemic agent or insul in 
6 % of not incident T2DM patients not receiving insul in 24.8 ( 1 6.5) 1 1 .9 ( 1 .0) 
prescribed a second ora l antihyperglycaemic drug from 
a different class if with one ora l  antihyperglycaemic drug 
HbAl c remained >7% 
7 % ofT2DM patients who are prescribed insul in if with 1 1 .1 ( 1 8.0) 8.3 (l .O) 
combination of two oral drugs HbA 1 c remained > 7 % 
8 % of overweight prevalent T2DM patients prescribed a 70.1 ( 1 4.0) 64.0 (5.0) 
multiple drug regime conta ining metformin 
9 % T2DM patients with LDL � 2.5 or TC� 4.5 who are 62.6 ( 1 2.6) 39.2 (2.9) 
prescribed a statin 
1 0  % ofT2DM patients with history of cardiovascular disease 62.4 ( 1 9.7) 25.8 (3.3) 
prescribed acetyl sa l icyl ic acid 
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Table 2 (continued) 
Prescribing Quality Indicators Merged to PQl3 
% ofT2DM patients without hypertension with 
albuminuria prescribed RAAS-inhibitor 
% ofT2DM incident for hypertension patients with 
albuminuria prescribed RAAS-inhibitor 
% ofT2DM prevalent for hypertension patients with 
albuminuria prescribed a multiple drug regime containing 
RAAS-inhibitor 
54 (32) 4.8 (0.4) 
89 (31) 1 .8 (0.3) 
78 (22) 9.8 (0.8) 
T2DM:type 2 diabetes mellitus; RAAS-inhibitor: renin-angiotensin-aldosterone system inhibitor; HbA 1 c: 
glycosilated haemoglobin; LDL: low density lipoproteins; TC: total cholesterol 
The first two factors focused on general first step drug treatment recommendations for majority 
of T2DM patients. The first factor named "starting treatment I" included three indicators reflecting, 
such as prescription of metformin, statin, and any anti hypertensive medication. (table 3) The second 
factor, "starting treatment w: consisted of two other PQI focusing on treatment initiation of T2DM 
patients with specific risk factors, i.e. prescribing glucose lowering medication in patients with 
elevated HbA 1 c levels and prescribing renin-angiotensin system (RAS) inhibitors in T2DM patients 
with albminuria . .  The fourth identified factor reflected treatment of T2DM patients with CVD, and 
comprised both PQI from our set of indicators concerning patients with a history of CVD, focusing 
on prescription of beta blockers and acetyl salicylic acid. Finally, there were two factors focusing 
on next steps of treatment intensification. The factor named "step 1 treatment intensification" 
included only one PQI focusing on adding a second drug in patients with hyperglycemia despite 
monotherapy with oral glucose lowering medication. The "step 2 treatment intensification" factor 
comprised a PQI focusing on adding a second class antihypertensive medication if one class was 
not sufficient to control the blood pressure, and a PQI on prescribing insulin in patients with 
uncontrolled HbA 1 c levels despite oral glucose-lowering treatment. Subanalysis limited to family 
practices that had at least 70T2DM patients showed similar results with PQI loading across the same 
identified dimensions as for the total population. 
Within each dimension we selected the indicator with the highest loading as the PQI that could 
represent that dimensions (PQI 1 ,  4, 5, 6, 7). To assess the influence of this selection of PQI on 
prescribing quality assessment, we ranked the family practices based on the composite scores of 
all initial PQI and the five PQI selected. Distribution of composite scores by quintiles showed that 
81.5 % of family practices had an acceptable shift by either remaining within the same quintile or 
shifting only by one quintile; 10.5 % had an intermediate shift by 2 quintiles; and only for 8% of 
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%  o f T 2 D M  p a t i e n t s  w i t h  s y s t o l i c  b l o o d  p r e s s u r e  2'..  1 4 0  a n d  p r e s c r i b e d  a n y  a n t i  h y p e r t e n s i v e  , 8 6 5  , 2 1 2  , 0 4 1  , 0 8 9  - , 0 9 5  . 8 1 1  
d r u g  
2  
%  o f  T 2 D M  p a t i e n t s  p r e s c r i b e d  a  s e c o n d  a n t i  h y p e r t e n s i v e  d r u g  f r o m  a  d i f f e r e n t  c l a s s  i f  
- , 1 7 5  , 2 5 4  , 3 0 0  - , 3 7 4  , 5 6 2  
. 6 4 1  
s y s t o l i c  b l o o d  p r e s s u r e  r e m a i n e d ;:=::  1 4 0  w i t h  fi r s t  c l a s s  o f  a n t i h y p e r t e n s i v e  d r u g  
3  %  o f T 2 D M  p a t i e n t s  w i t h  a l b u m i n u r i a  p r e s c r i b e d  R A A S - i n h i b i t o r  ,  1 1 9  , 5 4 3  
, 1 8 2  
, 4 3 8  , 3 5 5  
. 6 6 0  
4  
%  o f T 2 D M  p a t i e n t s  w i t h  h i s t o r y  o f  i s c h e m i c  h e a r t  d i s e a s e  o r  m y o c a r d i a l  i n f a r c t i o n  p r e s c r i b e d  , 1 4 3  , 1 1 9  , 7 3 0  - , 0 6 8  - , 1 6 2  . 5 9 8  
13 - b l o c k e r  
5  %  o f  p r e v a l e n t T 2 D M  p a t i e n t s  w i t h  H b A  1  c  > 7  %  a n d  p r e s c r i b e d  a n y  o r a l  a n t i h y p e r g l y c a e m i c  , 0 7 0  , 7 9 0  - , 1 2 7  - , 0 4 5  - , 0 6 9  
. 6 5 2  
a g e n t  o r  i n s u l i n  
6  
%  o f  p r e v a l e n t  T 2 D M  p a t i e n t s  n o t  r e c e i v i n g  i n s u l i n  p r e s c r i b e d  a  s e c o n d  o r a l  - , 0 6 0  , 0 0 7  , 0 7 2  , 8 2 0  - , 0 6 2  
. 6 8 5  
a n t i  h y p e r g l y c a e m i c  d r u g  f r o m  a  d i f f e r e n t  c l a s s  i f  w i t h  o n e  o r a l  a n t i h y p e r g l y c a e m i c  d r u g  
H b A l c  r e m a i n e d  > 7 %  
7  %  o f T 2 D M  p a t i e n t s  w h o  a r e  p r e s c r i b e d  i n s u l i n  i f  w i t h  c o m b i n a t i o n  o f  t w o  o r a l  d r u g s  H b A  1  c  , 0 3 3  - , 1 2 3  - , 1 4 9  , 0 5 0  , 8 0 4  
. 6 8 7  
r e m a i n e d  > 7  %  
8  %  o f  o v e r w e i g h t  p r e v a l e n t T 2 D M  p a t i e n t s  p r e s c r i b e d  a  m u l t i p l e  d r u g  r e g i m e  c o n t a i n i n g  , 5 4 6  , 5 0 2  
, 1 5 7  - , 0 2 0  -,239 . 6 3 3  
m e t f o r m i n  
9  %  T 2 D M  p a t i e n t s  w i t h  L D L  ;:=::  2 . 5  o r  T C ;:=::  4 . 5  w h o  a r e  p r e s c r i b e d  a  s t a t i n  , 6 7 6  - , 1 9 8  
- , 1 2 3  - , 2 2 5  , 4 1 1  . 7 3 1  
1 0  
%  o f T 2 D M  p a t i e n t s  w i t h  h i s t o r y  o f  c a r d i o v a s c u l a r  d i s e a s e  p r e s c r i b e d  a c e t y l  s a l i c y l i c  a c i d  - ,  1 2 1  - , 1 9 2  
, 7 2 7  
, 2 1 0  , 1 0 5  
. 6 3 6  
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Table 4 Agreement between composite scores per family practice based on five versus 1 0  PQI* 
Composite Score based on 5 PQI 
Composite score 
based on 1 0  PQI 
2 4 5 Total 
1 5  
2 
1 6  
3 1 5  
4 1 5  
5 1 5  
Total 76 
* Rows represent quinti le d istribution of family practices based on a composite score of in itial 1 0  PQI; Columns 
represent quintile distribution of fami ly practices based on a composite score of the selected five PQI.  
Dark grey cel ls represent family practice practices with acceptable agreement between two composite 
prescribing scores. 
I ntermediate grey cel ls represent family practice practices with intermediate agreement between two composite 
prescribing scores. 
Light grey cel ls represent family practice practices with poor agreement between two composite p rescribing 
scores. 
DISCUSSION 
By means of factor analysis we selected five POI representing the identified dimensions within our 
dataset: two dimensions on initiation of treatment, two on treatment intensification steps, and 
one on the treatment of T2DM patients with a history of cardiovascular disease. A composite score 
based on these indicators showed good agreement for ranking the family practices on the assessed 
prescribing quality in comparison to a composite score bases on the initial 10 indicators. 
One might expect that POI focusing on management of the same risk factor, for example hyper­
tension or hyperglyceamia, would correlate highly and would therefore constitute one dimension. 
Our study, however, showed that the POI that loaded on the same factor often represented 
management of different clinical risk factors related to diabetes. Previous studies have shown that 
relationship between prescribing indicators is often unpredictable with very different prescribing 
indicators correlating to a high degree.1 7 Instead of correlations within a risk factor, we observed 
relationships between different indicators which appear to be linked to different steps in treatment. 
The first two factors included POI that assessed the first step in pharmacological treatment ofT2DM 
patients such as initiation of antihypertensive and glucose lowering treatment, and prescription 
of statins and RAS-system inhibitors. The third and fifth factor reflected the second or third step in 
treatment of T2DM patients, assessing more aggressive management of uncontrolled risk factors. 
The fourth factor focused on secondary prevention of cardiovascular events in patients with known 





The composite score based on the five selected indicators showed in general good agreement 
with the score comprising all indicators, however, 8% of family physicians shifted by more than 
two quintiles. We had three very detailed indicators focusing in intensification of treatment that 
were triggered by a small number of patients even in large practices as they have multiple inclusion 
criteria. Such indicators have been shown to have a big influence on a composite score averaging 
indicators. 1 8 The composite score based on the selected five PQI included two indicators focusing 
on intensification of treatment. This could partially explain the poor disagreement between the two 
composite scores observed for few family practices. 
We had complete and valid information on medication prescriptions of family practitioners for 
all their T2DM patients in our dataset, since they all prescribe electronically. Although we used 
a large dataset comprising electronic health records of 76 family practices with more than 7944 
T2DM patients, our results may not be generalized to other datasets. We recognize that prescribing 
patterns of primary care doctors in different countries can be influenced by cultural differences,1 9;20 
and variation in national diabetes guideline recommendations that may vary both across and 
within countries.21;22 Therefore, a confirmation of our findings in different datasets and countries is 
recommended. 
To our knowledge, this is the first study to look at the dimensions of prescribing quality ofT2DM care. 
Our study presents an additional approach for minimizing the number of indicators and reducing 
the financial and administrative burden for collecting and reporting quality of care information. The 
results of this study indicate that when making selection from initial set of indicators and developing 
a minimum set, it is important to include the PQI that represent different levels of treatment 
intensity, i.e. PQI focusing on start of treatment, intensification of treatment and management of 
T2DM patients with known cardiovascular disease. 
Take-Away Points 
Using factor analysis we selected five PQI indicators representing the dimensions of prescribing 
quality in our dataset and showed that this subset of indicators adequately reflects the overall 
prescribing quality on a family practice level. 
• Factor analysis has an additional value for selecting a minimum set of prescribing quality 
indicators through identification of underlying dimensions of prescribing quality in T2DM 
• A minimal set of PQI for T2DM care should integrate different treatment intensity levels of 
clinical risk factor management. 
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This thesis fits into a growing body of research on healthcare quality indicators. The main aim of the 
research described in this thesis is to provide a valid and feasible set of prescribing quality indicators 
for type 2 diabetes management. In this chapter, the main findings from the particular studies are 
summarized, methodological strengths and limitations of the presented studies are addressed, 
and implications for implementation of the prescribing quality indicators and further research are 
discussed. 
SUMMARY OF RESULTS 
Objective 1 :  To develop a comprehensive, valid, and operationally feasible set of prescribing 
quality indicators for diabetes care. 
What is already known? 
o Prescribing quality indicators forT2DM management are underrepresented in national sets of 
quality indicators in many countries including the Netherlands. 
o A comprehensive set of prescribing quality indicators for T2DM management does not exist. 
o Validity, feasibility, and acceptability of indicators are essential for reliable measurement of 
(prescribing) quality. 
o Choice of methods and data sources to identify the target population (i.e. eligible patients) for 
treatment may have important consequences on quality assessment scores. 
What is new? 
o A set of prescribing quality indicators for diabetes management was developed with proven 
face and content validity as well as operational validity, covering all important aspects of 
pharmacotherapy in T2DM patients. 
o Use of clinical measurements provides a more sensitive approach than use of diagnostic 
codes to identify treated and especially untreated patients with hypertension and patients 
being overweight or obese. 
o Use of diagnostic codes to identify eligible patients results in overestimation of prescribing 
quality scores in situations when diagnostic codes are better registered for treated than 
untreated patients. 
Development of indicators 
In Chapter 2, we described the development and validation of prescribing quality indicators (PQI) for 
hypertension, hyperglycaemia, dyslipidaemia, anti platelet treatment, and prevention of secondary 
cardiovascular disease in T2DM patients for internal quality improvement in ambulatory setting. The 
indicators were derived from multiple diabetes guidelines and assessed in the panel of nationally 
recognized experts followed by a panel of GPs and diabetologists working in the field. Out of 31 
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potential prescribing indicators reflecting the main recommendations regarding pharmacological 
management of T2DM patients, the expert panel considered 18 indicators as sufficiently valid, of 
which 14 indicators remained valid after assessment of GPs and diabetologists. 
Our results underline the importance of combining scientific evidence with expert and field opinion. 
We found that diabetologists and GPs disagreed on some first choice drug recommendations in 
the guidelines. Since our aim was to select indicators for which there was a consensus between 
both groups of professionals, indicators considered relevant by only some panel members were not 
included in the final selection. The final set included prescribing indicators focusing on all five areas 
of pharmacological management. Most of the selected indicators were supported by evidence 
classified as grade A. None of the indicators focusing on dosage or safety reached sufficient face 
and content validity. There was disagreement between experts on such indicators. The main reasons 
for disagreement and subsequent discarding of the indicators were lack of scientific evidence 
supporting an indicator, lack of clinical information on patient level that is necessary for calculating 
such indicators, and a high sensitivity of some indicators to patient case-mix. 
Testing operational validity of the developed indicators 
Operational validity for most of the POI was good: we were able to calculate 13 out of 14 POI using 
electronic health records of T2DM patients (Chapter 2). Many of our final indicators required 
information on clinical measurement values such as blood pressure, HbA 1 c, albuminuria, etc. For 
example, prescription of an additional class antihypertensive medication in patients with systolic 
blood pressure higher than 140 mm/Hg despite treatment with one class of antihypertensive 
medication. Not all needed information was available for all patients, possibly because some clinical 
measurements are not assessed or registered on annual basis. We concluded that the developed 
indicators can be used among patients with registered values for internal quality improvement 
initiatives. 
Defining patients with specific conditions in need of treatment 
The denominators of some of the developed indicators could be operationalized in our database 
by means of diagnostic codes or the clinical measurements values. For example, overweight or 
obese patients could be identified with an increased body-mass index (BMI) but also by using the 
diagnostic ICPC codes T82 and T83. Similarly, patients with hypertension could be identified by 
elevated blood pressure values or by the corresponding diagnostic codes (ICPC codes K85, K86, 
K87). We studied the effect of the different ways of operationalizing the denominators on the results 
of the indicators. (Chapter 3) 
Using three indicators from our set of indicators as an example, we showed that in specific situations 
prescribing quality scores may differ depending on the method (diagnostic codes versus clinical 




measurement values) to define target population. The choice of methods influences the indicator 
score when there is information bias favoring registration of diagnostic codes in patients who receive 
the recommended treatment. We observed such bias for the indicator measuring prescription of 
any antihypertensive medication in patients with hypertension. Patients with registered diagnostic 
codes for hypertension had a higher chance of being prescribed antihypertensive medication than 
patients without such codes but with elevated blood pressure values. Another relevant finding was 
that the clinical measurement-based approach had a higher ability to identify eligible patients who 
were not prescribed the recommended treatment compared to a diagnostic code-based approach. 
Use of diagnostic codes resulted in missing a higher number of undertreated patients that could 
benefit from the improved treatment compared to a clinical measurement-based approach. 
Objective 2: To improve the general understanding on clinimetric characteristics of PQI for type 2 
diabetes care and cardiovascular risk management. 
What is already known? 
o Many PQI have been developed, but there is no clear overview of their clinimetric 
characteristics. 
o Requirements for indicators developed for internal or external use are different. 
What is new? 
o Content and face validity of most prescribing indicators for management of diabetes and 
cardiovascular risk factors is well established. 
o Inter-rater reliability of prescribing indicators is high. 
o Predictive validity of individual prescribing indicators is not yet known. 
o Prescribing indicators focusing on treatment modification in response to elevated risk factor 
levels are more accurate measures of provided quality than commonly used cross-sectional 
treatment indicators. 
o Case-mix and sample size problems are not always addressed for prescribing indicators used 
for external quality assessment. 
Clinimetrics of existing PQI 
In Chapter 4, we described the results of a systematic literature review to identify and classify 
existing prescribing indicators for diabetes and cardiovascular risk management. We classified the 
indicators in different types and summarized their clinimetric characteristics. We identified more 
than 200 distinct prescribing indicators, and grouped similar indicators to 16 subtypes of indicators 
covering first-choice treatment, safety issues, dosing, costs, sufficient and timely treatment. We 
provided the clinimetric characteristics as evaluated and documented in the literature on this 
subgroup level. As a result of our analysis, we came up with a short-list of specific indicators with the 
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best assessment results regarding different types of validity tested. These indicators were based on 
grade A evidence, and showed good clinimetrics in different settings. They focused on prescribing 
drugs for a specific indication, in particular (a) statins in high cardiovascular risk patients, (b) aspirin 
or antiplatelet medication in high cardiovascular risk patients, (c) ACE-inhibitors in T2DM patients 
with hypertension and/or albuminuria, (d) treatment of patients with elevated HbA 1 c levels, (e) 
treatment of patients with elevated blood pressure levels, and (f ) b-blocker in patients with coronary 
heart disease or history of myocardial infarction. 
We concluded that assessment of face and content validity, i.e. ensuring that the indicator is 
reflecting scientific evidence and is accepted by professionals has become the norm but additional 
validity testing is not that common. The reliability of prescribing indicators was found to be very 
good. Explicit definitions of indicators do not allow room for individual judgments on provided 
quality resulting in a high inter-rater reliability scores. These features enable the use of PQI for 
internal quality improvement initiatives. For external accountability purposes, however, this is 
not sufficient. We found that for many prescribing indicators used for external quality assessment 
no case-mix adjustment or minimal sample size calculation is provided. More attention has to be 
paid to these clinimetrics for reliable and fair comparisons across different health care providers. In 
addition, predictive validity of individual prescribing indicators is not established yet. 
Objective 3: To build up the knowledge on stakeholder preferences and selection of relevant PQI 
from existing sets of indicators. 
What is already known? 
o The number of quality indicators is increasing due to the implementation of new disease 
management and quality improvement programs. 
o Different stakeholders have a different perspective on quality of health care. 
o Using large numbers of indicators introduces time, financial, and administrative burden for all 
involved stakeholders. 
o Quality indicators have to correspond to the aims of quality measurement. 
o Some stakeholders are interested in a smaller number of informative indicators. 
What is new? 
o All stakeholders indicate the importance of PQI for assessing overall quality of diabetes care. 
o PQI focusing on undertreatment in diabetes are prioritized by all stakeholders, while the 
stakeholders differed in their preferences for prescribing indicators focusing on safety, costs, 
and first choice drug selection. 
o A minimal set of PQI for T2DM care should not just focus on management of different clinical 
risk factors, but also reflect different steps of treatment intensification. 




Selection of prescribing quality indicators based on specific preferences of involved 
stakeholders 
In Chapter 5, we described the preferences for specific PQI for diabetes care. We concluded that the 
preferences of stakeholders are closely related to their aims for quality measurement. PQI focusing 
on undertreatment were considered relevant by all stakeholders, but otherwise the stakeholders 
had differing preferences. Health care providers and policy makers valued PQI focusing on the 
safety of medication, insurance companies prioritized indicators focusing on prescribing costs, and 
patients' representatives valued indicators focusing on the interpersonal aspects of prescribing. 
We found that the preferences of stakeholders also depend on their ability to control the issue 
described in the quality indicator. For example, pharmacists preferred indicators focusing on safety 
of medication, because they can directly contribute to the improvement of safety issues related to 
prescribed medication. Similarly, health insurance companies preferred indicators focusing on costs, 
because of their aim of cost containment in health care, and their ability to control costs through 
existing mechanisms such as reimbursement policies. Lack of documented information on reasons 
for deviating from guideline recommendations appeared to be the most important barrier for using 
prescribing quality indicators. Health care providers mentioned that there are many legitimate 
reasons for deviating from the guideline recommendation - and subsequently not achieving high 
levels on the prescribing indicators - ranging from side effects of the drug to the individual choice 
of patients. Patient representatives implied that they want their health care providers to prescribe 
the treatment based on specific patient situation. All stakeholders preferred positive formulation of 
prescribing quality indicators scores to encourage participation of health care providers in quality 
improvement programs. Composite scores were found to be a useful starting point for quality 
assessment, but individual indicators scores were preferred eventually by all stakeholders both for 
internal quality improvement and for external accountability purposes. 
Selection of prescribing quality indicators based on prescribing quality domains identified 
through a data reduction technique 
Chapter 6 presents the results of a data reduction technique to reduce the number of PQI for 
diabetes care. For this analysis we used our initial set of indicators described in Chapter 2 with 
some modifications to increase the number of eligible patients per PQI in HGP practices. As a results 
of these modifications, the final set comprised 1 O PQI. (Chapter 6) We explored the relationships 
between these PQI using factor analysis. We identified five prescribing quality dimensions in a 
dataset from 76 general practices: two dimensions assessing general pharmacotherapy of different 
risk factors related to T2DM, two on stepwise intensification of risk factor treatment, and one on 
treatment of diabetic patients with a known cardiovascular disease. It is important to highlight that 
the prescribing indicators were clustered on different levels of therapy intensification and not per 
clinical risk factor. Within each of the five identified dimensions, we selected the indicator with the 
highest loading to represent each dimension. We found that a composite score comprising these 
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five selected indicators showed good agreement with the composite score comprising all indicators 
at practice level. Using comparisons of rankings, 82% of the practices either did not change their 
position or shifting their ranking by not more than one quintile. This suggests that this set of five PQI 
can be used to represent prescribing quality as defined by the wider set of indicators. 
METHODOLOGICAL CONSIDERATIONS 
Within the research described in this thesis, a variety of methods has been applied, being a modified 
Delphi technique (RAND Appropriateness Method), a systematic literature review, cross-sectional 
analyses of prescribing quality scores using electronic health records (EHR), qualitative research 
methods, and a data reduction technique, i.e. factor analysis. Subsequently, the strengths and 
limitations of these methods are discussed. 
Development of PQI using Rand Appropriateness Method 
We have chosen the Rand Appropriateness Method for the development of our set of prescribing 
indicators as this is a systematic method allowing to combine scientific evidence with expert 
opinion. 1 In fact, we had several indicators based on guidelines that experts disagreed with and this 
resulted in discarding such indicators from the final set. Another strong point of this study is that 
we used IPRAS (lnterpercentile Range Adjusted for Asymmetry) method to assess disagreement 
between experts during all rounds of indicator rating. This methods has shown 100% sensitivity 
with a good specificity after being tested in more than 16,400 theoretical indications and more than 
6,500 real cases.2 
As in any Delphi technique, the final selection of indicators is sensitive to the panel composition. It 
is known that panel members from different groups may have different judgments, which affects 
the ratings.3 Judgments made by any expert panel may not be representative for all health care 
professionals. However, in our study, we had two different panels, making the final selection of 
indicators more reliable and generalizable. 
Operational validity testing 
We showed that the majority of the developed prescribing quality indicators had a good operational 
validity when electronic health records (EHR) are used for their calculation. We combined patient 
clinical information stored in two data EHR sources to enhance completeness of data collection.In 
addition, diagnoses were coded from text lines to improve the registration of diagnostic codes. It 
has to be born in mind, however, that EHR may not be widely available, limiting the use of indicators 
that are based on detailed clinical information. 
We compared methods to identify target population using a reference method that was based on a 
combination of available information about registered diagnostic codes and clinical measurement 
values. Such a reference method is likely to be affected by inadequate registration of diagnostic 




codes and clinical measurements. However, EHR are often considered the "gold standard"for quality 
measurement, and we chose this as the most complete source of information for prescribing quality 
assessment. 
Literature review of clinimetric characteristics of existing PQI 
We tried to make our systematic literature search as comprehensive as possible by including two 
major databases (MEDLINE and EM BASE), by having no language restriction for formally published 
papers, and by careful screening the grey literature, references of included papers from peer­
reviewed journals, and relevant national WebPages. We had a sensitive search strategy with 88% (46 
out of 52) of papers found through the main search strategy. However, we might have missed some 
documents, especially concerning grey literature from non English speaking countries. 
We developed a system for classifying indicators based on their clinimetrics. We used a list of 
definitions for clinimetrics to identify their assessment, since in many studies the assessment of such 
clinimetric characteristics of the indicators was not the main objective of the study. 
We grouped the large number of identified indicators into 16 main subgroups. These subgroups 
were created by aggregating similar prescribing indicators, for example, prescription of statins in 
patients with increased cardiovascular risk and prescription of statins in patients with history of 
cardiovascular disease. Presentation of clinimetric characteristics on a subgroup level does not give 
details regarding a specific individual indicator, i.e. the exact indicator definition and clinimetrics. 
However, we chose to present clinimetric characteristics of similar indicators on an aggregated, 
subgroup level for two main reasons. First of all, it summarizes the assessment of different 
clinimetrics for similar indicators in different countries, at different times and by different authors. 
This provides a more complete picture of assessed clinimetrics for a specific type of indicators. Next, 
the classification on subgroup level makes the provided overview more user friendly, i.e. instead of 
more than 200 individual prescribing indicators, 16 subgroups are presented. 
Eliciting preferences of stakeholders regarding prescribing quality indicators 
As there were no studies conducted previously to describe preferences of different stakeholders 
regarding prescribing indicators, a qualitative study was the most appropriate method to explore 
the preferences of stakeholders and to identify reasons for prioritizing specific indicators. In this 
study, we used several techniques to ensure credibility of our data including data and investigator 
triangulation.4;5 A possible limitation of the study was the small number of representatives from 
some stakeholders that may limit generalizability of our findings. However, we involved the most 
relevant organizations, and within those organizations we identified the key informants. It is a 
relatively small group of people in the Netherlands who discuss possible sets of quality indicators. 
We are confident that we have recruited the most experienced stakeholders in regard to PQI for 
T2DM managment. 
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Use of factor analysis to reduce the number of PQI for T2DM management 
Factor analysis can be a helpful technique for minimizing the number of prescribing quality 
indicators through identification of underlying dimensions of prescribing quality. The advantage of 
this method is identification of relationships between different prescribing indicators on a general 
practice level that are otherwise not visible. This allows not only reducing the number of prescribing 
indicators, but also identifies the most important dimensions of prescribing quality. We were able to 
reduce the number of prescribing quality indicators from ten to five. This might not be considered 
a significant reduction, but further reduction in the number of indicators would result in losing 
important domains that were supported by statistical analysis. 
We confirmed the findings of this study by, repeating the analysis only for those practices that had at 
least 70 T2DM patients. The identified dimensions and loadings of indicators across the dimension 
did not change for th is subset of general practices. In addition, we confirmed that the selected PQI 
reflect the overall prescribing quality by showing good agreement between the rankings of general 
practices based on composite scores comprising all initial indicators and the rankings based on the 
composite score comprising five PQI selected through the factor analysis. 
IMPLICATIONS FOR IMPLEMENTATION OF PQI 
Aims of using PQI 
The developed set of prescribing quality indicators for T2DM ambulatory care(6) can be used for 
internal quality improvement by health care providers. (Table 1 )  The developed indicators are 
face and content valid, reliable, and operationally valid The majority (1 1 out of 14) of the selected 
indicators are supported by A grade evidence coming from the randomized controlled clinical trials 
that provide basis for many diabetes guidelines recommendations regarding pharmacotherapy in 
T2DM. All indicators in our set of PQI belong to the indicators with the best assessment results on 
clinimetrics out of all existing PQI for T2DM and cardiovascular risk management.7 It is important, 
however, to realize that the final set of indicators should be updated over time to ensure that the 
indicators are reflecting the best available evidence. In general, it is recommended to update the 
quality indicators biannually or more frequently if new guidelines or evidence emerges.8 
The developed PQI can be used for external quality assessment if the minimum sample size per 
PQI is known and available and case-mix adjustments are conducted to ensure reliable comparison 
between providers. 




Table 1 .  Proposed set of prescribing qual ity ind icators forT2DM management 
% ofT2DM patients with systolic blood pressure L 1 40 and prescribed any anti hypertensive d rug 
% of T2DM patients prescribed a second antihypertensive drug from a different class if systol ic blood 
pressure remained � 1 40 with first class of anti hypertensive d rug 
% ofT2DM patients with albuminuria prescribed RAAS-inhib itor 
% ofT2DM patients with history of ischemic heart disease or myocard ial infarction prescribed �-blocker 
% of not incidentT2DM patients with HbA 1 c >7 % and prescribed any oral antihyperglycaemic agent or 
insu l in 
% of not incidentT2DM patients not receiving insu l in prescribed a second ora l antihyperglycaemic d rug 
from a different class if with one ora l  antihyperglycaemic d rug HbAl c remained >7% 
% ofT2DM patients who are prescribed insul in if with combination of two oral d rugs HbA 1 c remained > 7 % 
% of overweight preva lentT2DM patients prescribed a multiple drug regime contain ing metformin 
% T2DM patients with LDL � 2.5 or TC� 4.5 who are prescribed a statin 
% ofT2DM patients with history of cardiovascular d isease prescribed acetyl sal icylic acid 
T2DM: type 2 diabetes mell itus; RAAS-inh ibitor:Ren in Angiotensin Aldosteron system inhibitors; HbA 1 c: 
G l ucosylated Hemoglobin; LDL: Low density Upoproteins; TC: Total Cholesterol 
International comparability 
The proposed set of PQI is also of international value, because it has been shown that existing 
diabetes guidelines share a considerable amount of recommendations,9 and the selected indicators 
a re based on the recommendations found in many nationa I and international diabetes guidelines 10•15• 
Before introducing this set of indicators in another country, however, it is recommended to re-test 
the face validity, as expert panels from different countries may have different ratings regarding the 
same indicator set.16;17 The information on reliability, concurrent validity, and methods to adjust 
for case mix and improve sample size per indicator can be transferred and generalized to other 
countries and settings, as these properties are less prone to be influenced by expert opinion, health 
care systems or data availability. For example, the reliability of prescribing quality indicators with 
clear definitions once found to be very good does not need further assessment. 
The proposed set of indicators requires detailed clinical data on a patient level that are usually 
available in medical records. In countries with no widely available EHR the use of our PQI would 
require manual medical record review. Therefore, prior to use in a new setting or country, the PQI 
should be tested for operational validity, as this characteristic largely depends on type and source 
of data used for calculation of indicators.6;1 5;1s 
We demonstrated that the use of diagnostic codes to identify eligible patients for prescribing 
quality assessment may overestimate the provided quality of care. This is likely to happen in 
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other countries and settings due to the presence of many factors influencing the registration of 
diagnostic codes, such as purpose of registration, skills and knowledge of the coder, prioritizing the 
coding of some conditions over others by physicians, and incompleteness of a disease classification 
system.19;20 There are other conditions, different from hypertension and obesity that can also be 
identified by both diagnostic codes and clinical measurements, for example dyslipidemia, impaired 
liver and kidney function, etc. Future studies are needed to investigate the influence of the choice 
of a method to identify patients (diagnostic codes versus clinical measurement values) with such 
conditions on quality assessment scores. 
The specific preferences of stakeholders regarding different types of prescribing quality indicators 
found in our qualitative study may not be generalizable to other countries due to differences in 
health care systems and possible different roles of stakeholders. The need to incorporate preferences 
of involved stakeholders for development and selection of quality indicators is acknowledged by 
several organizations developing indicators in different countries, and similar studies need to be 
conducted in other countries for selection of prescribing quality indicators. 
Validity versus feasibility of PQI 
In general, different clinimetric characteristics of PQI are interrelated. For example, prescribing 
indicators that are sensitive to case-mix issues may not be selected by experts during assessment 
(Chapter 2), and therefore such indicators will be considered as lacking face validity. Prescribing 
indicators that exclude patients that have side effects or contraindications to the recommended 
medication, partially remove the case-mix effect. However, these indicators require much clinical 
information that is not always available, and therefore are lacking operational validity. (Chapter 4) 
Similarly, indicators that incorporate longitudinal way of quality measurement, i.e. linking health care 
provider actions to patient clinical outcomes seem more accurate measures of provided care than 
commonly used cross-sectional indicators. Longitudinal indicators were the only type of indicators 
for which the concurrent validity has been shown, and there is a growing body of evidence showing 
that longitudinal indicators provide the fairest estimates of provided quality.21;22 However, these 
indicators are more difficult to calculate than cross-sectional indicators, and they require availability 
of detailed clinical information hampering operational validity. In any case, the stakeholders need 
to make a trade off between the additional advantages provided by specific indicators and efforts 
to collect the necessary data for their calculation. 
For prescribing quality assessment the choice of clinical information to reliably identify the patients 
with specific conditions is very important. Since our data showed that the combination of diagnostic 
codes and clinical measurement values is the most informative method to identify undertreated 
patients, we recommend this approach for internal quality assessment by health care providers to 





prescribing quality scores are used by policy makers for comparison across different health care 
providers, it is advised to avoid the use of diagnostic codes in situations where there is imbalance of 
diagnosis registration in relation to a treatment status of the patient. If there is no such imbalance, 
the choice of the method is not likely to influence the prescribing quality score, and both approaches 
can be used for prescribing quality assessment depending on which data are available or easier to 
obtain. 
Relevance of prescribing quality indicators for assessment of diabetes care 
Although prescribing quality indicators are still underrepresented in sets of quality indicators, our 
results showed that all stakeholders stressed the importance of including PQI for the assessment of 
diabetes care in the public domain. (Chapter 5) Recently there is an increased interest from different 
stakeholders in receiving information on quality and safety of medication use in the Netherlands. 
(Chapter 4) In 2008 financial incentives to general practitioners were introduced by some insurance 
companies for meeting prescribing indicators related to diabetes care.23 In addition, the recent 
endorsement of prescribing indicators for pharmacies confirms this trend.24 Similarly, the National 
Quality Forum in the United States acknowledged that there are too few measures available to 
improve the quality and safety of medication use and management, and endorsed 18 prescribing 
quality measures as a starting point. These measures focus on managing over-the-counter and 
prescription medication related to several conditions including diabetes.25 
Selection of minimum set of prescribing quality indicators 
Health care providers and other stakeholders have to deal with a large number of quality indicators 
due to the growing number of different quality-reporting programs. The administrative and financial 
burden of data collection and reporting is considered to be very high by health care providers, and 
different strategies are sought to reduce the number of quality indicators used. This thesis enables 
selection of prescribing quality indicators for T2DM management using three different approaches. 
Selection of prescribing indicators based on their clinimetric characteristics, i.e. face, content, 
concurrent and operational validity is an important component of indicator selection process. 
Prioritization of clinimetric characteristics should reflect the aim of using prescribing indicators. 
Another step in the selection process is considering stakeholder preferences in relation to the 
aim of quality assessment.3;26 Our results imply that prescribing quality indicators focusing on 
undertreatment issues would be the best candidates for inclusion in a uniform set of indicators for 
T2DM management intended for all involved stakeholders. The information on stakeholders' specific 
preferences for other prescribing indicators should be used for the development of customized sets 
of indicators for specific stakeholders. 
Finally, factor analysis is a useful technique to reduce the number of prescribing quality indicators 
122 
General discussion 
developed for a specific condition or disease while not losing the overall picture of prescribing 
quality provided by general practitioners. As prescribing patterns of doctors may vary from country 
to country,27;28 a confirmation of our findings in different datasets and countries is recommended. In 
addition, it would be interesting to explore whether the relationships of prescribing indicators for 
management of other chronic conditions follow the same pattern (i.e. cluster on different levels of 
treatment intensification) as for T2DM management. 
Process (prescribing) indicators and health outcome indicators 
According to the Donabedian's Triad Model of healthcare quality assessment,29 improved process 
of care results in improved patients outcomes. However, process of care is only one determinant 
of successful health outcome. Differences in health outcomes might be observed due to case-mix, 
environment, lifestyle, i.e. diet, smoking, etc. In addition, different data collection methods may also 
explain differences in health outcomes. It is argued that outcome indicators should be only used 
situations where it is likely that variations in health care might lead to significant variations in health 
outcome.30 If these conditions are not met, then alternative strategies such as process measurement 
are preferable for quality assessment and improvement. 
Prescribing indicators are typical process indicators as they refer to the treatment of patients. The 
advantages of process measures are that they are more sensitive to differences in the quality of care 
and they are direct measures of quality. Prescribing quality indicators have a special position among 
other process indicators. Unlike indicators focusing on measurement and registration of clinical 
values (e.g. % of T2DM patients with blood pressure measurement), the PQI reflect the actions of 
health care providers in response to observing certain clinical values (e.g. % of T2DM patients with 
hypertension prescribed antihypertensive medication). For that reason, the PQI present a better 
opportunity for informing and improving quality of provided diabetes care. 
In general, process indicators are considered to be less affected by clinical characteristics of patients 
compared to the outcome indicators.30This is particularly true for process indicators focusing on 
percentages of patients in whom certain laboratory measurements have been conducted, or who 
have received a foot or eye exam. With regard to sensitivity to patient case-mix, however, PQI require 
caution. Presence of comorbidities, patients' age, co-prescribed medications, contraindications, and 
possible side effects can all be relevant for the prescribing process, and subsequently the scores 
of PQI. Although information on predictive validity of individual prescribing indicators is lacking, 
prescribing is the best researched part of diabetes treatment, and it reflects the actions of health 
care providers. Therefore, prescribing indicators constitute a promising target for improving quality 






All stakeholders are convinced that prescribing quality indicators are necessary for assessment 
of quality of care provided to TDM patients. Therefore, a concise set of valid indicators is needed 
which can be measured in a reliable way. We have developed and tested a set of prescribing quality 
indicators for T2DM management that cover all pharmacological treatment areas relevant for 
diabetes management. 
Based on our studies, we can recommend the use of the selected and validated 10 PQI that can be 
applied at the level of GPs or GP-practices. (Table 1) Criteria for selecting these indicators were good 
face and content validity, reliability, and operational feasibility (the definitions of the indicators are 
operational, and data needed for calculating the indicators are available). In addition, all 1 0  PQI are 
focusing on undertreatment, and therefore, they constitute the preferences of all stakeholders. 
The selected indicators have been validated in different countries and by different authors for the 
clinimetric characteristics with good assessment results. The conducted systematic literature review 
did not provide any additional valid indicators. 
When making further selection from this set of indicators and developing a minimum set, it is 
important to include the PQI from this set that represent different levels of treatment intensity, i.e. 
PQI focusing on start of treatment, intensification of treatment and management ofT2DM patients 
with known cardiovascular disease. 
If the selected indicators are to be used for external quality assessment, i.e. comparison of individual 
health care providers, it is important to mention that the necessary requirements for valid external 
quality assessment, i.e. sufficient sample size per PQI, adjustment for case-mix and longitudinal way 
of calculation, are not per se included in the definition of indicators, but rather should be taken into 
account and applied by indicator users. 
FUTURE PERSPECTIVES 
The ultimate aim of prescribing quality assessment regardless of stakeholders' perspective is patient 
health gain. To ensure the highest impact on patient intermediate and hard outcomes, it is necessary 
to focus on prescribing indicators with proven predictive validity. We have found that predictive 
validity is assessed for few prescribing indicators for T2DM management with controversial results. 
Most studies used a cross-sectional design to investigate the association between process of care 
and patient outcomes, and it remains unclear if the observed associations were due to adequate 
treatment or to other unmeasured processes of care. Well designed prospective studies are needed 
to assess predictive validity of individual indicators on a practice level. In addition, information on 




In the study on stakeholder preferences we have found that all stakeholders considered the lack 
of information on reasons for deviation from guidelines to be the most important barrier for use 
of prescribing quality indicators. Development of information systems to account for legitimate 
deviations from guidelines recommendations would provide better opportunities for fair and 
efficient prescribing quality assessment through use of prescribing quality indicators. This can be 
done for example, by adopting an exception reporting system similar to one used by the Quality 
and Outcome Framework in UK with development of coding system to register the reasons for not 
prescribing the recommended medication. The administrative burden could be counterbalanced 
by a healthier environment for external quality assessment. 
Finally, guidelines or checklists for assessment of prescribing quality indicators need to be developed. 
We found that sometimes prescribing indicators are being used for external aim without sufficient 
testing. At the moment no standardized approach exists for assessment of clinimetric characteristics 
of prescribing indicators with different authors using different criteria for validation of indicators. 
Such a checklist should discriminate between clinimetric requirements for indicators with internal 
or external aims and should be described for different available data sources. Availability of such a 
checklist will serve two main purposes. First, it will enable assessment of prescribing indicators in 
relation to their aim before usage. Second, it will allow identifying gaps in assessment of indicators 
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In het afgelopen decennium is er wereldwijd veel aandacht besteed aan diabeteszorg. In veel landen, 
waaronder Nederland, was diabetes een van de eerste ziektes waarvoor een ketenzorg disease 
management programma werd ontwikkeld. Daarbij zijn verschillende indicatoren ontwikkeld om 
de kwaliteit van diabeteszorg te monitoren in verschillende nationale sets. Er bestaan specifieke 
nationale en internationale projecten over kwaliteitsindicatoren die zijn gericht op het verbeteren 
van de kwaliteit van diabeteszorg. Hoewel sommige van deze programma's ook voorschrijf 
-indicatoren voor diabetesmanagement bevatten, ontbreekt er nog een allesomvattende reeks. 
Bovendien ontbreekt informatie over de validiteit van de reeds bestaande voorschrijf-indicatoren 
voor diabeteszorg. 
Omdat bij de meeste diabetici een juiste medicamenteuze behandeling de kans op cardiovasculaire 
complicaties kan verlagen, kunnen voorschrijf-indicatoren voor zorg aan mensen met diabetes 
mellitus type 2 (T2DM) in potentie de zorg informeren en de kwaliteit van diabeteszorg te 
verbeteren. Daarvoor moeten ze echter wel voldoen aan aan aantal criteria. Een voorschrijf­
indicator moet tenminste gestoeld zijn op het beste bewijs voorhanden en worden geaccepteerd 
door de beroepsbeoefenaren. De data waarmee de voorschrijf-indicator wordt berekend moeten 
eenvoudig te verkrijgen zijn en systematisch verzameld worden. De indicator moet betrouwbaar 
zijn en het moet mogelijk zijn om een eerlijke vergelijking tussen zorgverleners te maken. Op basis 
van deze criteria kunnen de indicatoren gekozen worden die het meest geschikt zijn om de kwaliteit 
te beoordelen. 
Voorschrijf-indicatoren worden vereist en gebruikt door verschillende belanghebbenden, zoals 
beleidsmakers, zorgverzekeraars, zorgverleners en patientenverenigingen. Deze belanghebbenden 
krijgen met een toenemend aantal kwaliteitsindicatoren te ma ken voor een groeiend aantal ziektes. 
De financiele en administratieve werkdruk neemt toe door gegevensverzameling, rapportage 
en het verwerken van grote hoeveelheden kwaliteitsinformatie. Het is daarom van belang 
wetenschappelijk degelijke methodes te gebruiken om de belangrijkste indicatoren te selecteren 
en zo de werklast en kosten van kwaliteitsbeoordeling zo beperkt mogelijk te houden. 
In dit proefschrift is de ontwikkeling, validatie en selectie van voorschrijf-indicatoren voor 
diabeteszorg beschreven. De drie primaire doelen, hieronder beschreven, zijn gericht op de 
medicamenteuze behandeling van diabetes mellitus type 2. 
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• Het ontwikkelen van een alomvattende, valide en operationeel haalbare set van 
voorschrijf-indicatoren voor diabeteszorg. 
• Het verbeteren van inzicht in de klinimetrische eigenschappen van voorschrijf-indicatoren 
voor T2DM-patienten en cardiovasculair risicomanagement. 
• Het opbouwen van kennis over het selecteren van relevante voorschrijf-indicatoren uit 
bestaande sets van indicatoren die in het publieke domein gebruikt kunnen worden. 
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In Hoofdstuk 2 hebben we de ontwikkeli ng en va I ida tie bes ch rev en van voorschrijf-i ndicatoren voor 
hypertensie, hyperglycemie, dys l ipidemie, behandel ingen met trombocytenaggregatieremmers en 
de preventie van secundaire cardiovascu la i re aandoeningen bij T2DM-patienten in de ambulante 
setting. De indicatoren waren afkomstig van verschi l lende diabetesrichtl ijnen en werden eerst 
besproken door een deskundigenpanel, daarna door een panel van praktijkdeskundigen. Van de 3 1  
potentiele voorschrijf-indicatoren, gebaseerd o p  d e  belangrijkste aanbevelingen ten aanzien van 
de med icamenteuze behandel ing van T2DM-patienten, werden 1 8  indicatoren als voldoende val ide 
beschouwd door de deskundigen. Daarvan bleven 14 indicatoren over nadat deze ook door de 
hu isartsen en diabetologen i n  het veld waren beoordeeld. 
Onze resultaten onderstrepen hoe belangrijk het is om wetenschappel ijk  bewijs met de mening 
van deskund igen en mensen in  het veld te combineren. We zagen dat diabetologen en huisa rtsen 
onderl ing van mening verschi lden over de aanbevel ingen voor eerstekeusmiddelen in de 
richtlijnen. Aangezien het ons doel was om indicatoren te selecteren waar  beide groepen het over 
eens waren, werden a l leen die indicatoren in de definitieve selectie opgenomen. De definitieve set 
van indicatoren bestond u it voorschrijf-indicatoren die gericht zijn op a l le vijf de gebieden van de 
medicamenteuze behandeling. Het grootste deel van de geselecteerde indicatoren is gestaafd met 
wetenschappelijk bewijs dat geclassificeerd is als klasse A. Zowel de i ndruks- a ls  de inhoudsval id iteit 
van de indicatoren gericht op dosering en vei l igheid werden als onvoldoende beschouwd. 
Over deze indicatoren konden de experts het n iet eens worden. De belangrijkste redenen voor 
onenigheid waren een gebrek aan wetenschappelijk bewijs om de indicator te ondersteunen, te 
weinig kl i n ische patientengegevens die nod ig zijn om zulke indicatoren te berekenen en het feit dat 
sommige indicatoren erg gevoel ig waren voor casemix. De operationele va l id iteit van de meeste 
voorschrijf-indicatoren was goed: we konden 1 3  van de 1 4  ind icatoren berekenen aan de hand van 
elektronische gezondheidsdossiers van T2DM-patienten. 
De noemers van sommige geformu leerde indicatoren konden geoperational iseerd worden in  onze 
database door middel van diagnostische codes of de kl i n ische meetwaarde. ln  hoofdstuk 3 namen 
we d rie indicatoren u it onze set van indicatoren a l s  voorbeeld en l ieten zien dat kwal iteitsscores 
van voorschrijf- indicatoren n iet noodzakel ijkerwijs hoeven te veranderen bij een verschi l lende 
methode (diagnostische code of kl in ische meetwaarde) om de doelgroep te definieren. De 
keuze voor een bepaalde methode be"invloedt de indicatorscore echter wel als er informatiebias 
is door het bevorderen van registratie van diagnostische codes bij patienten die de aanbevolen 
behandel ing krijgen. Een dergelijke informatiebias kwam voor bij de indicator die het voorschrijven 
van antihypertensiva bij patienten met hypertensie meet. Patienten met een geregistreerde 
diagnostische code voor hypertensie kregen vaker antihypertensiva voorgeschreven dan patienten 
zonder die code maar wel met een verhoogde bloeddruk. Een a ndere relevante bevinding was dat 
met behu lp van de kl in ische meetwaardes er meer patienten, konden worden ge'identificeerd die 
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niet de voor hen aanbevolen behandeling kregen, dan bij het gebruik van de diagnostische code. Bij 
het gebruik van diagnostische codes werden meer onderbehandelde patienten gemist die hadden 
kunnen profiteren van de verbeterde behandeling dan bij gebruik van klinische meetwaarde. 
In hoofdstuk 4 beschreven we de resultaten van een systematische literatuurstudie om bestaande 
voorschrijf-indicatoren voor diabetes en cardiovasculair risicomanagement te identificeren en te 
classificeren. We classificeerden de verschillende soorten indicatoren en gaven een samenvatting 
van hun klinimetrische eigenschappen. We vonden meer dan 200 verschillende voorschrijf­
indicatoren en groepeerden gelijksoortige indicatoren in 16 subtypes van eerste-keus behandeling, 
veiligheid, dosering, kosten en adequate en tijdige behandeling. We bepaalden de klinimetrische 
eigenschappen op dit subgroepniveau zoals beoordeeld en gedocumenteerd in de literatuur . 
U iteindelijk kwamen we met een short-list van indicatoren die het meest valide werden bevonden. 
Deze indicatoren waren gebaseerd op bewijs van hoge kwaliteit en lieten goede klinimetrische 
eigenschappen zien in verschillende settings. Ze waren gericht op het voorschrijven van medicatie 
voor een specifieke indicatie, vooral (a) statines bij patienten met een hoog cardiovasculair risico, 
(b) aspirine of trombocytenaggregatieremmers bij patienten met een verhoogd cardiovasculair 
risico, (c) ACE-inhibitoren bij T2DM-patienten met hypertensie en/of albuminurie, (d) betablokkers 
bij patienten met coronaire hartziekte of met in de voorgeschiedenis een myocardinfarct, (e) de 
behandeling van patienten met een verhoogde HbA 1 c-waarde en (f ) de behandeling van patienten 
met een verhoogde bloeddruk. 
In hoofdstuk 5 beschreven we de voorkeuren voor specifieke voorschrijf-indicatoren in de 
diabeteszorg. We zagen dat de voorkeuren van belanghebbenden vooral te maken hebben met 
de doelstellingen die zij met de kwaliteitsmeting op het oog hebben, en die zijn verschillend voor 
de verschillende groepen. Alie belanghebbenden vonden de voorschrijf-indicatoren gericht op 
onderbehandeling relevant, maar verder hadden ze verschillende voorkeuren. Zorgverleners en 
beleidsmakers vonden de indicatoren gericht op medicatieveiligheid belangrijk, verzekeraars gaven 
de voorkeur aan voorschrijfkosten en patientenvertegenwoordigers waren meer gericht op de 
interpersoonlijke aspecten van het voorschrijven. Niet alleen is de voorkeur van belanghebbenden 
afhankelijk van het doel van de kwaliteitsmeting, maar ook van de mogelijkheid om invloed uit te 
oefenen op het aspect beschreven in de kwaliteitsindicator. De apothekers, bijvoorbeeld, gaven 
de voorkeur aan indicatoren gericht op medicatieveiligheid omdat ze direct kunnen bijdragen 
aan het verbeteren van de veiligheidsmaatregelen. Op dezelfde manier gaven de verzekeraars 
de voorkeur aan indicatoren gericht op kosten omdat hun doel kostenbeheersing is en ze hier 
ook actief aan kunnen bijdragen zoals bij het vergoeden van kosten. Het belangrijkste obstakel 
om voorschrijf-indicatoren te gebruiken bleek het gebrek aan gedocumenteerde informatie over 
redenen om af te wijken van aanbevolen richtlijnen. Zorgaanbieders noemden een aantal legitieme 
redenen om af te wijken van de aanbevolen richtlijnen - met als gevolg minder hoge waarden van 
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de voorschrijf- indicatoren - zoa ls de bijwerkingen van een medicijn  of de individuele keuze van 
een patient. Patientvertegenwoord igers wi l len dat hun zorgaanbieders de behandel ing baseren 
op de wensen van de individuele patient. Al ie belanghebbenden gaven de voorkeur aan positieve 
formu lering van voorschrijf- indicatorenscores om zorgverleners te stimuleren mee te doen aan 
kwaliteitsverbeteringprojecten. De belanghebbenden vonden samengestelde scores bruikbaar 
a ls  beg inpunt om de kwal iteit te beoordelen maar gaven u iteindel ijk  de voorkeur aan individuele 
scores voor zowel het verbeteren van de interne kwaliteit a lsook voor het afleggen va n externe 
verantwoord ing. 
I n  hoofdstuk 6 zijn de resultaten beschreven van een datareductietechniek om het aanta l 
voorschrijf-indicatoren voor diabeteszorg te verminderen. We gebru ikten een gemodificeerde 
versie van de set van indicatoren beschreven in  hoofdstuk 2 en onderzochten de relatie tussen 
de verschi l lende voorschrijf-indicatoren met behu lp van factoranalyse. We identificeerden vijf 
dimensies van voorschrijf-kwa l iteits in een dataset van 76 huisartsenpraktijken: twee d imensies 
beoordeelden de a lgemene farmacotherapie van verschi l lende risicofactoren met betrekking tot 
T2DM, twee beoordeelden de stapsgewijze intensivering van de behandel ing van risicofactoren 
en een was gericht op de behandel ing van diabetespatienten bekend met een cardiovascula i re 
ziekte. Het is belangrijk om te benadrukken dat de versch i l lende d imensies eerder versch i l lende 
niveaus van therapie intensivering aangeven dan de afzonderlijke kl i n ische risicofactoren.  B innen 
elk van de vijf d imensies kozen we de indicator met de hoogste factorlading om die d imensie 
weer te geven .. We vonden dat de samengestelde score uit deze vijf geselecteerde i ndicatoren op 
praktijkniveau g rotendeels overeenkwam met de samengestelde score u it al le 1 0  oorspronke l ij ke 
indicatoren. Als we kijken naar de rangorde dan behield 82% van de praktijken dezelfde positie of 
verschoof hoogstens een kwintiel. Dit geeft aan dat de set van geselecteerde in idcatoren een goed 
beeld geven over de kwal iteit van de medicamenteuze behandel ing van d iabetes 2 per p ra ktijk. 
We zijn tot de conclusie gekomen dat voorschrijf-indicatoren noodzakel ijk  zijn voor de 
kwaliteitsbeoordel ing van zorg aan T2DM-patienten. Daar is een beknopte set van val ide 
indicatoren voor nod ig die op een betrouwbare manier gemeten kunnen warden. We hebben een 
set van voorschrijf- indicatoren ontwikkeld en getoetst die het gehele kl in ische gebied relevant 
voor diabetesmanagement behelst. Op basis van ons onderzoek adviseren we het gebru ik  van 
de 1 O geselecteerde en geval ideerde voorschrijf-indicatoren (Tabel 1 )  die in huisartspraktijken 
gebruikt kunnen worden. Criteria om deze indicatoren te selecteren waren een goede indruks- en 
inhoudsval id iteit, betrouwbaarheid en operationele uitvoerbaa rheid (de definities van de indicatoren 
zijn operationeel en de data d ie nodig zijn om de indicatoren te berekenen zijn beschikbaar) .  
Daarnaast richten al le 10 indicatoren zich op onderbehandel ing en vertegenwoordigen zo de 
voorkeur van a l le belanghebbenden. 
De kl in imetrische eigenschappen van de geselecteerde indicatoren zijn in verschi l lende landen 
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en door verschi l lende auteurs geval ideerd met goede beoorde l ingsresu ltaten. De u itgevoerde 
literatuurbespreking leverde n iet meer va l ide i nd icatoren op. 
l ndien een verdere selectie uit deze set van indicatoren wordt gemaakt om een min imum set te 
formuleren, is het belangrijk dat indicatoren geselecteerd warden gericht op de verschi l lende fases 
van de behandeling, dat wil zeggen indicatoren gericht op het begin van de behandel ing, het 
intensiveren van de behandel ing en het beheer van T2DM-patienten bekend met cardiovascu laire 
ziekte. 
Als de geselecteerde ind icatoren gebru ikt warden voor externe kwa I iteitsbeoordel i  ng, dat wi I zeggen 
voor het vergelijken van individuele zorgaanbieders, dan moet er rekening mee gehouden warden 
dat de eisen voor va l ide externe kwaliteitsbeoordel ing, namelij k  een voldoende steekproefgrootte 
per ind icator, aanpassing voor casemix en longitudinale bereken ing, niet per se betrokken zijn bij 
de definitie van indicatoren.  Daar moeten gebruikers steeds zelf rekening mee houden en zo nodig 
aanpassingen aanbrengen om ze geschikt te maken voor de eigen situatie . .  
label 1 Voorgestelde set van voorsch rijf-indicatoren voorT2DM-management. 
% van T2DM-patienten met systolische bloeddruk � 1 40 aan wie een antihypertensivum is voorgeschreven 
% van T2DM-patienten aan wie een tweede antihypertensivum is voorgeschreven u it een andere klasse als de 
systolische bloeddruk � 1 40 bleef met eerste-keuze antihypertensivum 
% van T2DM-patienten met a lbuminurie aan wie een RAAS-inhibitor is voorgeschreven 
% van T2DM-patienten met een voorgeschiedenis van ischemische hartziekte of myocardinfarct en aan wie 
een betablokker is voorgesch reven 
% van niet-incidente T2DM-patienten met een HbA 1 c-waarde van >7 % en aan wie een oraal a ntidiabeticum 
of insuline werd voorgeschreven 
% van niet-incidente T2DM-patienten die geen insul ine gebruiken en aan wie een tweede oraal antid iabeticum 
werd voorgeschreven van een andere klasse als met een enkel oraal antidiabeticum de HbA 1 c-waarde > 7 % 
bleef 
% van T2DM-patienten aan wie insul ine werd voorgeschreven als in combinatie met twee orale medicijnen de 
HbA 1 c-waarde > 7% bleef 
%van T2DM-patienten met overgewicht die verschil lende soorten medicatie gebruiken waaronder metformine 
% T2DM-patienten met LDL � 2,5 ofTC � 4,5 aan wie een statine is voorgesch reven 
% van T2DM-patienten met een voorgeschiedenis van cardiovasculaire ziekte aan wie acetylsal icylzuur is 
voorgeschreven 
T2DM: diabetes mell itus type 2; RAAS-inhibitor: renine-angiotensine-a ldosterone systeem inhibitoren; HbA 1 c: 
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